Aetna Better Health of Illinois
Prior Authorization Guidelines

Medication/Policy	Requirements	Duration of Approval if Requirements Are Met
Brand Name Medication Requests	**Aetna Medicaid requires use of generic agents that are considered therapeutically equivalent by the Food and Drug Administration (FDA)** **For authorization of the Brand Name Medication, submit the following:** • A hard copy or confirmation of electronic submittal of the Food and Drug Administration (FDA) MedWatch form detailing trial and failure, or intolerance/adverse effect to the generic formulation that is made by two different manufacturers • The completed hard copy form requires to be submitted to the Food and Drug Administration (FDA) and is available at: FDA MedWatch Form • Online reporting of the Food and Drug Administration (FDA) MedWatch form can be accessed at: https://www.accessdata.fda.gov/scripts/medwatch/index.cfm?action=professional.reporting1	**Approval Duration:** One year

Non-Formulary Medication Guideline	**Requests for Non-Formulary Medications that do not have specific Prior Authorization Guidelines will be reviewed based on the following:**
	• Appropriate diagnosis/indication for requested medication
	• Appropriate dose of medication based on age and indication
	• Member meets one of the following:
	  ○ Documented trial of at least 2 formulary agents for adequate duration has not been effective or tolerated
	  ○ All other formulary medications are contraindicated based on member diagnosis, other medical conditions or other medication therapy
		Initial Approval:
		Six months or lesser of requested duration based on course of therapy
		
		Renewal Approval:
		One year or lesser of requested duration based on course of therapy
		
		Requires:

Last Update: 12.1.2020, 12.4.2020, 3.1.2021, 5.11.2021, 6.28.2021, 8.1.2021, 9.13.2021, 10.1.2021, 12.17.2021, 1.9.2022, 2.1.2022, 2.17.2022, 2.28.2022, 3.11.2022, 4.5.2022, 4.7.2022, 4.26.2022, 5.11.2022, 5.19.2022, 6.7.2022, 7.9.2022, 8.1.2022, 12.16.2022, 1.1.2023, 1.13.2023, 2.1.2023
,
Current Update: 2.10.2023

	○ There are no other medications available on the formulary to treat member condition • For combination drug product requests: ○ Documented reasoning that combination product is clinically necessary and not just for convenience Note: Members' medication trials and adherence are determined by review of pharmacy claims data over preceding twelve months. Additional information may be requested on a case-by-case basis to allow for proper review. **Off-Label and Orphan Drugs can be approved when the following criteria is met:** • Prescribed by physician treating a chronic, disabling, or life-threatening disease • The drug has been approved by the Food and Drug Administration (FDA) • Documentation of trial and failure, intolerance or contraindication to Food and Drug Administration (FDA) approved medications (formulary and non-formulary) for same indication, if available • The drug is listed in any of the following standard drug reference compendium as accepted for off-label use ○ The United States Pharmacopoeia Drug Information ○ National Comprehensive Cancer Network ○ American Hospital Formulary Service Drug Information ○ Thomson Micromedex DrugDex ○ Clinical Pharmacology	○ Documentation of positive response to therapy

Aetna Better Health of Illinois
Prior Authorization Guidelines

Quantity Level Limits	Requests that exceed established Quantity Level Limits will require prior authorization Drugs subject to additional utilization management requirements (for example, non-formulary, clinical prior authorization, and step therapy) must meet clinical criteria and medical necessity for approval, in addition to any established Quantity Level Limit Approval of Quantity Level Limit exceptions are considered after medication specific prior authorization guideline and medical necessity review **Authorization Criteria for Quantity Limit Exceptions:** • **Quantities that Exceed Food and Drug Administration (FDA) Maximum Dose:** o Member is tolerating medication with no side effect, but had inadequate response at lower dose, and the inadequate response is not due to medication non-adherence	**Initial Approval:** One year **Renewal Approval:** One year

Last Update: 12.1.2020, 12.4.2020, 3.1.2021, 5.11.2021, 6.28.2021, 8.1.2021, 9.13.2021, 10.1.2021, 12.17.2021, 1.9.2022, 2.1.2022, 2.17.2022, 2.28.2022, 3.11.2022, 4.5.2022, 4.7.2022, 4.26.2022, 5.11.2022, 5.19.2022, 6.7.2022, 7.9.2022, 8.1.2022, 12.16.2022, 1.1.2023, 1.13.2023, 2.1.2023
,
Current Update: 2.10.2023

	○ Request meets one of the following: ▪ Dose is included in drug compendia or evidence-based clinical practice guidelines for same indication ▪ Published randomized, double blind, controlled trial, demonstrating safety and efficacy of requested dose is submitted with request • **Quantities that <u>do not</u> Exceed Food and Drug Administration (FDA) Maximum Dose (Dose Optimization):** ○ Request meets one of the following: ▪ There was inadequate response or intolerable side effect to optimized dose ▪ There is a manufacturer shortage of higher strengths ▪ Member is unable to swallow tablet/capsule due to size, and dosage form cannot be crushed ▪ Effect of medication is wearing off between doses ▪ Member cannot tolerate entire dose in one administration • **Quantities for Medications that <u>do not</u> have Established Food and Drug Administration (FDA) Maximum Dose:** ○ Member is tolerating medication with no side effects, but had inadequate response at lower dose, and the inadequate response is not due to medication non-adherence ○ Requested dose is considered medically necessary	
Everolimus / Everolimus Dispersible Tablet (Afinitor / Afinitor disperz) [i]	**General Criteria:** • Prescribed by, or in consultation with oncologist • Member is 18 years of age or older • Age exception: Afinitor disperz and everolimus dispersible tablet for the following diagnosis: ○ Subependymal Giant Cell Astrocytoma (SEGA) ○ Tuberous Sclerosis Complex Associated Partial-Onset Seizures	**<u>Initial Approval:</u>** 6 months **<u>Renewal Approval:</u>** 12 months ***Requires*:**

	In addition, may be authorized when one of the following criteria are met:
	Breast Cancer
	• Human epidermal growth factor receptor 2 (HER2)-Negative breast cancer and Hormone receptor positive
	  ○ For example, estrogen-receptor positive, or progesterone-receptor positive
	• Member status meets one of the following:
	  ○ Postmenopausal
	  ○ Premenopausal woman being treated with ovarian ablation/suppression
	  ○ Male
	• Failure of treatment with letrozole, anastrozole, or tamoxifen
	• Used in combination with exemestane
	Advanced Neuroendocrine Tumors
	• Member meets one of the following criteria:
	  ○ Progressive neuroendocrine tumor of pancreatic origin
	  ○ Progressive, well-differentiated, non-functional neuroendocrine tumors of gastrointestinal tract or lung
	• Note: Afinitor tablets is not indicated for treatment of members with functional carcinoid tumors
	Tuberous Sclerosis Complex (TSC)
	• Renal angiomyolipoma, not requiring immediate surgery
	Subependymal giant cell tumor (SEGA)
	• Member is not a candidate for surgical resection
	Advanced Renal Cell Carcinoma
	• Member meets one of the following criteria:
	  ○ Non-clear cell histology
	  ○ Clear cell histology
	  ○ Trial and failure with Sutent) or sorafenib (Nexavar)
	Waldenstrom Macroglobulinemia -Lymphoplasmacytic Lymphoma
	• Trial and failure with a first line chemotherapy regimen
		Clinically significant improvement or stabilization of disease state

	○ For example, bendamustine-rituximab, bortezomib-dexamethasone-rituximab, rituximab-cyclophosphamide-dexamethasone, or others • **Soft Tissue Sarcoma** ○ Member has one of the following diagnosis: ▪ Perivacular epithelioid cell ▪ Recurrent Angiomyolipoma ▪ Lymphangioleiomyomatosis **Soft Tissue Sarcoma - Gastrointestinal Stromal Tumors (GIST)** • Member had trial and failure with imatinib, Sutent and Stivarga • Will be used in combination with imatinib, Sutent, or Stivarga **Classical Hodgkin Lymphoma** • Relapse or refractory disease ○ Failure to first line chemotherapy regimen ▪ ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine), or BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone), or others **Thyroid Carcinoma** • Member has locally advanced or metastatic disease • Diagnosis is of follicular, Hürthle cell, or Papillary carcinoma **Thymomas and Thymic Carcinomas** • Trial and failure with at least one first line chemotherapy regimen ○ For example, cisplatin, doxorubicin, cyclophosphamide preferred for thymoma, or carboplatin-paclitaxel preferred for thymic carcinoma, or others **Endometrial Carcinoma** • Used in combination with letrozole **Meningioma** • Disease is recurrent or progressive and surgery or radiation is not possible **Bone cancer**	

	• Member has relapsed, refractory or metastatic Osteosarcoma • Member had failure with at least one first line chemotherapy regimen • Used in combination with Nexavar **<u>Afinitor Disperz tablets for oral suspension</u>** **Subependymal Giant Cell Astrocytoma (SEGA) associated with Tuberous Sclerosis Complex (TSC)** • Age is 1 year or older • Member is not a candidate for surgical resection **Tuberous Sclerosis Complex (TSC) Associated Partial-Onset Seizures** • Age is 2 years or older • Treatment is adjunctive with antiepileptic medication	
Anthelmintic[ii] Albendazole (Albenza)	**<u>Albendazole</u> pays at Point of Sale when one of the following infections is present:** o Tapeworm ▪ Taeniasis ▪ Cystericerosis/Neurocystercosis ▪ Hydatid disease/Echinococcosis o Roundworm ▪ Capillariasis ▪ Trichinellosis/Trichinosis ▪ Ascariasis ▪ Toxocariasis ▪ Baylisascariasis o Flukes ▪ Clonorchiasias ▪ Opisthorchis	**<u>Initial Approval:</u>** Roundworm: 21 days All others: 3 days **<u>Exceptions to Initial Approval</u>**: • Cysticercosis/Neurocysticercosis: 120 tablets per month • Clonorchiasis and Opisthorchiasis: Up to 7 days • Hydatid Disease: Up to 112 tablets every 42 days for 4 months (112 tablets every 28 days with a 14-day drug-free

	Prescriptions for albendazole that do not pay at Point of Sale may be approved for members who meet one of the following:
	• Trial and failure with praziquantel
	• Infection is with one of the following:
	  ○ Tapeworm
	  ▪ Taeniasis
	  ▪ Cystericerosis/Neurocystercosis
	  ▪ Hydatid disease/Echinococcosis
	  ○ Roundworm
	  ▪ Capillariasis
	  ▪ Trichinellosis/Trichinosis
	  ▪ Ascariasis
	  ▪ Toxocariasis
	  ▪ Baylisascariasis
	  ○ Flukes
	  ▪ Clonorchiasias
	  ▪ Opisthorchis
		period. Repeat up to 2 more cycles)
		• Toxocariasis: 400 mg by mouth twice a day for five days

Antidepressants Non-Preferred[iii] **Selective Serotonin Reuptake Inhibitors (SSRI):** Trintellix Viibryd Pexeva Fluoxetine weekly Fluoxetine tablets PMDD	• Members who are stable (new to plan and/or using samples) that are on non-preferred antidepressant will receive 3-month approval as continuity of care, in order to transition to preferred antidepressant • Members who have started non-preferred antidepressant during recent hospitalization will receive 1-year initial approval **General Criteria for All New Starts** • Member is 18 years of age or older (except for fluvoxamine and fluoxetine) • Requested agent is Food and Drug Administration (FDA) approved for the indication being treated	**Initial Approval:** 1 year **Renewal Approval:** 1 year ***Requires*:** Response to therapy **Quantity Level Limits:** Pristiq, desvenlafaxine, Trintellix, Viibryd, Fetzima, Aplenzin, Forfivo XL, paroxetine ER:

(Premenstrual syndrome)
Fluvoxamine ER
Paroxetine ER
Paroxetine mesylate capsule
 	
Serotonin and Norepinephrine Reuptake Inhibitors (SNRI):
Fetzima
Venlafaxine SR tabs
Pristiq
Khedezla
desvenlafaxine
 	
Other:
Aplenzin
Forfivo XL
Nefazodone
	• If formulary preferred agent is available in different formulation with same ingredient (for example, Pexeva, Aplenzin, Forfivo XL, fluvoxamine ER, paroxetine mesylate, fluoxetine weekly), member must have documented trial and failure of that formulary agent
	
	Additional Criteria Based on Indication
	
	Major Depressive Disorder or Seasonal Affective Disorder (One of the Following)
	• Documented failure, or intolerance to 3 formulary agents from at least 2 different classes of antidepressants
	  ○ Selective Serotonin Reuptake Inhibitor, Serotonin Norepinephrine Reuptake Inhibitor, bupropion, or mirtazapine at adequate dose and duration (at least 4 weeks)
	  ▪ One of these trials must be with preferred formulary agent from same class (Selective Serotonin Reuptake Inhibitor, or Serotonin Norepinephrine Reuptake Inhibitor)
	• Documented failure, or intolerance to 2 formulary agents and acceptable antidepressant augmentation regimen
	  ○ Selective Serotonin Reuptake Inhibitor, or Serotonin Norepinephrine Reuptake Inhibitor, plus bupropion, lithium, atypical antipsychotic, buspirone, or liothyronine, at adequate dose and duration (at least 4 weeks)
	  ▪ One of these trials must be with preferred formulary agent from same class (Selective Serotonin Reuptake Inhibitor, or Serotonin Norepinephrine Reuptake Inhibitor)
	Obsessive-Compulsive Disorder
	• Documented failure, or intolerance to 3 formulary agents
	  ○ Selective Serotonin Reuptake Inhibitors, clomipramine, at adequate dose and duration (at least 4 weeks)
	Panic Disorder or Generalized Anxiety Disorder
		1 tablet/capsule per day
		
		<u>Pexeva</u>:
		10mg and 20mg:
		1 tablet per day
		30mg: 2 tablets per day
		40mg: 1.5 tablets per day
		
		<u>Fluoxetine Tablets (Sarafem)</u>:
		1 tablet per day
		
		<u>Fluvoxamine ER</u>:
		2 tablets per day
		
		<u>Fluoxetine weekly</u>:
		1 pack per 28 days
		
		<u>Paroxetine mesylate capsule</u>**:**
		1 tablet per day
		
		<u>Venlafaxine SR Tablets</u>:
		37.5mg, 75mg, and 225mg: 1 tablet per day
		150mg: 2 tablets per day
		
		<u>Nefazodone</u>:
		2 tablets/day; up to 600mg max daily dose

	• Documented failure, or intolerance to 3 formulary agents from at least 2 different classes of antidepressants
	  ○ Selective Serotonin Reuptake Inhibitors, or Serotonin Norepinephrine Reuptake Inhibitors, at adequate dose and duration (at least 4 weeks)
	Hot Flashes Associated with Menopause
	• Documented failure, or intolerance to 3 formulary agents from at least 2 different classes of antidepressants
	  ○ Selective Serotonin Reuptake Inhibitors, or Serotonin Norepinephrine Reuptake Inhibitors, at adequate dose and duration (at least 4 weeks)
	  ▪ Trial and failure, intolerance, or contraindication, or member preference to avoid hormonal therapy
	Premenstrual Dysphoric Disorder
	• Documented failure, or intolerance to 3 formulary Selective Serotonin Reuptake Inhibitors, at adequate dose and duration (at least 4 weeks)	

Anticoagulant - Injectable[iv]
 	
Low Molecular Weight Heparins:
 	
Enoxaparin
Fondaparinux
Fragmin
	Enoxaparin is the preferred medication AND will require prior authorization after exceeding recommended limit of 21 days' supply
	
	May be authorized for the following indications:
	• Prophylaxis for Venous Thromboembolism (VTE), Deep Vein Thrombosis (DVT), or Pulmonary Embolism (PE):
	  ○ In members undergoing hip or knee replacement or hip fracture surgery
	  ○ In members with restricted mobility during acute illness
	  ○ Bridge therapy for perioperative warfarin discontinuation
	  ○ In high-risk pregnancy
		<u>Initial Approval</u>:
		• Prophylaxis (post-ortho surgery) – Up to 35 days
		• Prophylaxis (non-ortho surgery and major trauma) – Up to 14 days
		• Prophylaxis (post-surgery with cancer) – 4 weeks
		• Venous thromboembolism (VTE) treatment, bridge therapy with warfarin – 10 days or as requested

	▪ For example, homozygous for factor V Leiden deficiency, prothrombin mutation 20210 or family history of venous thromboembolism (VTE) ○ In cancer members with solid tumors who are at high risk of thrombosis ▪ For example, previous venous thromboembolism (VTE), immobilization, hormonal therapy, angiogenesis inhibitors, thalidomide, or lenalidomide) ○ In members undergoing general and abdominal-pelvic surgery who are at moderate to high risk for venous thromboembolism (VTE) ○ In members with major trauma ▪ For example, traumatic brain injury (TBI) or Spinal Cord Injury ○ In members with atrial fibrillation undergoing cardioversion (up to 3 weeks before and 4 weeks after) • Treatment for Venous thromboembolism (VTE), deep vein thrombosis (DVT), or Pulmonary Embolism (PE): ○ After trial and failure of Eliquis or Xarelto and warfarin (in non-cancer patients for long-term treatment) ○ In members who are taking warfarin until international normalized ratio (INR) is in therapeutic range for 5 days ○ In high-risk pregnancy ○ For recurrent venous thromboembolism (VTE) that occurred while taking oral anticoagulants ○ For superficial vein thrombosis (SVT) of lower limb ○ For acute upper-extremity deep vein thrombosis (UEDVT) that involves axillary or more proximal veins **In addition, for all non-formulary agents**:	• Cardioversion with warfarin – up to 7 weeks • High risk pregnancy – Until 6 weeks after delivery (estimated date of confinement required for authorization) • Prophylaxis in cancer – 6 months • Lower-limb Superficial Vein Thrombosis (SVT) – 45 days • Venous thromboembolism (VTE) and cancer Low to moderate bleeding risk – indefinite; High bleeding risk – 3 months • Provoked venous thromboembolism (VTE) –3 months • Unprovoked venous thromboembolism (VTE) Low to moderate bleeding risk – indefinite; High bleeding risk – 3 months **Renewal Approval:** • Length of renewal authorization based on anticipated length of therapy, indication and/or recent

	• Documentation to support trial and failure, intolerance, or contraindication to enoxaparin	international normalized ratio (INR) if on warfarin
Anticoagulants - Oral[v] **<u>Preferred Agents</u>:** Xarelto Eliquis **<u>Non-Preferred Agents</u>:** Pradaxa Savaysa	**Xarelto and Eliquis are the formulary preferred agents, and may be authorized for members who meet all of the following:** • Age is 18 years or older • Diagnosis is for one of the following: o Prophylaxis of Deep Vein Thrombosis after hip or knee replacement surgery o Non-Valvular Atrial Fibrillation ▪ There is no moderate-to-severe mitral stenosis or mechanical heart valve ▪ Documentation of a CHA_2DS_2-VASc score of 1 or more (greater than or equal to 1 in males or greater than or equal to 2 in females) o Treatment of Deep Vein Thrombosis and Pulmonary Embolism o Risk reduction of recurrent Deep Vein Thrombosis or Pulmonary Embolism ▪ Received at least 6 months of standard anticoagulation treatment o <u>Xarelto only</u>: Prophylaxis of venous thromboembolism during and post-hospitalization in acute illness with high risk of thromboembolic complications and not at high risk of bleeding o <u>Xarelto only</u>: combination use with aspirin for risk reduction of cardiovascular events in chronic coronary artery disease or peripheral artery disease	**<u>Initial Approval:</u>**

	▪ Note: Includes those who have recently undergone a lower extremity revascularization due to symptomatic peripheral artery disease **In Addition, for All Non-Formulary Agents**: • Documentation to support trial and failure, intolerance, or contraindication to Xarelto or Eliquis **Pradaxa may be authorized for members who meet all of the following:** • Member is 18 years of age or older for prophylaxis of Deep Vein Thrombosis after hip or knee surgery or Non-Valvular Atrial Fibrillation ○ Note: requests for other diagnoses are approved for pediatric members • Diagnosis is for one of the following: ○ Prophylaxis of Deep Vein Thrombosis after hip or knee replacement surgery ○ Non-Valvular Atrial Fibrillation ▪ There is no moderate-to-severe mitral stenosis or mechanical heart valve ▪ Documentation of a CHA_2DS_2-VASc score of 1 or more (greater than or equal to 1 in males or greater than or equal to 2 in females) ○ Treatment of Deep Vein Thrombosis and Pulmonary Embolism ▪ Adults: Member received 5 – 10 days of initial therapy with parenteral anticoagulant ▪ Pediatrics: Member received 5 – 21 days of initial therapy with parenteral anticoagulant ○ Risk reduction of recurrent Deep Vein Thrombosis or Pulmonary Embolism	• Atrial fibrillation: 1 year • Knee replacement: ○ Up to 12 days from day of surgery • Hip replacement: ○ Up to 35 days from day of surgery • Treatment of Deep Vein Thrombosis or Pulmonary Embolism: ○ 3 months • Risk reduction of recurrent Deep Vein Thrombosis or Pulmonary Embolism: ○ 6 months • Xarelto for Venous Thromboembolism Prophylaxis for Acute illness: ○ Up to 39 days of total treatment • Xarelto for Coronary Artery Disease or Peripheral Artery Disease: ○ 3 months **<u>Renewal Approval:</u>**

	▪ Member has received at least 3 months of standard anticoagulation treatment **Savaysa may be authorized for members who meet all of the following:** • Age is 18 years or older • Diagnosis is for one of the following: ○ Non-valvular atrial fibrillation ▪ There is no moderate-to-severe mitral stenosis or mechanical heart valve ▪ Documentation of a CHA_2DS_2-VASc score of 1 or more (greater than or equal to 1 in males or greater than or equal to 2 in females) ▪ Creatinine clearance is less than 95 milliliters per minute ○ Treatment of Deep Vein Thrombosis and Pulmonary Embolism ▪ There was 5 – 10 days of initial therapy with parenteral anticoagulant	• Atrial fibrillation: ○ 1 year • Treatment of Deep Vein Thrombosis or Pulmonary Embolism: ○ 3 months • Risk reduction of recurrent Deep Vein Thrombosis or Pulmonary Embolism: ○ 6 months • American College of Chest Physicians (CHEST) recommends 3-month duration for most acute Venous Thromboembolism treatment • Xarelto for Coronary Artery Disease or Peripheral Artery Disease: ○ 6 months **<u>Quantity Level Limit:</u>** • Pradaxa: 2 caps per day for adults and 6 caps per day for pediatric members • Savaysa: 1 tablet per day • Eliquis: 2 tablets per day • Xarelto: 1 tablet per day

Last Update: 12.1.2020, 12.4.2020, 3.1.2021, 5.11.2021, 6.28.2021, 8.1.2021, 9.13.2021, 10.1.2021, 12.17.2021, 1.9.2022, 2.1.2022, 2.17.2022, 2.28.2022, 3.11.2022, 4.5.2022, 4.7.2022, 4.26.2022, 5.11.2022, 5.19.2022, 6.7.2022, 7.9.2022, 8.1.2022, 12.16.2022, 1.1.2023, 1.13.2023, 2.1.2023
,
Current Update: 2.10.2023

		• Xarelto for Coronary Artery Disease or Peripheral Artery Disease: 2 tablets per day •
Antihistamines[vi] Levocetirizine solution	**May be authorized when the following criteria is met:** • Member had a trial and failure with the amount of formulary alternatives required by the plan ○ Alternatives: Cetirizine, diphenhydramine, loratadine, fexofenadine, levocetirizine tablet NOTE: For members unable to swallow solid dosage forms, formulary agents such as, but not limited to, loratadine chewable tablet/dispersible tablet/syrup/solution, cetirizine solution, or diphenhydramine liquid/elixir are options	**Initial Approval:** 1 year **Renewal Approval:** 1 year ***Requires:*** Response to treatment

Balversa[vii]	**General Criteria:**
	• Must be prescribed by or in consultation with an oncologist
	• Member must be 18 years of age or older
	
	In addition, Balversa may be authorized when the following criteria are met:
	• Diagnosis of locally advanced or metastatic urothelial carcinoma
	• Presence of a susceptible fibroblast growth factor receptor (FGFR) gene alteration in FGFR2 or FGFR3 confirmed by a Food and Drug Administration- (FDA) approved test
	• Member meets one of the following:
	  ○ Disease has progressed during or following at least one line of prior platinum-containing chemotherapy
	  ○ Cisplatin ineligible and a checkpoint inhibitor (atezolizumab or pembrolizumab) was used as first-line therapy
		Initial Approval:
		1 year
		
		Renewal Approval:
		3 years
		
		Requires:
		Member has been on Balversa and does not show evidence of progressive disease while on therapy
		
		Quantity Level Limits
		• 3mg – 3 tablets per day
		• 4mg – 2 tablets per day
		• 5mg – 1 tablet per day

	• Monthly ophthalmologic exams will be completed for the first four months and every 3 months afterwards	

Bonjesta
 	
Doxylamine Succinate and Pyridoxine Hydrochloride
 	
(Diclegis)[viii]
	May be authorized when the following criteria are met:
	• Member is at least 18 years of age
	• Diagnosis of nausea and vomiting in pregnancy
	• Inadequate response or intolerable side effects to dietary and lifestyle changes
	  ○ For example, avoiding stimuli/triggers, avoiding spicy or fatty foods, eating frequent small meals, or inadequate response to ginger
	• Use of individual products (over the counter doxylamine and pyridoxine) as separate dosage forms has not achieved adequate treatment response
	  ○ Pyridoxine is available as a single agent and recommended dose 10-25mg orally every six to eight hours.
	  ○ Doxylamine is available as over the counter and as prescription products, with recommended dose as one-half 25mg over-the-counter tablet, or two chewable 5mg prescription tablets
		Initial Approval:
		3 months
		
		Renewal Approval:
		3 months
		
		Requires:
		• Documentation member is still pregnant and continues to have nausea and vomiting symptoms
		
		Quantity Level Limit:
		Diclegis or generic Doxylamine Succinate and Pyridoxine Hydrochloride:
		4 tablets per day
		
		Bonjesta:
		2 tablets per day

Aetna Better Health of Illinois
Prior Authorization Guidelines

Botulinum Toxins **Botox** **Myobloc** **Dysport** **Xeomin**	Botulinum Toxins 4th Qtr P&T Aetna Standa	

Cablivi[ix]	**Member meets all the following criteria:**
	• Age is 18 years or older
	• Medication is prescribed by, or in consultation with a hematologist
	• Diagnosis is for acquired thrombotic thrombocytopenic purpura (aTTP)
	• Diagnosis is confirmed by one of the following:
	  ○ Member has severe thrombocytopenia with microangiopathic hemolytic anemia (MAHA), confirmed by red blood cell fragmentation on peripheral blood smear
	  ▪ For example, schistocytes
	  ○ Testing shows ADAMTS13 activity levels of less than 10%
	• Medication will be given in combination with plasma exchange and immunosuppressive therapy
	  ○ For example, systemic glucocorticoids, rituximab
	• Cablivi will be discontinued if member experiences more than 2 recurrences of aTTP while on treatment with Cablivi
		Initial Approval:
		30 days
		
		Renewal Approval:
		28 days
		
		Requires:
		Additional therapy up to a maximum of 28 additional days will be considered when provider submits the following:
		• Documentation of remaining signs of persistent underlying disease
		  ○ For example, suppressed ADAMTS13 activity levels
		• Documentation date of prior episode and date of new episode
		• Medication will be given in combination with plasma exchange and immunosuppressive therapy
		  ○ For example, systemic glucocorticoids, rituximab

		• Member has not experienced more than 2 recurrences while on Cablivi **<u>Quantity Level Limit:</u>** Total treatment duration per episode is limited to 58 days beyond last therapeutic plasma exchange
Calcipotriene[x]	**Calcipotriene will pay at the point of sale without requiring a prior authorization for 2 months when the following criteria is met:** • Diagnosis of psoriasis ○ ICD-10 L40.0 through L40.9 **Prescriptions that do not pay at point of sale require prior authorization and may be authorized for members who meet the following criteria:** • Diagnosis of psoriasis	**<u>Initial Approval:</u>** 2 months **<u>Renewal Approval:</u>** 2 months ***Requires*:** Improvement in symptoms **<u>Quantity Level Limit</u>**: <u>Ointment, cream</u>: 120gm/30 days <u>Solution</u>: 60ml/30 days

Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonists[xi]	**Aimovig and Ajovy may be authorized when the following criteria are met:**
	• Member has a diagnosis of one of the following:
	  ○ Episodic Migraine
	  ○ Chronic Migraine
	• Attestation stating that no more than 2 agents will be used to prevent or reduce migraine frequency
		<u>Initial Approval:</u>
		3 months
		
		<u>Renewal Approval:</u>
		6 months
		
		Requires:

Aetna Better Health of Illinois
Prior Authorization Guidelines

Preferred Agents: Aimovig Ajovy Nurtec ODT Qulipta Ubrelvy **Non-Preferred Agents:** Emgality Ubrelvy Vyepti	• Aimovig 140mg monthly injection, requires trial and failure with the 70mg injection • Medication will not be used in combination with another Calcitonin Gene-Related Peptide Receptor (CGRP) antagonist, or with Botulinum toxin (Botox) **All other agents may be authorized when the following criteria are met:** • Request for Non-Preferred agent requires trial and failure of two preferred agents, where indicated • Prescribed by, or in consultation with neurologist for preventative treatment of migraines, treatment of acute migraines, or treatment of cluster headaches. • Age is 18 years or older • **Chronic Migraine** (Emgality, Vyepti): o Headache occurring on 15 or more days per month with at least 8 migraine days per month for more than 3 months • **Episodic Migraine** (Emgality, Qulipta, Nurtec ODT, Vyepti): o Headache occurring less than 15 days per month with 4 to 14 migraine days per month • For Chronic and Episodic migraines, there is documented inadequate response, or intolerable side effects, to at least two medications for migraine prophylaxis from two different classes, for at least 3 months: o Beta-Blockers: Propranolol, metoprolol, atenolol o Anticonvulsants: Valproic acid, or divalproex, topiramate o Antidepressants: Amitriptyline, venlafaxine o Angiotensin-Converting Enzyme Inhibitors (ACE-Is)/Angiotensin II	• Documentation of clinical response to treatment by reduction in migraine or headache days • Aimovig 140mg monthly injection requires trial and failure with the 70mg injection • Vyepti 300mg 90- day intravenous infusion requires trial and failure with the 100mg infusion • Medication will not be used in combination with another Calcitonin Gene-Related Peptide Receptor (CGRP) antagonist, or with Botulinum toxin (Botox) **Quantity Level Limits:** **Aimovig:** • 1mL per 30 days **Ajovy:** • 1.5mL per 30 days or 4.5mL per 90 days **Emgality for Cluster Headaches:** • 3mL for 1st 30 days then 1mL per 30 days **Emgality for Migraine Headaches:**

Last Update: 12.1.2020, 12.4.2020, 3.1.2021, 5.11.2021, 6.28.2021, 8.1.2021, 9.13.2021, 10.1.2021, 12.17.2021, 1.9.2022, 2.1.2022, 2.17.2022, 2.28.2022, 3.11.2022, 4.5.2022, 4.7.2022, 4.26.2022, 5.11.2022, 5.19.2022, 6.7.2022, 7.9.2022, 8.1.2022, 12.16.2022, 1.1.2023, 1.13.2023, 2.1.2023
,
Current Update: 2.10.2023

	○ Receptor Blockers (ARBs): Lisinopril, candesartan, losartan, valsartan ○ Calcium Channel Blockers: Diltiazem, nifedipine, nimodipine, verapamil • **Acute Migraine** (Ubrelvy): ○ Medication is for moderate or severe pain intensity ○ Documented inadequate response, or intolerable side effect, with at least two triptans, or member has a contraindication to triptan use ○ Ubrelvy: ▪ Member does not have End Stage Renal Disease (CrCl less than 15 mL/min) ▪ Member does not experience more than 8 migraine days per month • Acute Migraine (Nurtec ODT): ○ Member does not experience more than 15 migraine days per month ○ Member does not have End Stage Renal Disease (CrCl less than 15 mL/min or is on hemodialysis ○ Member does not have severe hepatic impairment (Child-Pugh class C) • **Episodic Cluster Headaches:** (Emgality) ○ Headaches occurring at maximum 8 attacks per day, or minimum one attack every other day ○ Trial and failure with verapamil for preventive treatment or sumatriptan (nasal or subcutaneous) for acute treatment • Vyepti 300mg 90-day intravenous infusion requires trial and failure with the 100mg intravenous infusion	• 2mL for 1st 30 days then 1mL per 30 days **Qulipta:** • 60mg per day **Nurtec ODT:** • 15 tablets per 30 days **Ubrelvy:** • 16 tablets per 30 days **Vyepti:** • 3mL per 90 days

Last Update: 12.1.2020, 12.4.2020, 3.1.2021, 5.11.2021, 6.28.2021, 8.1.2021, 9.13.2021, 10.1.2021, 12.17.2021, 1.9.2022, 2.1.2022, 2.17.2022, 2.28.2022, 3.11.2022, 4.5.2022, 4.7.2022, 4.26.2022, 5.11.2022, 5.19.2022, 6.7.2022, 7.9.2022, 8.1.2022, 12.16.2022, 1.1.2023, 1.13.2023, 2.1.2023
,
Current Update: 2.10.2023

	• Medication will not be used in combination with another Calcitonin Gene-Related Peptide Receptor (CGRP) antagonist, or with Botulinum toxin (Botox)	

Capecitabine (Xeloda)[xii]	**General Criteria:**
	• Prescribed by or in consultation with an oncologist
	• Member is 18 years of age or older
	In addition, capecitabine may be authorized when one of the following criteria is met:
	• Locally unresectable or metastatic colorectal cancer
	• Triple negative breast cancer (estrogen receptor, progesterone receptor, and HER2-negative) when there is residual disease after preoperative therapy with a taxane, an alkylator, and an anthracycline
	• Recurrent or metastatic breast cancer with one of the following:
	  ○ Human epidermal growth factor receptor 2 (HER2) negative alone or in combination with docetaxel
	  ○ Human epidermal growth factor receptor 2 (HER2) positive recurrent or metastatic breast cancer in combination with trastuzumab (Herceptin), lapatinib (Tykerb), or neratinib (Nerlynx)
	• Rectal cancer
	• Metastatic renal cell carcinoma (RCC) in combination with gemcitabine
	• Pancreatic adenocarcinoma and pancreatic neuroendocrine tumors (PNET) (Islet tumors)
	• Esophageal, esophagogastric junction or gastric cancers
	• Recurrent, unresectable, or metastatic head and neck cancer
	• Hepatobiliary cancers (extra/intra – hepatic cholangiocarcinoma and gallbladder cancer)
		Initial Approval:
		1 year
		
		Renewal Approval:
		3 years
		
		Requires:
		Clinically significant improvement or stabilization of disease state

	• Neuroendocrine tumors of lung and thymus • Poorly differentiated neuroendocrine carcinoma (PDNEC) • Occult primary tumors • Ovarian cancer • Penile cancer	

Celecoxib[xiii]	**Celecoxib pays at Point of Sale when one of the following Step Therapy criteria are met:**
	• Member has filled 3 oral formulary Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) in the previous 180 days
	• Member has filled one of the following in the previous 90 days:
	  ○ Proton Pump Inhibitor
	  ○ Histamine H2 Receptor Antagonist
	  ○ Prednisone
	  ○ Warfarin
	  ○ Xarelto
	  ○ Pradaxa
	  ○ Eliquis
	Prescriptions that do not pay at Point of Sale require prior authorization and may be authorized when one of the following criteria are met:
	• Member had previous history of Gastro-Intestinal bleed, or Peptic Ulcer Disease
	• Trial and failure of 3 formulary oral Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
	• Member had a trial with one of the following:
	  ○ Proton Pump Inhibitor
	  ○ Histamine H2 Receptor Antagonist
	  ○ Prednisone
	  ○ Warfarin
	  ○ Xarelto
	  ○ Pradaxa
		Initial and Renewal Approval:
		One Year
		
		Quantity Level Limit:
		50mg, 100mg, 200mg:
		60 capsules per 30 days
		400mg:
		30 capsules per 30 days

Aetna Better Health of Illinois
Prior Authorization Guidelines

	○ Eliquis	
Central Nervous System (CNS) Stimulants[xiv] Dexmethylphenidate caps ER bi-phasic Methylphenidate tab ER 24hr Methylphenidate caps ER bi-phasic Methylphenidate tablet chew Methylphenidate soln Evekeo Aptensio XR Daytrana Quillivant XR Methamphet-amine Dyanavel XR Mydayis Adhansia XR Jornay PM	**Authorization Guidelines for All Agents:** • Stimulant is prescribed within Food and Drug Administration (FDA) approved daily dosing guidelines • Member will be taking only one type of stimulant medication as therapy (methylphenidate or amphetamine-based drug) ○ A short-acting stimulant medication to be combined with a long-acting stimulant medication of the same drug type may be approved when there is documentation of the long-acting version not lasting for sufficient daily duration • Member meets criteria noted based on age • Member has adverse reaction or contraindication to all preferred agents that does not also exist for the requested non-preferred drug, **or** • Member has failed to respond to at least two formulary stimulants (one formulary stimulant from each of the stimulant subclasses) (for example, amphetamine/dextroamphetamine and methylphenidate/dexmethylphenidate). ○ Requests for non-preferred, extended-release product, require failure of extended-release formulation of the preferred agents ○ Requests for non-preferred, immediate release product, require failure of the immediate release formulation of the preferred agents **Additional Guidelines for Adults over 18:** • Member has diagnosis of Attention Deficit Hyperactivity Disorder/Attention Deficit Disorder (ADHD/ADD), narcolepsy, idiopathic hypersomnia, or fatigue related to cancer or multiple sclerosis	**Initial Approval:** • Attention Deficit Hyperactivity Disorder/Attention Deficit Disorder (ADHD/ADD) less than 6 years: 1 year • Attention Deficit Hyperactivity Disorder/Attention Deficit Disorder (ADHD/ADD) 6-18 years: Up to age 21 • Attention Deficit Hyperactivity Disorder/Attention Deficit Disorder (ADHD/ADD) greater than 18 years: 1 year • Narcolepsy, idiopathic hypersomnia, or fatigue related to cancer or multiple sclerosis: 1 year ***Renewal Approval:*** • Attention Deficit Hyperactivity Disorder/Attention Deficit Disorder (ADHD/ADD) less than 6 years: 1 year • Attention Deficit Hyperactivity Disorder/Attention Deficit Disorder (ADHD/ADD) 6-18 years: up to age 21 • Attention Deficit Hyperactivity Disorder/Attention Deficit

Last Update: 12.1.2020, 12.4.2020, 3.1.2021, 5.11.2021, 6.28.2021, 8.1.2021, 9.13.2021, 10.1.2021, 12.17.2021, 1.9.2022, 2.1.2022, 2.17.2022, 2.28.2022, 3.11.2022, 4.5.2022, 4.7.2022, 4.26.2022, 5.11.2022, 5.19.2022, 6.7.2022, 7.9.2022, 8.1.2022, 12.16.2022, 1.1.2023, 1.13.2023, 2.1.2023
,
Current Update: 2.10.2023

Aptensio XR
Contempla XR-ODT
	• In addition, members initiating stimulant for Attention Deficit Hyperactivity Disorder/Attention Deficit Disorder (ADHD/ADD) must meet the following:
	  ○ Attention Deficit Hyperactivity Disorder/Attention Deficit Disorder (ADHD/ADD) diagnosis is documented in medical record and is based on comprehensive evaluation by appropriate specialist, and includes evidence-based rating scale
	  ▪ For example, but not limited to Adult Self Report Scale V1.1 (ASRS V1.1).
	  ▪ The symptoms must also meet Diagnostic and Statistical Manual of Mental Disorders (DSM5) criteria
	  ○ Other conditions (such as depression, anxiety, conduct disorder or tics) have been ruled out or are being appropriately treated
	  ○ For members with history of substance abuse disorder, a urine drug screen is included in the treatment plan (does not require submission of results)
	Additional Guidelines for Children Ages 6-18:
	• Member has diagnosis of Attention Deficit Hyperactivity Disorder/Attention Deficit Disorder (ADHD/ADD), or narcolepsy
	• In addition, members initiating stimulant for of Attention Deficit Hyperactivity Disorder/Attention Deficit Disorder (ADHD/ADD) must meet the following:
	  ○ Attention Deficit Hyperactivity Disorder/Attention Deficit Disorder (ADHD/ADD) diagnosis is documented in medical record and is based on comprehensive evaluation by appropriate specialist or primary care provider.
	  ○ The evaluation must include an evidence-based rating scale
	  ▪ For example, but not limited to Swanson, Nolan, Pelham-IV Questionnaire (SNAP-IV)).
		Disorder (ADHD/ADD) greater than 18 years: 1 year
		• Narcolepsy, idiopathic hypersomnia, or fatigue related to cancer or multiple sclerosis: 1 year
		
		Renewal Requirements for Attention Deficit Hyperactivity Disorder/Attention Deficit Disorder (ADHD/ADD) and Narcolepsy:
		• Attestation of response to therapy
		• Attestation of member adherence to therapy

	▪ The symptoms must also meet Diagnostic and Statistical Manual of Mental Disorders (DSM5) criteria ○ Other conditions (such as depression, anxiety, conduct disorder or tics) have been ruled out or are being appropriately treated ○ For members with history of substance abuse disorder, a urine drug screen is included in the treatment plan (does not require submission of results) ○ Evidence-based behavioral therapy (child, teacher, and/or caregiver) has been considered as part of treatment plan. The therapy can be ongoing, previously completed or noted as not appropriate or necessary in this case **Additional Guidelines for Children Ages 5 years and Under:** • Member continues to have Attention Deficit Hyperactivity Disorder/Attention Deficit Disorder (ADHD/ADD) symptoms despite evidence-based parent and/or teacher-administered behavior therapy • Requests for use in children ages 5 and under are generally not considered to be medically necessary, since many stimulant medications are not Food and Drug Administration (FDA) approved for use in this age group • Safety and efficacy in this age group has not been established and is not supported by the currently published peer-reviewed medical literature **Additional Guidelines for Non-Preferred Agents:** • Member meets criteria noted above based on age • Member has adverse reaction or contraindication to all preferred agents that does not also exist for the requested non-preferred drug, **or**	

	• Member has failed to respond to at least two formulary stimulants (one formulary stimulant from each of the stimulant subclasses) (for example, amphetamine/dextroamphetamine and methylphenidate/ dexmethylphenidate). ○ Requests for a non-preferred, extended-release product, require failure of extended-release formulation of the preferred agents • Requests for a non-preferred, immediate release product, require failure of the immediate release formulation of the preferred agents	

Cinacalcet[xv] **(Sensipar)**	**Secondary Hyperparathyroidism due to Chronic Kidney Disease on Dialysis:**
	• Member is at least 18 years of age
	• Serum calcium greater than or equal to 8.4mg/dL, prior to initiation of therapy
	• Intact parathyroid hormone (iPTH) greater than or equal to 300pg/mL, prior to initiation of therapy
	• Inadequate response or intolerable side effect to at least one type of phosphate binder
	• Member meets one of the following criteria:
	  ○ Inadequate response or intolerable side effect to calcitriol or paricalcitol
	  ○ Serum phosphate greater than or equal to 5.5mg/dL, or serum calcium greater than or equal to 9.5mg/dL, and there is persistently elevated parathyroid hormone (PTH), despite maximum therapies to decrease phosphate
	Parathyroid Cancer:
	• Member is at least 18 years of age
	• Serum calcium is greater than or equal to 12.5mg/dL, prior to initiation of therapy
	Primary Hyperparathyroidism:
		Initial Approval:
		6 months
		
		Renewal Approval:
		1 year
		Requires:
		Serum Calcium 8.4-12.5mg/dL
		
		Dosing information:
		• Dialysis member with secondary hyperparathyroidism: Up to 300 mg/day
		• Hypercalcemia associated with parathyroid carcinoma or primary hyperparathyroidism: Up to 360 mg/day

Aetna Better Health of Illinois
Prior Authorization Guidelines

	• Member is at least 18 years of age • Member is not a candidate for parathyroidectomy • Serum calcium greater than or equal to 12.5mg/dL, prior to initiation of therapy	
Colony Stimulating Factors	4th Quarter P&T Illinois Specific Colony	

Continuous Glucose Monitoring[xvi]
 	
Dexcom G6
 	
FreeStyle Libre
	Criteria to Receive Formulary Continuous Glucose Monitoring System (FreeStyle Libre, Dexcom):
	• Member meets all the following:
	  ○ Prescribed by, or in consultation with endocrinologist
	  ○ Diagnosis of Type 1 or Type 2 Diabetes
	  ○ Age is appropriate for prescribed Continuous Glucose Monitor
	  ▪ Dexcom: Age is at least 2 years
	  ▪ Freestyle Libre 10 & 14 day: Age is at least 18 years
	  ▪ Freestyle Libre 2: Age is at least 4 years
	  ○ Currently on an insulin pump or requires multiple daily insulin injections (2 or more per day)
	  ○ Compliance with self-monitoring along with *one* of the following:
	  ▪ Monitoring blood glucose 4 or more times per day with frequent self-adjustments of insulin dosage
	  ▪ History of hypoglycemic unawareness
	  ○ Attestation member completed a comprehensive diabetes education program
	
	Criteria to receive another Continuous Glucose Monitoring system
	• Member meets all the following:
	  ○ Current monitor is not functionally operating
	  ○ Current monitor is out of warranty
		Initial Approval for Continuous Glucose Monitoring:
		Six months
		• Readers:
		  ○ FreeStyle Libre 10, FreeStyle Libre 14 & FreeStyle Libre 2
		  ▪ 1 reader per year
		• Sensors:
		  ○ Freestyle Libre 14 day & Freestyle Libre 2:
		  ▪ 2 sensors per 28 days
		  ○ Freestyle Libre 10
		  ▪ 3 sensors per 30 days
		  ○ Dexcom G6:
		  ▪ 3 sensors per 30 days
		• Transmitters:
		  ○ Dexcom G6:
		  ○ 1 transmitter per 90 days
		
		Renewal Approval for Continuous Glucose Monitoring:
		6 months

Last Update: 12.1.2020, 12.4.2020, 3.1.2021, 5.11.2021, 6.28.2021, 8.1.2021, 9.13.2021, 10.1.2021, 12.17.2021, 1.9.2022, 2.1.2022, 2.17.2022, 2.28.2022, 3.11.2022, 4.5.2022, 4.7.2022, 4.26.2022, 5.11.2022, 5.19.2022, 6.7.2022, 7.9.2022, 8.1.2022, 12.16.2022, 1.1.2023, 1.13.2023, 2.1.2023
,
Current Update: 2.10.2023

	NOTE: Requests for all other CGM products besides the preferred Dexcom and Freestyle Libre are to go through the medical benefit.	***Requires:***
		Documentation of continued medical necessity
		• Readers:
		  ○ FreeStyle Libre 10, FreeStyle Libre 14 & FreeStyle Libre 2
		  ▪ 1 reader per year
		• Sensors:
		  ○ Freestyle Libre 14 day & Freestyle Libre 2:
		  ▪ 2 sensors per 28 days
		  ○ Freestyle Libre 10
		  ▪ 3 sensors per 30 days
		  ○ Dexcom G6:
		  ▪ 3 sensors per 30 days
		• Transmitters:
		  ○ Dexcom G6:
		  ▪ 1 transmitter per 90 days

Corlanor[xvii]	**May be authorized for members 18 years of age or older when the following criteria are met:** • Diagnosis of stable symptomatic chronic heart failure (New York Heart Association (NYHA) Class II-III) • Left ventricular ejection fraction (LVEF) is less than or equal to 35% • Member is in sinus rhythm with a resting heart rate greater than or equal to 70 beats per minute • Continuation of therapy with maximally tolerated beta-blocker, or there is intolerance or contraindication to beta-blockers	**Initial Approval:** 6 months **Renewal Approval:** 1 year ***Requires:*** • Member is responding to treatment • Heart rate is within

	• Continuation of therapy with angiotensin-converting-enzyme inhibitor (ACEI)/Angiotensin Receptor Blockers (ARB), or Entresto, or there is intolerance, or contraindication to angiotensin-converting-enzyme inhibitor (ACEI)/Angiotensin Receptor Blockers (ARB), or Entresto
	  ○ Note: Entresto requires Prior Authorization
	• Provider attestation that no contraindications to treatment exist:
	  ○ Acute decompensated heart failure
	  ○ Blood pressure less than 90/50 mmHg
	  ○ Pacemaker dependent (for example: heart rate maintained exclusively by pacemaker)
	  ○ Sick sinus syndrome, sinoatrial block of third-degree AV block (unless functioning demand pacemaker is present)
	  ○ Severe hepatic impairment (Child-Pugh class C)
	
	May be authorized for pediatric members 6 months of age or older when the following criteria are met:
	• Diagnosis of heart failure due to dilated cardiomyopathy
	• Member is in sinus rhythm with a resting heart rate of greater than or equal to 70 beats per minute
	• Provider attestation that no contraindications to treatment exist:
	  ○ Acute decompensated heart failure
	  ○ Blood pressure less than 90/50 mmHg
	  ○ Pacemaker dependent (for example, heart rate maintained exclusively by pacemaker)
	  ○ Sick sinus syndrome, sinoatrial block of third-degree AV block (unless functioning demand pacemaker is present)
	  ○ Severe hepatic impairment (Child-Pugh class C)
		recommended range for continuation of maintenance dose
		  ▪ For example, 50-60 beats per minute, or dose adjusted accordingly to achieve goal
		
		<u>Quantity Level Limit</u>:
		○ Adults and Pediatrics: 60 tablets per 30 days
		○ Oral solution for pediatrics: 120 ampules per 30 days

Aetna Better Health of Illinois
Prior Authorization Guidelines

Cystic Fibrosis (pulmonary) Medications[xviii] Tobramycin Nebulizer Tobi Podhaler Bethkis Cayston Kalydeco Orkambi Symdeko Trikafta	**Medical Records required for all Cystic Fibrosis Medications** **Tobramycin Nebulizer Solution (generic for Tobi), Tobi Podhaler, or Bethkis, may be authorized when the following are met:** • Diagnosis is for Cystic Fibrosis • Member is at least 6 years of age • Forced Expiratory Volume in one second (FEV_1) is between 25-80% predicted • Sputum cultures are positive for *P.aeruginosa.* • Member is not colonized with *Burkholderia cepacia* **Tobramycin Nebulizer Solution (generic for Tobi), Tobi Podhaler or Bethkis may be authorized for non-cystic fibrosis bronchiectasis when the following are met** • Sputum cultures or chart notes document presence of pseudomonas aeruginosa • Member has tried formulary alternatives (for example, ciprofloxacin, sulfamethoxazole/trimethoprim), or formulary alternatives are contraindicated for non-cystic fibrosis bronchiectasis **Cayston may be authorized when the following are met:** • Diagnosis is for Cystic Fibrosis • Member is at least 7 years of age • Forced expiratory volume in one second (FEV_1) is between 25-75% predicted • Sputum cultures are positive for *P.aeruginosa.* • Member is not colonized with *Burkholderia cepacia* • There was inadequate response, or intolerable side effect with 2 different formulary tobramycin nebulizer solution products, or sputum cultures show resistance to tobramycin **Kalydeco can be recommended for approval when the following are met:**	**Initial Approval:** Kalydeco, Symdeko and Orkambi, Trikafta: 3 months **Non-cystic fibrosis bronchiectasis:** Tobramycin nebulizer solution, Tobi Podhaler, Bethkis: 12 months All others: Indefinite **Renewal Approval:** Kalydeco, Symdeko, Orkambi, Trikafta: 12 months ***Requires:*** • Documentation to support response to therapy (symptom improvement and/or stable Forced Expiratory Volume in one second (FEV_1)) • Pediatric members: Eye exam due to the possible development of cataracts. • Member is not concurrently receiving another Cystic Fibrosis Transmembrane

Last Update: 12.1.2020, 12.4.2020, 3.1.2021, 5.11.2021, 6.28.2021, 8.1.2021, 9.13.2021, 10.1.2021, 12.17.2021, 1.9.2022, 2.1.2022, 2.17.2022, 2.28.2022, 3.11.2022, 4.5.2022, 4.7.2022, 4.26.2022, 5.11.2022, 5.19.2022, 6.7.2022, 7.9.2022, 8.1.2022, 12.16.2022, 1.1.2023, 1.13.2023, 2.1.2023
,
Current Update: 2.10.2023

	• Prescribed by, or in consultation with, a pulmonologist • Diagnosis is for Cystic Fibrosis • Member is at least 4 months of age • Lab results to support member has at least one mutation in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene that is responsive to Kalydeco • Member is not homozygous for the Phe*508del* mutation in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene • For pediatric members, an eye examination is required at baseline and periodically throughout therapy • Member is not concurrently receiving another Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) agent • Transaminase (Aminotransferase (ALT), Aspartate Aminotransferase (AST)) monitoring, and Liver Function Tests (LFTs) have been evaluated, and dose reduced, for members with moderate to severe hepatic impairment • For members taking a moderate or strong CYP3A inhibitor, reduce the Kalydeco dose ○ Fluconazole, erythromycin, ketoconazole, itraconazole, posaconazole, voriconazole, telithromycin, clarithromycin **Orkambi can be recommended for approval when the following are met:** • Prescribed by, or in consultation with pulmonologist • Diagnosis is for Cystic Fibrosis • Member is at least 2 years of age • Lab results to support member is homozygous for the F508del mutation in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene	Conductance Regulator (CFTR) agent • Transaminase (Aminotransferase (ALT), Aspartate Aminotransferase (AST)) monitoring • Liver Function Tests (LFTs): Temporarily discontinue if Alanine Aminotransferase (ALT)/Aspartate Aminotransferase (AST) are greater than 5 times upper limit of normal (ULN), or Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) is greater than3 times the upper limit of normal (ULN) with bilirubin greater than 2 times upper limit of normal (ULN) **<u>Non-cystic fibrosis bronchiectasis</u>** - Tobramycin nebulizer solution, Tobi Podhaler, Bethkis: 12 months ***Requires*:** Documentation to support response to therapy

	• For pediatric members, an eye examination is required at baseline and periodically throughout therapy.
	• Member is not concurrently receiving another Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) agent
	• Transaminase (Aminotransferase (ALT), Aspartate Aminotransferase (AST)) monitoring at baseline, and Liver Function Tests (LFTs) have been evaluated, and dose reduced for members with moderate to severe hepatic impairment
	• For members initiating Orkambi and are currently taking a strong Cytochrome P450, family 3, subfamily A (CYP3A) inhibitor, reduce the Orkambi dose
	  ○ Ketoconazole, itraconazole, posaconazole, voriconazole, telithromycin, and clarithromycin
	Symdeko can be recommended for approval when the following are met:
	• Prescribed by, or in consultation with pulmonologist
	• Diagnosis is for Cystic Fibrosis
	• Member is at least 6 years of age
	• Lab results to support one of the following:
	  ○ Member is homozygous for the F508del mutation in the Cystic Fibrosis Transmembrane Regulator (CFTR) gene
	  ○ Member has at least one mutation in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene that is responsive to Symdeko
	• For members who are homozygous for the F508del mutation in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene, there was inadequate response, or intolerable side effect with Orkambi
	• For pediatric members, an eye examination is required at baseline and periodically throughout therapy
		Quantity Level Limits:
		• Tobramycin:
		56 ampules per 56 days (28 days of therapy followed by 28 days off)
		• Cayston:
		84 ampules per 56 days (28 days of therapy followed by 28 days off)
		• Kalydeco:
		56 tablets per 28 days
		• Orkambi:
		112 tablets per 28 days
		• Symdeko:
		56 tablets per 28 days
		• Trikafta:
		84 tablets per 28 days

Last Update: 12.1.2020, 12.4.2020, 3.1.2021, 5.11.2021, 6.28.2021, 8.1.2021, 9.13.2021, 10.1.2021, 12.17.2021, 1.9.2022, 2.1.2022, 2.17.2022, 2.28.2022, 3.11.2022, 4.5.2022, 4.7.2022, 4.26.2022, 5.11.2022, 5.19.2022, 6.7.2022, 7.9.2022, 8.1.2022, 12.16.2022, 1.1.2023, 1.13.2023, 2.1.2023
,
Current Update: 2.10.2023

	• Member is not concurrently receiving another Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) agent
	• Transaminase (Aminotransferase (ALT), Aspartate Aminotransferase (AST)) monitoring at baseline, and Liver Function Tests (LFTs) have been evaluated, and dose reduced for members with moderate to severe hepatic impairment
	• For members taking a moderate to strong Cytochrome P450, family 3, subfamily A (CYP3A) inhibitor, reduce the Symdeko dose
	  ○ Fluconazole, erythromycin, ketoconazole, itraconazole, posaconazole, voriconazole, telithromycin, clarithromycin
	Trikafta can be recommended for approval when the following are met:
	• Prescribed by, or in consultation with pulmonologist
	• Diagnosis is for Cystic Fibrosis
	• Pretreatment forced expiratory volume (FEV_1)
	• Member is at least 6 years of age
	• Lab results to support one of the following:
	  ○ Member has at least one F508del mutation in the Cystic Fibrosis Transmembrane Regulator (CFTR) gene
	  ○ Member has at least one mutation in the Cystic Fibrosis Transmembrane Regulator (CFTR) gene that is responsive to Trikafta
	• For members who are homozygous for the F508del mutation in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene, there was inadequate response, or intolerable side effect with Orkambi
	• For pediatric members, an eye examination is required at baseline and periodically throughout therapy
	• Member is not concurrently receiving another Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) agent	

	• Transaminase (Aminotransferase (ALT), Aspartate Aminotransferase (AST)) monitoring at baseline, and Liver Function Tests (LFTs) have been evaluated, and dose reduced for members with moderate to severe hepatic impairment • For members taking a moderate to strong Cytochrome P450, family 3, subfamily A (CYP3A) inhibitor, reduce the Trikafta dose ○ Fluconazole, erythromycin, ketoconazole, itraconazole, posaconazole, voriconazole, telithromycin, clarithromycin	
Cytokines CAM Antagonist	Cytokine CAM Antagonists IL Guideli	

Dalfampridine (Ampyra)[xix]	**May be approved when documentation of the following criteria is presented:**
	• Prescribed by, or in consultation with, a neurologist
	• Member is 18 years of age or older
	• Diagnosis of multiple sclerosis with one of the following:
	  ○ Impaired walking ability defined as a baseline 25-foot walking test between 8 and 45 seconds
	  ○ Expanded Disability Status Scale between 4.5 and 6.5
	• Member is not wheelchair-bound
	• Does not have a history of seizures
	• Member has not had disease exacerbation in the previous 60 days
	• Does not have moderate to severe renal impairment (Creatinine Clearance less than 50 mL/min)
		Initial Approval:
		3 months
		
		Renewal Approval:
		1 year
		
		Requires:
		• Member meets one of the following criteria:
		  ○ There is improvement in timed walking speed on 25-foot walk
		  ○ There is stability or improvement in Expanded Disability Status Scale score
		• Member does not have moderate to severe renal

		impairment (creatinine clearance less than 50 mL/min) **Quantity Level Limit:** 2 tablets per day

Direct Renin Inhibitors[xx]
 	
Aliskiren (Tekturna)
Tekturna HCT
	○ Member is 6 years of age or older
	○ Diagnosis of hypertension
	○ For oral pellets:
	  ○ Member is unable to swallow tablets
	○ There was inadequate response, or inability to tolerate at least 2 formulary antihypertensive agents from any of the following therapeutic classes:
	  ○ Thiazide-type diuretic
	  ○ Calcium Channel Blocker
	  ○ Angiotensin-converting-enzyme (ACE) Inhibitor
	  ○ Angiotensin receptor blocker (ARB)
	  ○ Member is not pregnant
		Initial Approval:
		6 months
		
		Renewal Approval:
		6 months
		
		***Requires*:**
		• Positive response to treatment
		• Member is not pregnant

Dupixent[xxi]	**For Moderate to Severe Atopic Dermatitis, may be authorized when all of the following is met:** • Member is 6 months or older • There was an inadequate response or intolerable side effects to all of the following: ○ One preferred (medium to very high potency) topical corticosteroids (for example triamcinolone, clobetasol, mometasone, betamethasone, fluocinonide), or one preferred low potency topical corticosteroid, for sensitive areas, such as the face	**Initial Approval:** 6 months **Renewal Approval:** 12 months ***Requires:*** **Atopic Dermatitis:** Physician attestation to response to therapy

	○ Generic immunosuppressant if appropriate; OR topical calcineurin inhibitors OR phototherapy, OR phosphodiesterase 4 inhibitor **Moderate to Severe Asthma may be authorized when all of the following is met:** • Documented diagnosis of moderate to severe asthma with one of the following (submission of medical records required): ○ Eosinophilic phenotype, with pretreatment eosinophil count greater than or equal to 150/microliter and 1 exacerbation (Oral Corticosteroid burst, ER visit, hospital, office visit) ○ Corticosteroid dependent asthma ○ Member meets both of the following: ▪ A baseline Forced Expiratory Volume (FEV1) that is less than 80% predicted for adults and less than 90% for adolescents ▪ Compliant with medium or high dose Inhaled Corticosteroid (ICS) and one controller (for example, Long Acing Bea Agonis (LABA) or Long-Acting Muscarinic Antagonist (LAMA)) • Prescribed by, or in consultation with a pulmonologist, allergist, or immunologist **Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP) may be authorized when all of the following is met:** • Documented diagnosis of chronic rhinosinusitis with nasal polyposis • Prescribed by, or in consultation with an allergist, pulmonologist, or otolaryngologist (ENT) • Member's condition has been inadequately controlled by two of the following:	**Asthma of Eosinophilic Phenotype:** • Response to therapy (for example, by a decrease in exacerbations from baseline, improvement in Forced Expiratory Volume in less than one second (FEV1) from baseline, etc.) **Corticosteroid Dependent Asthma:** • Response to therapy (for example, by a decrease in dose of oral steroids from baseline, a decrease in exacerbations from baseline, improvement in Forced Expiratory Volume in less than one second (FEV1) from baseline, etc.) **Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)** • Response to therapy (for example, by a decrease in the bilateral endoscopic nasal polyps score (NPS) or nasal congestion/obstruction score (NC) from baseline) **Eosinophilic Esophagitis (EoE)** • Physician attestation to response to therapy

	○ Systemic corticosteroids, intranasal corticosteroids, budesonide nebulizer solution, and/or sinus surgery following intranasal corticosteroids **Eosinophilic Esophagitis (EoE) may be authorized when all of the following are met:** • Member is 12 years of age or older • Weight is at least 40 kg • Eosinophilic Esophagitis diagnosis is confirmed by endoscopic esophageal biopsy showing the presence of eosinophils (≥ 15 eosinophils per high-power field) • There was a failure, intolerance, or contraindication to both of the following: ○ 8 weeks of use with Proton Pump Inhibitors (esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole) ○ Topical glucocorticoids (fluticasone using a Metered Dose Inhaler without a spacer or budesonide administered as an oral slurry)	
Egrifta[xxii]	• Diagnosis of human immunodeficiency virus (HIV)-associated lipodystrophy • Documentation of waist circumference greater than or equal to 95 cm for males, or greater than or equal to 94 cm for females at start of therapy • Member is currently receiving anti-retroviral therapy • Baseline evaluation within the past 3 months of the following: ○ Hemoglobin A1c (HbA1c) ○ Insulin-like growth factor 1 (IGF-1) • Attestation Hemoglobin A1c (HbA1c) will be monitored every 3 to 4 months • Member is at risk for medical complications due to excess abdominal fat	**Initial Approval:** 6 months **Renewal Approval:** 6 months ***Requires*:** Documentation of a positive clinical response: • Hemoglobin A1c (HbA1c) within normal range (for the lab)

	• Member does not have active malignancy • Member does not have disruption of the hypothalamic-pituitary gland axis or head trauma • Women of childbearing age are not pregnant and are using appropriate contraception	• Insulin-like growth factor 1 (IGF-1) within normal range (for the lab) • Decrease in waist circumference

Emflaza[xxiii]	**May be approved when all the following criteria are met:**
	• Prescribed by or in consultation with a neurologist
	• Member is 2 years of age or older
	• Documentation indicating diagnosis is for Duchenne Muscular Dystrophy (DMD) and is confirmed by one of the following:
	  ○ Genetic testing demonstrating a mutation in the dystrophin gene
	  ○ Muscle biopsy evidence of total absence of dystrophin or abnormal dystrophin
	• Serum creatine kinase (CK) at least 10 times the upper limit of normal
	• Documentation member had a trial of prednisone for at least 6 months with unmanageable and clinically significant weight gain/obesity or psychiatric/behavioral issues (for example abnormal behavior, aggression, or irritability)
	• Documentation of baseline motor milestone scores by one of the following assessments:
	  ○ 6-minute walk test (6MWT)
	  ○ North Star Ambulatory Assessment (NSAA)
	  ○ Motor Function Measure (MFM)
	  ○ Hammersmith Functional Motor Scale (HFMS)
	• Attestation of all the following:
	  ○ Emflaza will not be given concurrently with live vaccinations
	  ○ Member does not currently have an active infection (including Hepatitis B Virus (HBV))
		Approval Duration:
		Indefinite
		
		○

	• For members with history of Hepatitis B Virus (HBV) infection, prescriber agrees to monitor for Hepatitis B Virus (HBV) reinfection	
Epidiolex[xxiv]	**May be authorized when the following criteria are met:** • Member is at least 1 years of age • Prescribed by, or in consultation with a neurologist • Medication will be taken as adjunctive therapy to at least one other antiepileptic drug • Attestation that serum transaminases and total bilirubin levels have been obtained prior to initiation and will be taken periodically as appropriate (per Food and Drug Administration (FDA) approved labeling) • Dose must be appropriate for member's liver function and should not exceed 20mg/kg/day • **For Lennox-Gastaut syndrome:** o Documentation member has tried and failed or has intolerance or contraindication to Onfi® (clobazam) and two of the following: ▪ Valproic acid, topiramate, lamotrigine, and/or felbamate • **For Dravet syndrome:** o Documentation member has tried and failed or has intolerance or contraindication to Onfi® (clobazam), valproic acid, and one of the following: ▪ Topiramate, levetiracetam, zonisamide, lamotrigine, or felbamate • **For seizures associated with tuberous sclerosis complex:** o Documentation member has tried and failed or has intolerance or contraindication any two antiepileptic agents *Note zonisamide and lamotrigine are not generally recommended in Dravet Syndrome treatment but will be recognized as previous therapy trials should they have been previously used.	**Initial Approval:** 6 months **Renewal Approval:** 1 year ***Requires*:** • Member has had decrease in seizure frequency from baseline • Serum transaminase level has not been greater than 3 times the upper limit of normal (ULN) while accompanied by bilirubin greater than 2 times the ULN • Serum transaminase level has not been sustained at greater than 5 times the upper limit of normal (ULN) **Quantity Level Limit:** • Lennox-Gastaut Syndrome and Dravet Syndrome: 20 mg/kg/day • Tuberous Sclerosis Complex: 25 mg/kg/day

Aetna Better Health of Illinois
Prior Authorization Guidelines

		All requests require current weight to confirm correct dose not being exceeded

Erythromycin Ethylsuccinate Suspension [xxv]	**May be authorized when one of the following criteria is met:**
	• Member has diagnosis of gastroparesis characterized by delayed gastric emptying
	  ○ There is no presence of mechanical obstruction
	  ○ There was Inadequate response, intolerable side effect, or contraindication to metoclopramide
	• Member has bacterial infection other than gastroparesis
	• There was inadequate response, intolerable side effect, or contraindication to both azithromycin and clarithromycin
		Initial Approval:
		• Gastroparesis:
		  ○ 4 weeks
		• Bacterial infections:
		  ○ Requested duration of therapy
		
		Renewal Approval:
		4 weeks
		
		Requires:
		• Continued improvement in symptoms from baseline
		• Member tolerates oral feeding

Erythropoiesis Stimulating Agents (ESAs)[xxvi] **Preferred Agents:** Epogen Procrit **Non-Preferred Agents:** Retacrit Aranesp	**Preferred Agents:** • Epogen and Procrit are the preferred Erythropoiesis Stimulating Agents (ESA). **Non-Preferred Agents:** • Requests for Aranesp, Retacrit and Mircera require trial and failure of Epogen and Procrit. **General Authorization Guidelines for All Indications:** • Member does not have uncontrolled hypertension • Member has adequate iron stores to support erythropoiesis demonstrated by one of the following: ○ Serum ferritin greater than or equal to 100 ng/mL, and transferrin saturation (iron saturation) greater than or equal to	**Initial Approval:** • Perioperative: Up to 21 days of therapy per surgery • All other indications: 3 months **Renewal Approval:** 3 months ***Requires:*** • Follow up iron studies showing member has adequate iron to

Mircera	20% ○ Reticulocyte hemoglobin content (CHr) greater than 29 pg **Additional Criteria Based on Indication:** **Anemia due to Chronic Kidney Disease** • Hemoglobin less than 10 g/dL within the last 2 weeks **Anemia due to Cancer Chemotherapy** (Procrit, Epogen, Retacrit, Aranesp) • Prescribed by, or in consultation with, an oncologist or hematologist • Anemia is because of concomitant myelosuppressive chemotherapy • Diagnosis of non-myeloid malignancy (for example, solid tumor) and expected outcome is not cure • There is a minimum of two additional months of planned chemotherapy • Hemoglobin less than 10 g/dL within the last 2 weeks **Anemia in Members with Human Immunodeficiency Virus receiving zidovudine** (Procrit, Epogen, Retacrit) • Zidovudine dose less than or equal to 4200 mg/week • Endogenous erythropoietin levels ≤ 500 IU/L • Hemoglobin <10 g/dL within the last 2 weeks **Reducing transfusions in members undergoing elective, non-cardiac, nonvascular surgery** (Procrit, Epogen, Retacrit) • Hemoglobin greater than 10 g/dL, and less than or equal to 13 g/dL within 30 days prior to planned surgery date • Member is at high risk for perioperative blood loss • Member is unable or unwilling to donate autologous blood preoperatively	support erythropoiesis Anemia due to Chronic Kidney Disease: ○ Adults: Hemoglobin less than 11 g/dL for those on dialysis, or less than 10g/dL for those not on dialysis within the last 2 weeks ○ Pediatrics: Hemoglobin less than 12 g/dL in the last 2 weeks • Anemia due to cancer chemotherapy, or member with Human Immunodeficiency Virus: ○ Hemoglobin less than 11 g/dL within the last 2 weeks • Anemia due to Myelodysplastic Syndrome: ○ Hemoglobin less than 12 g/dL in the last 2 weeks

	Anemia associated with Myelodysplastic Syndrome (Procrit, Epogen, Retacrit, Aranesp) • Prescribed by, or in consultation with, an oncologist or hematologist • Recent endogenous erythropoietin level less than or equal to 500 IU/L • Hemoglobin less than 10 g/dL within the last 2 weeks **Anemia in member receiving Hepatitis C treatment** (Procrit, Epogen, Retacrit) • Member is receiving combination therapy with ribavirin and interferon alpha • Hemoglobin less than 12 g/dL within the last 2 weeks	

Entresto[xxvii]	**May be approved when the following criteria are met:**
	• Diagnosis of heart failure and member meets one of the following:
	  ○ 18 years of age and older with chronic heart failure
	  ○ 1 year or older with symptomatic heart failure and systemic left ventricular systolic dysfunction
	• For members 1 year or older with symptomatic heart failure and systemic left ventricular systolic dysfunction:
	  ○ Member has tried and failed enalapril
	• Member is not pregnant
	• Attestation that Entresto will not be used concomitantly or within 36 hours of the last dose of an angiotensin-converting-enzyme inhibitor (ACEI), or a medication containing aliskiren (For example Tekturna or Tekturna-hydrochlorothiazide)
	• Attestation member does not have:
	  ○ Severe hepatic impairment (Child Pugh Class C)
	  ○ History of angioedema
		Initial Approval:
		One year
		
		Renewal Approval:
		One year
		
		Requires:
		• Response to treatment
		• Claims history review to verify use in conjunction with other heart failure therapies (For example beta blockers, aldosterone antagonist, and combination therapy with hydralazine and isosorbide dinitrate) for members 18 or older with heart failure
		• Member is not pregnant

		Quantity Level Limit: • 24/26mg: 6 tablets per day (pediatric members only) • Other strengths: 2 tablets per day

Eucrisa[xxviii]	**May be authorized when all of the following criteria is met:**
	• Member is at least 3 months of age
	• Diagnosis of mild to moderate atopic dermatitis
	• For members 3 months to less than 2 years of age, there was inadequate response or intolerable side effects to all the following:
	  ○ Attestation that non-drug therapies have been attempted to manage condition
	  ▪ For example, maintaining skin hydration, avoiding irritants, minimizing triggers, and appropriate lubrication of the skin
	  ○ One preferred topical corticosteroids of any potency
	• For members 2 years of age and older, there was inadequate response, intolerable side effects to all the following:
	  ○ One preferred medium or low potency topical corticosteroids
	  ○ One preferred topical calcineurin inhibitor such as tacrolimus
		Initial Approval:
		6 months
		
		Renewal Approval:
		12 months
		
		Requires:
		• Response to therapy as evidenced by improvement in any of the following signs and symptoms:
		  ○ Erythema (redness)
		  ○ Exudation (oozing and crusting)
		  ○ Excoriation (scratching)
		  ○ Induration (hardening)/papulation (formation of papules)
		  ○ Lichenification (epidermal thickening)
		  ○ Pruritus (itching)
		
		Quantity Level Limit:
		• 60 gm tube per month
		• 100 gm tube per month

Aetna Better Health of Illinois
Prior Authorization Guidelines

Evrysdi[xxix]	**May be authorized when documentation is presented to meet all the following criteria:**
	• Treatment is for Spinal Muscular Atrophy in member that is 2 months to 25 years of age at the initiation of treatment
	• Evrysdi is prescribed by, or is in consultation with a neurologist
	• Diagnosis of Spinal Muscular Atrophy is confirmed by genetic testing indicating presence of chromosome 5q homozygous gene mutation, homozygous gene deletion, or compound heterozygous mutation
	• Type I, Type II, or Type III Spinal Muscular Atrophy is confirmed to have at least 2 copies of the Survival Motor Neuron-2 (SMN2) gene
	• Member is not maintained on either of the following:
	  ○ Invasive ventilation or tracheostomy
	  ○ Use of non-invasive ventilation beyond naps and nighttime sleep
	• Females of reproductive potential require a negative pregnancy test prior to start of treatment and use contraception during treatment
	• For members with previous treatment history with Zolgensma, there was worsening clinical status as shown in one of the motor milestone score exams used:
	  ○ Hammersmith Infant Neurologic Exam Part 2 (HINE-2):
	  ▪ Decline of at least 2 points on kicking and 1 point on any other milestone (excluding voluntary grasp)
	  ○ Hammersmith Functional Motor Scale Expanded (HFMSE):
	  ▪ Decline of at least 3 points
	  ○ Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND):
	  ▪ Decline of at least 4 points
		Initial Approval:
		6 months
		
		Renewal Approval:
		12 months
		
		Requires:
		• Response to therapy as demonstrated by medical records of one of the following:
		  ○ Maintained, or improved motor milestone score, using the same exam as performed at baseline (refer to specific exam below)
		  ○ Achieved, and maintained any new motor milestones, when otherwise would be unexpected to do so, using the same exam as performed at baseline
		• Females of reproductive potential continue to use contraception during treatment

Last Update: 12.1.2020, 12.4.2020, 3.1.2021, 5.11.2021, 6.28.2021, 8.1.2021, 9.13.2021, 10.1.2021, 12.17.2021, 1.9.2022, 2.1.2022, 2.17.2022, 2.28.2022, 3.11.2022, 4.5.2022, 4.7.2022, 4.26.2022, 5.11.2022, 5.19.2022, 6.7.2022, 7.9.2022, 8.1.2022, 12.16.2022, 1.1.2023, 1.13.2023, 2.1.2023
,
Current Update: 2.10.2023

	Additional Criteria for Infantile Onset SMA or SMA Type I:
	• Baseline motor milestone score from Bayley Scales of Infant and Toddler Development-Third Edition (BSID-III), Item 22 and one of the following tests:
	  ○ Hammersmith Infant Neurological Examination Section 2 (HINE-2)
	  ○ Baseline Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND)
	
	Additional Criteria for Later Onset SMA, or SMA Type II or Type III:
	• Baseline motor milestone score from Motor Function Measure 32 (MFM32) and one of the following tests:
	  ○ Revised Upper Limb Module (RULM)
	  ○ Hammersmith Functional Motor Scale Expanded (HFMSE)
	  ○ 6-Minute Walk Test (6MWT)
	
	Exclusion Criteria:
	• Pediatric members below the age of 2 months, as safety and effectiveness have not been established
	• Medication is not concurrently prescribed with Spinraza or Zolgensma
		Additionally, after 12 months of treatment:
		• Infantile Onset SMA or SMA Type I: Bayley Scales of Infant and Toddler Development-3rd Edition (BSID-III) gross motor scale Item 22
		  ○ Ability to sit without support for at least 5 seconds
		• SMA Type II or Type III: Motor Function Measure 32 (MFM32) had a 3-point or greater change from baseline in total score
		• Member is not maintained on either of the following:
		  ○ Invasive ventilation or tracheostomy
		  ○ Use of non-invasive ventilation beyond naps and nighttime sleep
		• Females of reproductive potential continue to use contraception during treatment

Last Update: 12.1.2020, 12.4.2020, 3.1.2021, 5.11.2021, 6.28.2021, 8.1.2021, 9.13.2021, 10.1.2021, 12.17.2021, 1.9.2022, 2.1.2022, 2.17.2022, 2.28.2022, 3.11.2022, 4.5.2022, 4.7.2022, 4.26.2022, 5.11.2022, 5.19.2022, 6.7.2022, 7.9.2022, 8.1.2022, 12.16.2022, 1.1.2023, 1.13.2023, 2.1.2023
,
Current Update: 2.10.2023

		Additional Requirements per Exam Performed:
		
		Hammersmith Infant Neurologic Exam Part 2 (HINE-2)
		• One of the following:
		  ○ Improvement, or maintenance of previous improvement, of at least a 2-point increase in ability to kick
		  ○ Improvement, or maintenance of previous improvement, of at least a 1-point increase, in any other milestone (for example, head control, rolling, sitting, crawling), excluding voluntary grasp
		
		Hammersmith Functional Motor Scale Expanded (HFMSE)
		• Improvement, or maintenance of previous improvement, of at least a 3-point increase in score from baseline

		Revised Upper Limb Module (RULM) • Improvement, or maintenance of previous improvement, of at least a 2-point increase in score from baseline **Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND)** • Improvement, or maintenance of previous improvement, of at least a 4-point increase in score from baseline **6-Minute Walk Test (6MWT)** • Maintained, or improved score from baseline
Exondys[xxx]	**May be authorized when documentation is presented to meet all the following criteria:** • Genetic testing to confirm member diagnosis of Duchenne Muscular Dystrophy and to identify the specific type of DMD gene mutation • Prescribed by or in consultation with a physician who specializes in treatment of Duchenne Muscular Dystrophy • Lab results showing a DMD gene mutation is amenable to exon 51 skipping	**Initial Approval:** 6 months **Renewal Approval:** 12 months ***Requires:*** • Documentation of response to

	• Treatment is initiated prior to the age of 14 years • Member is able to achieve an average distance of at least 180 meters while walking independently over 6 minutes	therapy as evidenced by remaining ambulatory ○ For example, member is able to walk with or without assistance, and is not wheelchair dependent
Gonadotropin Releasing Hormone (GnRH) Analogs[xxxi] Leuprolide acetate Lupaneta Pack Lupron Depot Lupron Depot-PED Eligard Fensolvi Orilissa Trelstar Triptodur Vantas Synarel Supprelin LA	**Requests for non-preferred agents require trial of <u>one</u> preferred agent in addition to clinical criteria (exception for gender dysphoria/gender incongruence)** **Endometriosis** • Prescribed by, or in consultation with a gynecologist or obstetrician • Member is at least 18 years of age • Meets one of the following criteria: ○ Trial and failure of at least one formulary hormonal cycle control agent (for example, Portia, Ocella, Previfem), or medroxyprogesterone, in combination with a non-steroidal anti-inflammatory drug (NSAID) or NSAID alone for those who were attempting to conceive ○ Member has severe disease or recurrent symptoms **Note: requests for the treatment of dyspareunia without endometriosis is not a covered benefit **Uterine Leiomyoma (fibroids)** • Prescribed by, or in consultation with a gynecologist or obstetrician • Member is at least 18 years of age • Prescribed to improve anemia and/or reduce uterine size prior to planned surgical intervention • Trial and failure of iron to correct anemia **Endometrial Thinning for Dysfunctional Uterine Bleeding** • Prescribed by, or in consultation with gynecologist or obstetrician	**<u>Initial Approval:</u>** **Endometriosis** 6 months **Uterine Leiomyoma (fibroids)** 3 months **Dysfunctional uterine bleeding** 2 months **Central Precocious Puberty** Supprelin LA: 12 months All others: 6 months **Cancer** 2 years **Gender Dysphoria** 6 months **<u>Renewal Approval:</u>** **Central Precocious Puberty** 6 months - 1 year (up to age 11 for females, and age 12 for males) ***Requires:*** • Documentation of clinical

	• Member is at least 18 years of age • Prescribed to thin endometrium prior to planned endometrial ablation or hysterectomy within the next 4-8 weeks **Central Precocious Puberty** • Prescribed by, or in consultation with endocrinologist • Magnetic Resonance Imaging (MRI) or Computed Tomography (CT) Scan has been performed to rule out brain lesions or tumors • Onset of secondary sexual characteristics earlier than 8 years in females, and 9 years in males • Response to a Gonadotropin Releasing Hormone (GnRH) stimulation test or basal luteinizing hormone (LH), follicle-stimulating hormone (FSH), and estradiol and/or testosterone levels • Bone age supports the diagnosis (for example, but not limited to advanced greater than approximately 2 standard deviations (SD) beyond chronological age) • Documentation of baseline height and weight **Advanced Prostate Cancer** • Prescribed by, or in consultation with oncologist or urologist • Member is at least 18 years of age **Advanced Breast Cancer** • Prescribed by, or in consultation with an oncologist • Member is at least 18 years of age and premenopausal at time of diagnosis **Advanced Ovarian Cancer** • Prescribed by, or in consultation with an oncologist • Member is at least 18 years of age **Salivary Gland Cancer** • Prescribed by, or in consultation with an oncologist • Member has androgen receptor positive recurrent disease, with distant metastases	response to treatment (for example, pubertal slowing or decline, height velocity, bone age, estradiol, and testosterone level) **Endometriosis** (Lupron Depot/Lupaneta only): 6 months ***Requires*** • Treatment is for recurrence after initial course of therapy • Total duration of treatment for both initial and recurrent symptoms will not be longer than 12 months • Add-back therapy (norethindrone) will be used concurrently **Uterine Leiomyoma (fibroids) or Dysfunctional Uterine Bleeding** • Long-term use is not recommended **Gender Dysphoria** 12 months ***Requires:***

	Gender Dysphoria/Gender Incongruence in adolescents • Prescribed by a Pediatric Endocrinologist that has collaborated care with a Mental Health Provider or trained physician with the necessary experience to diagnose gender dysphoria • Member shows a persistent, well-documented diagnosis of gender non-conformity or dysphoria that worsened with puberty • Exhibits signs of puberty with a minimum Tanner stage 2 • Member has made a fully informed decision and has given consent, and parent/guardian consents to treatment, or member has been emancipated • The member's comorbid conditions are reasonably controlled • Member has been educated on any contraindications and side effects to therapy • Member has been informed of fertility preservation options prior to treatment **Gender Dysphoria/Gender Incongruence in Adults** • Member is 18 years of age or older • Prescribed by an Endocrinologist that has collaborated care with a Mental Health Provider or trained physician with the necessary experience to diagnose gender dysphoria • Member shows a persistent, well-documented diagnosis of gender dysphoria/incongruence • The member has the capacity to make a fully informed decision and consents to treatment • Mental health concerns, if present, are reasonably well controlled • Member has been informed of fertility preservation options prior to treatment	• Lab results to support response to treatment (for example, follicle-stimulating hormone (FSH), luteinizing hormone (LH), weight, height, tanner stage, bone age)

Aetna Better Health of Illinois
Prior Authorization Guidelines

Growth Hormone	4th Quarter P&T Illinois Specific Growt	

Hemophilia[xxxii]
 	
Factor VIIa
Factor VIII
Factor IX
 	
Novoseven
 	
Feiba
 	
Obizur
 	
Hemlibra
	Factor replacement is authorized when prescribed by a Hematology Specialist, and the following criteria are met:
	
	Approve 14 days for the following:
	• Hemophilia A or B, or Von Willebrand disease with current serious, or life-threatening bleeds
	  ○ For example, central nervous system bleed, ocular bleed, bleeding into hip, intra-abdominal bleed, bleeding into neck or throat, iliopsoas bleed, significant bleed from trauma
	Hemophilia A or B, or Von Willebrand Disease:
	• 3 months approval may be given for on-demand therapy in case of injury and/or bleed
	Hemophilia A - Inherited Factor VIII Deficiency:
	Advate, Adynovate, Afstyla, Alphanate, Eloctate, Esperoct, Helixate FS, Hemofil M, Humate P, Jivi, Koate, Koate DVI, Kogenate FS, Kovaltry, Monoclate-P, Novoeight, Nuwiq, Recombinate, Xyntha
	
	• Provider attestation to one of the following:
	  ○ Member has severe disease with less than 1% of normal Factor VIII (less than 0.01 IU/mL)
	  ○ History of one or more episodes of spontaneous bleeding into joints
	  ▪ Routine bleeding prophylaxis, hemorrhage, perioperative bleeding
	  ○ Member has mild or moderate disease with greater than or equal to 1% of normal Factor VIII (greater than or equal to 0.01 IU/mL)
		Initial Approval:
		On Demand Use:
		3 months
		
		Others:
		1 year
		
		Renewal Approval:
		On Demand Use:
		3 months
		
		Others:
		1 year
		
		Factors VIII and IX:
		Attestation member has been screened for inhibitors since last approval.
		
		If Inhibitor is Present:
		• There is a treatment plan to address inhibitors as appropriate.
		  ○ For example, changing product, monitoring if transient inhibitor or low responder, or if greater than 5 Bethesda units,

	▪ Occasional spontaneous bleeding episodes, or severe bleeding with serious injury, trauma, or surgery • Additional criteria for Jivi: o Member is 12 years of age or older **Hemophilia B - Inherited Factor IX Deficiency** Alphanine, Alprolix, Benefix, Idelvion, Ixinity, Mononine, Profilnine, Rixubis, Rebinyn • Provider attestation to one of the following: o Member has severe disease with less than 1% normal Factor IX (less than 0.01 IU/mL) o History of one or more episodes of spontaneous bleeding into joints ▪ Routine bleeding prophylaxis, hemorrhage, perioperative bleeding o Member has mild or moderate disease with greater than or equal to 1% of normal Factor VIII (greater than or equal to 0.01 IU/mL) ▪ Occasional spontaneous bleeding episodes, or severe bleeding with serious injury, trauma, or surgery **Von Willebrand Disease:** Vonvendi, Alphanate, Humate P, Wilate • Provider attestation to laboratory confirmed diagnosis • History of bleed o Prolonged wound bleed, post-surgical or dental bleed, nosebleeds, menorrhagia, excessive bruising, or family history of bleeding or bleeding disorder ▪ Vonvendi: Adults 18 years of age or older ▪ Alphanate, Humate P, Wilate **Novo-Seven RT - Recombinant Activated Factor VII Concentrate (Factor VIIa)**	increase dose and/or frequency for Immune Tolerance Induction, change to bypassing agent, and/or, addition of immunomodulator

	• Attestation of one of the following Food and Drug Administration (FDA) approved indications:
	  ○ Acquired hemophilia
	  ○ Hemophilia A or B with Inhibitors
	  ○ Glanzmann's thrombasthenia, when refractory to platelet transfusions, with or without antibodies to platelets
	  ○ Congenital Factor VII deficiency
	• Treatment of hemorrhagic complications, or prevention of bleeds, in surgical, or invasive procedures
	Feiba - Activated Prothrombin Complex Concentrate
	• Hemophilia A or Hemophilia B with inhibitors
	• Treatment of hemorrhagic complications, or prevention of bleeds, in surgical, or invasive procedures, or routine prophylaxis
	Obizur
	• Acquired Hemophilia A in adults for treatment of bleeding episodes
	• Attestation baseline anti-porcine Factor VIII inhibitor titer is not greater than 20 Bethesda Units
	• Will not be used for treatment of congenital hemophilia A or von Willebrand disease
	Hemlibra
	• For prophylaxis of Hemophilia A with or without inhibitors must meet one of the following:
	  ○ Member has severe disease with documentation showing less than 1% of normal Factor VIII (less than 0.01 IU/mL)
	  ○ Member has mild or moderate disease with documentation showing greater than or equal to 1% of normal Factor VIII (greater than or equal to 0.01 IU/mL)
	  ▪ Documentation showing at least two episodes of bleeding into the joints
	• Hemlibra will not be used for treatment of acute bleeds	

	• Provider confirms that member will discontinue any use of factor VIII products as prophylactic therapy while on Hemlibra ○ on-demand usage may be continued • A cumulative amount of greater than 100 U/kg/24 hours of activated prothrombin complex concentrate has not been administered for 24 hours or more Note: Examples of activated prothrombin complex concentrate include Feiba, Novoseven RT	
Hepatitis C	Illinois-Hepatitis-C-Guideline-Update-5.20	
Hereditary Angioedema	HAE AS Q4 2021 Final.doc.docx	
HP Acthar[xxxiii]	**Submission of medical records and clinical/chart notes is required** **May be authorized when the following criteria is met:** • Diagnosis of Infantile Spasm (West syndrome) • Member is less than two years of age • Prescribed by or in consultation with neurologist • Confirmation of diagnosis by electroencephalogram (EEG) • Documentation of current body surface area (BSA) NOTE: All other indications have not been supported by manufacturer clinical trials and are considered experimental and investigational, and hence not medically necessary and will not be covered	**Initial Approval**: One month **Renewal Approval:** Treatment beyond 4 weeks for same episode is not recommended, and not medically necessary, as prolonged use may lead to adrenal insufficiency or recurrent symptoms, which make it difficult to stop treatment
Hetlioz[xxxiv]	**Authorization criteria:**	**Initial Approval:** 6 months

	• Prescribed by, or in consultation with a sleep specialist (board-certified by the American Board of Sleep Medicine)
	• Diagnosis of non-24 sleep-wake disorder in members 18 years of age and older
	  ○ Requires at least 14 days of documentation of progressively shifting sleep-wake times with sleep diaries (may submit actigraphy if available) (submit documentation)
	  ○ Member is completely blind with no light perception
	  ○ No other concomitant sleep disorder (for example, sleep apnea, insomnia)
	  ○ Member did not achieve increases in nighttime sleep or decreases in daytime sleep that resulted in a change of entrainment status after a 3 month continuous trial of melatonin or has a documented intolerance or contraindication to the use of melatonin therapy (recommended dose for non-24-hour sleep wake disorder is melatonin 5-10 mg once daily)
	• Diagnosis of Nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) in members 3 years of age and older
	  ○ No other concomitant sleep disorder, for example, sleep apnea, insomnia
		Renewal Approval:
		1 year
		Requires:
		Attestation that circadian rhythms are entrained to normal 24-hour cycle
		Quantity Level Limit:
		Capsules:
		30 capsules every 30 days
		Liquid:
		Less than or equal to 28 kg: 0.7 mg/kg

Imatinib[xxxv] (Gleevec)	**General Criteria:** • Prescribed by or in consultation with an oncologist • Member is 18 years of age or older ○ Exceptions: pediatric members with newly diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL), who will receive imatinib in combination with chemotherapy, newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML), or Desmoid Tumors	**Initial Approval:** 1 year **Renewal Approval:** 1 year ***Requires:*** • Member does not show evidence of progressive disease while on therapy

	In addition, Imatinib can be authorized for members who meet one of the following criteria:
	• Adult and pediatric members with newly diagnosed chronic myeloid leukemia (CML)
	• Pediatric members with newly diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) in combination with chemotherapy
	• Relapsed or refractory Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)
	• Myelodysplastic/Myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene rearrangements, as determined by an Food and Drug Administration (FDA) approved test
	• Aggressive systemic mastocytosis (ASM) with one of the following:
	  ○ Food and Drug Administration (FDA) approved test showing member is without D816V c-Kit mutation
	  ○ Member's c-Kit mutational status is unknown
	• Hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL)
	• Unresectable, recurrent, or metastatic Dermatofibrosarcoma protuberans (DFSP) in adults
	• Kit-positive (CD117) unresectable and/or metastatic positive gastrointestinal stromal tumors (GIST)
	• Adjuvant treatment after complete gross resection of Kit-positive (CD117) gastrointestinal stromal tumors (GIST)
	• Bone cancer: Chordoma
	• Pigmented Villonodular Synovitis / Tenosynovial Giant Cell Tumor (PVNS/TGCT)
	• Steroid-Refractory Chronic Graft-Versus-Host Disease (GVHD)
		• Member does not have unacceptable toxicity from therapy
		
		Quantity Level Limit:
		100mg: 90 tablets per 30 days
		400mg: 60 tablets per 30 days

Last Update: 12.1.2020, 12.4.2020, 3.1.2021, 5.11.2021, 6.28.2021, 8.1.2021, 9.13.2021, 10.1.2021, 12.17.2021, 1.9.2022, 2.1.2022, 2.17.2022, 2.28.2022, 3.11.2022, 4.5.2022, 4.7.2022, 4.26.2022, 5.11.2022, 5.19.2022, 6.7.2022, 7.9.2022, 8.1.2022, 12.16.2022, 1.1.2023, 1.13.2023, 2.1.2023
,
Current Update: 2.10.2023

	• Metastatic or Unresectable Melanoma as second-line therapy for tumors with activating mutations of c-Kit • Adults and adolescents 12 and older for aggressive fibromatosis (desmoid tumor) that is unresectable or not susceptible to radiotherapy • Post-transplant relapse for chronic myeloid leukemia (CML) if member has not failed imatinib prior to transplant • AIDS-Related Kaposi Sarcoma as subsequent systemic therapy for relapsed/refractory disease	
Immune Globulin	Immune-Globulins-IL-Guideline-6.7.2022.d	**Guideline Last Updated 6.7.2022**

Intravaginal Progesterone Products[xxxvi]
 	
Crinone
	Crinone 8% Gel is Approved when ALL the following criteria are met:
	• Prescribed by, or in consultation with, a provider of obstetrical care
	• Member is not on Makena (17-hydroxyprogesterone)
	• Member is pregnant with singleton gestation and meets either of the following:
	  ○ History of spontaneous preterm birth (delivery of an infant less than 34 weeks gestation)
	  ○ Cervical length less than 25 mm before 24 weeks of gestation
	
	Crinone is approved for the treatment of secondary amenorrhea when ALL the following criteria are met:
	• Prescribed by, or in consultation with a provider of obstetrical care
	• Member has had an inadequate response, or intolerable side effects to, progesterone capsules
		Initial Approval:
		Approve as requested until 35 weeks gestation
		
		Begin progesterone use no earlier than 16 weeks, 0 days and no later than 23 weeks, 6 days
		
		Crinone 4% and 8%:
		For the treatment of amenorrhea: up to a total of 6 doses
		Requests for additional quantities will require review
		
		Progesterone products will not be covered for uses related to infertility

	• Crinone 8% Gel can be approved for use when 4% gel has been tried and failed	
Injectable Osteoporosis	Injectable Osteoporosis AS 3Q 2	

Inlyta (axitinib)[xxxvii]	**General Criteria:**
	• Prescribed by or in consultation with an oncologist
	• Member is 18 years of age or older
	In addition, Inlyta may be authorized when one of the following criteria is met:
	• Advanced renal cell carcinoma meets one of the following:
	  ○ Member has renal cell carcinoma with clear cell histology
	  ○ Member has renal cell carcinoma with non-clear cell histology AND
	  ▪ There was a trial and failure with Sutent (sutinib), Cometriq (cabozantinib), or Afinitor (everolimus)
	• Differentiated thyroid carcinoma (papillary, follicular, and Hürthle cell) meets all the following:
	  ○ Unresectable recurrent, persistent locoregional, or distant metastatic disease
	  ○ Progressive and/or symptomatic iodine-refractory disease
	  ○ Nexavar (sorafenib) and Lenvima (lenvatinib) are not available or are not clinically appropriate
		Initial Approval:
		1 year
		
		Renewal Approval:
		3 years
		
		Requires:
		Member has been on Inlyta and does not show evidence of progressive disease while on therapy
		
		Quantity Level Limit:
		20mg/day

Interferons[xxxviii] ***α-Interferon*** Alferon N Intron A Pegasys	**Chronic Hepatitis B** (Intron A, Pegasys) • Prescribed by, or in consultation with, an Infectious Disease physician, Gastroenterologist, Hepatologist, or Transplant physician • Diagnosis of Chronic Hepatitis B	**Initial Approval:** ***Hepatitis B*** Intron A • Adults: 16 weeks • Children: 24 weeks Pegasys

γ-Interferon
Actimmune
	• Current lab results to support one of the following:
	  ○ Documentation of Alanine Aminotransferase (ALT) greater than or equal to 2 times the Upper Limit of Normal (ULN)
	  ○ Significant histologic disease and documentation of elevated Hepatitis B Virus Deoxyribonucleic Acid (DNA) level above 2,000 IU/mL (Hepatitis B e-antigen (HBe-Ag negative)) or above 20,000 IU/mL (HBe-Ag positive)
	• Compensated Liver disease
	• Age restriction for Pegasys
	  ○ Pediatrics: 3 years of age or older, non-cirrhotic and Hepatitis B e-antigen (HBe-Ag) positive
	  ○ Adults: 18 years of age or older
	• Age restriction for Intron A:
	  ○ 1 year of age or older
	Follicular Non-Hodgkin's Lymphoma (Stage III/IV)
	(Intron A, Pegasys)
	• Member is 18 years of age or older
	• Prescribed by, or in consultation with Hematologist/Oncologist
	• Given in conjunction with anthracycline-containing combination chemotherapy
	Acquired Immune Deficiency Syndrome (AIDS)-related Kaposi's sarcoma
	(Intron A [powder for solution ONLY])
	• Member is 18 years of age or older
	• Prescribed by, or in consultation with Infectious Disease physician, or Human Immunodeficiency Virus specialist
	Hairy-cell Leukemia
	(Intron A, Pegasys)
	• Member is 18 years of age or older
	• Prescribed by, or in consultation with Hematologist/Oncologist
		• 48 weeks
		Osteopetrosis
		12 months
		Chronic Granulomatous Disease
		12 months
		Hairy-cell Leukemia
		6 months
		Kaposi's sarcoma
		16 weeks
		Follicular Non-Hodgkin's Lymphoma (Stage III/IV)
		6 months
		Condylomata Acuminate
		Intron A - 3 weeks
		Alferon N - 8 weeks
		
		Renewal Approval:
		Hepatitis B
		Intron A
		• Additional 16 weeks if still Hepatitis B e-antigen (HBe-Ag)-positive
		• Indefinite for Hepatitis B e-antigen (HBe-Ag)-negative
		Chronic Granulomatous Disease
		• 12 months, if no evidence of disease progression
		Osteopetrosis
		• 12 months, if no evidence of disease progression

	• Member meets one of the following:
	  ○ Demonstrated less than a complete response to cladribine or pentostatin
	  ○ Relapsed after less than 2 years of demonstrating a complete response to cladribine or pentostatin
	Chronic Granulomatous Disease
	(Actimmune)
	• Member is one year of age or older
	• Prescribed by, or in consultation with Immunologist, or Infectious Disease specialist
	Malignant Osteopetrosis
	(Actimmune)
	• For treatment of severe, malignant Osteopetrosis
	• Prescribed by, or in consultation with Hematologist, or Endocrinologist
	Condylomata acuminata – genital or venereal warts
	(Intron A, Alferon N)
	• Member is 18 years of age or older
	• For intra-lesional use
	• Lesions are small and limited in number
	• Trial and failure of topical treatments or surgical technique (for example, imiquimod cream, podofilox, cryotherapy, laser surgery, electrodessication, surgical excision)
		Condylomata acuminate
		Intron A
		• 3 weeks
		  ○ Treatment is administered at week 12 to week 16
		Alferon N
		• 8 weeks
		  ○ There is at least 3 months between treatments unless lesions grow, or new lesions appear
		All other indications
		• 12 months
		• For Hairy-Cell Leukemia it is not recommended to continue if disease has progressed

Insulin Pens[xxxix]
 	
Rapid Acting:
Admelog
Admelog Solostar
Apidra Solostar
	General criteria for all members:
	• Diagnosis of Type I or Type II Diabetes Mellitus
	  ○ Documentation to support inadequate response, intolerable side effect, or contraindication with two formulary insulins within the same class
	  ▪ For example, rapid, regular, or basal
	Toujeo Solostar and Toujeo Max Solostar only:
		Approval Duration:
		One year

Fiasp FlexTouch Lyumjev KwikPen Novolog FlexPen **<u>Intermediate Acting</u>:** Novolin 70/30 FlexPen Novolin N FlexPen **<u>Basal Insulin</u>:** Basaglar KwikPen Semglee Pen Tresiba Flextouch Toujeo Solostar Toujeo Max Solostar	• Documentation to support inadequate (three month) response, intolerable side effect, or contraindication to formulary basal insulin pens ○ For hypoglycemia: consistent evidence of hypoglycemia such as a Self-Monitoring Blood Glucose reading must be provided **OR** • Documentation to support required units of basal insulin exceeds 100 units/day	

Interleukin 5 (IL-5) Antagonists[xl]
 	
<u>Preferred Agents</u>:
Nucala Vial formulation
Nucala Auto Injector
Nucala Prefilled Syringe
Fasenra Prefilled Syringe
	Requests for non-preferred agents require trial and failure of preferred agent, where indicated
	
	May be authorized as add-on maintenance for the treatment of severe eosinophilic asthma when the following criteria are met:
	• Member is at least:
	  ○ 6 years of age (Nucala)
	  ○ 12 years old (Fasenra)
	  ○ 18 years old (Cinqair)
	• Prescribed by, or after consultation with a pulmonologist or allergist/immunologist
	• Lab results to support one of the following blood eosinophil counts:
	  ○ Greater than or equal to 150 cells/mcL within 6 weeks of dosing (Nucala, Fasenra)
		<u>Initial Approval</u>:
		6 months
		
		<u>Renewal for Severe Eosinophilic Asthma</u>:
		1 year
		
		Requires:
		• Demonstration of clinical improvement
		  ○ For example, decreased use of rescue medications, or systemic corticosteroids, reduction in number of emergency

Aetna Better Health of Illinois
Prior Authorization Guidelines

Fasenra Auto Injector Pen **<u>Non-Preferred Agent</u>:** Cinqair	○ Greater than or equal to 300 cells/mcL at any time in the past 12 months (Nucala, Fasenra) ○ Greater than or equal to 400 cells/mcL at baseline (Cinqair) • Member has been compliant with one of the following regimens for at least 3 months: ○ Medium or high dose inhaled corticosteroids (ICS) plus a long-acting beta agonist (LABA) ○ Other controller medications (for example, Leukotriene receptor antagonists (LTRA), or theophylline) if intolerant to a long-acting beta agonist (LABA) • Asthma symptoms are poorly controlled on one of the above regimens as defined by any of the following: ○ At least two exacerbations in the last 12 months requiring additional medical treatment (systemic corticosteroids, one or more emergency department visits, or hospitalization in the previous 12 months) ○ Daily use of rescue medications (short-acting inhaled beta-2 agonists) ○ Nighttime symptoms occurring more than once a week • Members with history of exacerbations must have an adequate 2-month compliant trial of tiotropium (requires prior authorization) • Member will not use agent concomitantly with other biologics indicated for asthma • Member will not receive in combination with Xolair or another Interleukin-5 (IL-5) inhibitor **Criteria for Eosinophilic Granulomatosis with Polyangiitis (EGPA) – (Nucala Only):** • Member is at least 18 years old • Prescribed by, or after consultation with a pulmonologist or allergist/immunologist	department visits, or hospitalizations • Compliance with asthma controller medications **Dosing for Severe Eosinophilic Asthma:** <u>Nucala</u>: 100mg every 4 weeks <u>Cinqair</u>: 3mg/kg every 4 weeks <u>Fasenra</u>: 30mg every 4 weeks for first 3 doses, then once every 8 weeks **<u>Renewal for Eosinophilic Granulomatosis with Polyangiitis (EGPA)</u>:** 1 year ***Requires:*** • Member response to treatment • Tapering of oral corticosteroid dose **Dosing for Eosinophilic Granulomatosis with Polyangiitis (EGPA):** Nucala: 300mg every 4 weeks as 3 separate 100mg injections **Renewal Approval for Hypereosinophilic Syndrome (HES):**

	• Diagnosis is for at least 6 months, with history of relapsing or refractory disease
	• Member has been on stable dose of oral prednisolone or prednisone greater than or equal to 7.5 mg/day but less than or equal to 50 mg/day for at least 4 weeks.
	• Member meets all the following:
	  ○ History or presence of asthma and blood eosinophil level of 10% or an absolute eosinophil count greater than 1000 cells/mm^3
	  ○ Presence of two or more criteria that are typical of eosinophilic granulomatosis with polyangiitis (for example, but not limited to histopathological evidence of eosinophilic vasculitis, perivascular eosinophilic infiltration, or eosinophil-rich granulomatous inflammation; neuropathy; pulmonary infiltrates; sinonasal abnormality; cardiomyopathy; etc.)
	• Member has a Five Factor Score (FFS) of less than 2.
	• Member had a trial and failure, or contraindication to cyclophosphamide.
	Treatment of Hypereosinophilic Syndrome (HES) – Nucala Only:
	• Prescribed by, or after consultation with pulmonologist or allergist/immunologist
	• Member is 12 years of age or older
	• Documentation of all the following:
	  ○ Diagnosis of Hypereosinophilic Syndrome for at least six months, with no identifiable non-hematologic secondary cause (for example HIV infection) and HES is not FIP1L1-PDGFRα kinase-positive
	  ○ Eosinophil counts are 1,000/mm^3 or higher with at least 2 hypereosinophilic syndrome related flares within the past 12 months
		Requires:
		• Documentation of response to treatment with improvement in clinical signs and symptoms
		• Tapering or elimination of hypereosinophilic syndrome therapy dose
		  ○ For example, oral corticosteroid, interferon alpha, or hydroxyurea
		• Lowering of blood eosinophil count
		Dosing for Hypereosinophilic Syndrome (HES):
		Nucala:
		300mg every 4 weeks as 3 separate 100mg injections
		
		Chronic Rhinosinusitis with Nasal Polyps (CRSwNP):
		• Response to therapy (for example, by a decrease in the bilateral endoscopic nasal polyps score or nasal congestion/obstruction score from baseline)
		• Continued use of Nucala as add-on therapy to intranasal corticosteroids

Last Update: 12.1.2020, 12.4.2020, 3.1.2021, 5.11.2021, 6.28.2021, 8.1.2021, 9.13.2021, 10.1.2021, 12.17.2021, 1.9.2022, 2.1.2022, 2.17.2022, 2.28.2022, 3.11.2022, 4.5.2022, 4.7.2022, 4.26.2022, 5.11.2022, 5.19.2022, 6.7.2022, 7.9.2022, 8.1.2022, 12.16.2022, 1.1.2023, 1.13.2023, 2.1.2023
,
Current Update: 2.10.2023

	▪ For example, worsening of symptoms or blood eosinophil counts requiring escalation in therapy o Member is stable on hypereosinophilic syndrome therapy for 4 weeks prior to start of treatment ▪ For example, oral steroids, interferon alpha, or hydroxyurea **Maintenance Treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) – Nucala Only:** • Member is 18 years of age or older • Documented diagnosis of chronic rhinosinusitis with nasal polyps • Nucala will be used as add-on therapy to intranasal corticosteroids • Prescribed by, or in consultation with an ear, nose, and throat (ENT) specialist or an allergist • Symptoms have persisted for at least 12 weeks and two out of four hallmark signs and symptoms are present: o Mucopurulent drainage o Nasal obstruction o Decreased sense of smell o Facial pain, pressure, and/or fullness • Attestation prescriber has confirmed mucosal inflammation is present • Member's condition has been inadequately controlled by systemic corticosteroids and/or sinus surgery following intranasal corticosteroids • Member will not use Nucala concomitantly with other biologics indicated for nasal polyps o For example, Dupixent or Xolair **Note: Not covered for treatment of other eosinophilic conditions or relief of acute bronchospasm or status asthmaticus**	**Dosing for Chronic Rhinosinusitis with Nasal Polyps (CRSwNP):** <u>Nucala:</u> 100mg every 4 weeks

Last Update: 12.1.2020, 12.4.2020, 3.1.2021, 5.11.2021, 6.28.2021, 8.1.2021, 9.13.2021, 10.1.2021, 12.17.2021, 1.9.2022, 2.1.2022, 2.17.2022, 2.28.2022, 3.11.2022, 4.5.2022, 4.7.2022, 4.26.2022, 5.11.2022, 5.19.2022, 6.7.2022, 7.9.2022, 8.1.2022, 12.16.2022, 1.1.2023, 1.13.2023, 2.1.2023
,
Current Update: 2.10.2023

Aetna Better Health of Illinois
Prior Authorization Guidelines

Janus Associated Kinase Inhibitors[xli]
 	
Inrebic
	General Authorization Guideline for All Indications:
	• Prescribed by, or in consultation with hematologist/oncologist
	• Member has been screened for tuberculosis
	  ○ If screening was positive for latent tuberculosis, member has received treatment for latent tuberculosis prior to initiating therapy
	• There is no evidence showing member has a serious current active infection
	
	Additional Criteria Based on Indication:
	
	Myelofibrosis:
	• Member is at least 18 years of age
	• Baseline platelet count is at least 50 X 10^9/L
	• Diagnosis is primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis
	• Intermediate or high-risk disease is defined as having two or more of the following risk factors:
	  ○ Age greater than 65 years
	  ○ Constitutional symptoms (weight loss greater than 10 percent from baseline and/or unexplained fever, or excessive sweats persisting for more than 1 month)
	  ○ Hemoglobin less than 10g/dL
	  ○ White Blood Cell greater than or equal to 25 x 10^9/L
	  ○ Peripheral Blood blasts greater than 1 percent
	  ○ Platelets less than 100 X 10^9/L
	  ○ Red Cell Transfusion
	  ○ Unfavorable karyotype [for example, complex karyotype, or sole, or two abnormalities that include trisomy 8, 7/7q-, i(17q), inv (3), 5/5q-, 12p- or 11q23 rearrangement]
		Initial Approval:
		6 months
		
		Renewal Approval:
		1 year
		
		Requires:
		
		Myelofibrosis:
		• Member meets one of the following criteria:
		  ○ Spleen size reduction of greater than or equal to 35 percent
		  ○ Symptom improvement
		  ▪ For example, greater than or equal to 50 percent reduction in total symptom score from baseline
		  ○ Absence of disease progression
		• Documentation that liver function tests, and thiamine levels are being monitored periodically during therapy

Last Update: 12.1.2020, 12.4.2020, 3.1.2021, 5.11.2021, 6.28.2021, 8.1.2021, 9.13.2021, 10.1.2021, 12.17.2021, 1.9.2022, 2.1.2022, 2.17.2022, 2.28.2022, 3.11.2022, 4.5.2022, 4.7.2022, 4.26.2022, 5.11.2022, 5.19.2022, 6.7.2022, 7.9.2022, 8.1.2022, 12.16.2022, 1.1.2023, 1.13.2023, 2.1.2023
,
Current Update: 2.10.2023

	• Documentation showing no signs of severe hepatic impairment (baseline total bilirubin level greater than 3-times the upper limit of normal) • Documentation of serum thiamine levels taken at baseline and periodically during therapy to avoid Wernicke's encephalopathy NOTE: Inrebic is only indicated for Myelofibrosis	

Juxtapid[xlii]	**Medical Records Required with Requests**
	
	May be authorized when all the following criteria are met:
	• Member is 18 years of age or older
	• Prescribed by, or in consultation with Cardiologist, Endocrinologist, or Lipid Specialist
	• Females of reproductive potential have a negative pregnancy test prior to starting treatment
	• Used as an adjunct to a low-fat diet and exercise
	• Diagnosis of homozygous familial hypercholesterolemia (HoFH) as evidenced by one of the following:
	  ○ Genetic confirmation of 2 mutant alleles at the Low-Density Lipoprotein Receptor (LDLR), Apolipoprotein B100 (APO-B100), or Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)
	  ○ History of untreated Low-Density Lipoprotein (LDL) greater than 500 mg/dL, or treated Low-Density Lipoprotein (LDL) greater than 300 mg/dL on maximum dosed statin and evidence of one of the following:
	  ▪ Presence of cutaneous xanthoma before the age of 10 years
	  ▪ Heterozygous familial hypercholesterolemia (HeFH) in both parents
	• Current lipid panel/Low-Density Lipoprotein (LDL) from past 90 days
		Initial Approval:
		3 months
		
		Renewal Approval:
		6 months
		
		Requires:
		• Member is continuing a low-fat diet and exercise regimen
		• Current lipid Panel within the past 90 days showing Low-Density Lipoprotein (LDL) reduction from baseline
		• Claims history to support compliance or adherence to Juxtapid and adjunctive lipid lowering therapies
		• Prescriber attestation of monitoring liver related tests, and dosing adjusted according to prescribing information
		• Females of reproductive potential are currently using contraception

	• Member had a failure or contraindication to a 90-day trial of a Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor (for example, Repatha or Praluent)
	• Attestation to the following:
	  ○ Member does not have significant hepatic impairment (Child-Pugh B or C)
	  ○ Will be used in conjunction with other lipid lowering therapies such as statins, ezetimibe, bile acid sequestrants, or Low-Density Lipoprotein (LDL) apheresis
		Quantity Level Limits:
		• Juxtapid:
		1 tablet per day

Korlym[xliii]	• Member is 18 years of age or older
	• Documentation (submit chart notes) that diagnosis is of endogenous Cushing syndrome with all the following:
	  ○ Uncontrolled hyperglycemia due to glucose intolerance or type 2 diabetes mellitus
	  ○ Member failed surgery or is not a candidate for surgery
	  ○ There was failure to achieve adequate glycemic control despite individualized diabetic management
	• Prescribed by or in consultation with endocrinologist
	• Baseline labs for hemoglobin A1c (HbA1c)
	• Prescriber attestation to all the following:
	  ○ Female members of childbearing potential are not pregnant
	  ○ Female members do not have history of unexplained vaginal bleeding, endometrial hyperplasia with atypia, or endometrial carcinoma
	  ○ Member does not require concurrent long-term corticosteroid use for serious medical conditions or illnesses (for example immunosuppression after organ transplant)
	• Other accepted and approved indications for mifepristone are not covered using the Korlym product
		Initial Approval:
		6 months
		
		Renewal Approval:
		12 months
		
		Requires:
		• Documentation of improved glycemic control as evidenced by Hemoglobin A1c (HbA1c) labs lower than baseline
		• Female members of childbearing potential are currently using non-hormonal contraception
		
		Quantity Level Limit:
		Maximum dose 1200 mg per day

Krystexxa[xliv]	**May be approved when all the following criteria are met:**	**Initial Approval:**

	• Treatment is for diagnosis of chronic gout refractory to conventional therapy
	• Age is 18 years or older
	• Member experienced one of the following in the previous 12 months:
	  ○ Two gout flares inadequately controlled by colchicine or Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
	  ○ One gout tophus or gouty arthritis
	• Member has been screened and does not have Glucose-6-phosphate dehydrogenase (G6PD) Deficiency
	• Attestation of provider monitoring during and after infusion for possible anaphylaxis, and infusion related reactions
	• Documented 3-month trial and failure, or intolerance with the following at maximum medically appropriate doses, or member has contraindication to the agents:
	  ○ Allopurinol or febuxostat
	  ○ Probenecid (alone or in combination with allopurinol or febuxostat)
	• Medication will not be used concomitantly with oral urate-lowering therapies
	• Note: Krystexxa is not covered for treatment of asymptomatic hyperuricemia
		12 months
		
		<u>Renewal Approval</u>:
		12 months
		Requires:
		Member had 2 consecutive uric acid levels that were not above 6 mg/dL since starting treatment
		
		<u>Dosing</u>:
		8mg given as IV infusion every two weeks

linezolid (Zyvox)	**May be covered when the following criteria are met:** • Member is being converted from intravenous formulation as prescribed or directed by Infectious Disease specialist for a NON-Tuberculosis bacterial infection OR • Member has any one of the following diagnoses: ○ Infection caused by vancomycin-resistant Enterococcus faecium including cases with concurrent bacteremia	**<u>Approval Duration:</u>** • Pulmonary Extensively Drug Resistant or treatment-intolerant or nonresponsive multidrug-resistant tuberculosis: 12 months

	○ Nosocomial (institution-acquired) pneumonia caused by Staphylococcus aureus (methicillin-susceptible and -resistant isolates) or Streptococcus pneumoniae ○ Community-acquired pneumonia caused by Streptococcus pneumoniae, including cases with concurrent bacteremia, or Staphylococcus aureus (methicillin-susceptible isolates only) ○ Complicated skin and skin structure infection including diabetic foot infections, without concomitant osteomyelitis, caused by Staphylococcus aureus (methicillin-susceptible and -resistant isolates), Streptococcus pyogenes, or Streptococcus agalactiae ○ Uncomplicated skin and skin structure infection caused by Staphylococcus aureus (methicillin-susceptible isolates only) or Streptococcus pyogenes • The infection is proven or strongly suspected to be caused by susceptible bacteria • Member experienced inadequate treatment response, intolerance, or contraindication to alternative therapies other bacteria are not susceptible to any other antibiotics OR • Medication is being prescribed for pulmonary extensively drug resistant or treatment-intolerant/nonresponsive multidrug-resistant tuberculosis AND • Medication is being prescribed as part of a combination regimen with Pretomanid and Sirturo	• All other indications: 28 days
Lucemyra[xlv] (lofexidine)	**May be authorized when the following criteria are met:** • Member is 18 years of age or older • Prescribed for mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation	**Initial Approval**: 14 days per episode of treatment (224 total tablets)

	• Opioids have been discontinued
	• Rationale as to why an opioid taper with buprenorphine products cannot be used
	• Member meets one of the following criteria:
	  ○ Trial and failure, or contraindication to clonidine, or member has a clinically significant adverse effect
	  ○ Medication was initiated in an inpatient setting
	• Member is on a behavioral modification plan for substance abuse counseling (psychosocial support)
	• Member is not currently taking benzodiazepines, alcohol, barbiturates, or other sedating agents
		Dosing:
		Three 0.18 mg tablets taken orally four times daily for 7 days
		
		Approvable for a maximum of 224 tablets per 14-day supply for a 1-month period
		
		Quantity Level Limit:
		Maximum dose 0.72 mg/dose (4 tablets) or 2.88 mg/day (16 tablets per day) or 224 tablets

Makena Injection **Makena Auto-Injector** [xlvi] Hydroxyprogesterone caproate injection	**Makena is the preferred formulary agent** **Requests for non-preferred agent requires trial and failure with Makena** **May be approved when all the following criteria are met:** • Member is currently pregnant with singleton gestation • Prescribed by, or in consultation with provider of obstetrical care • Member has history of spontaneous preterm singleton delivery • For example, delivery of infant less than 37 weeks gestation	**Initial Approval:** Until 37 weeks gestation Injections start no earlier than 16 weeks 0 days and no later than 23 weeks 6 days **Subcutaneous Administration:** Auto-Injector 275mg weekly **Intramuscular Administration:** Injection 250mg weekly
Monoamine Depletors [xlvii] **Non-Preferred Agents:** Ingrezza	**Medical Records is required for both initial and renewal requests** **Tardive Dyskinesia (Ingrezza, Austedo)** • Member is 18 years of age or older • Diagnosis of moderate to severe tardive dyskinesia • Prescribed by, or in consultation with a neurologist or psychiatrist • Member has an Abnormal Involuntary Movement Scale (AIMS) score of 3 or 4 on any one of the testing items 1 through 9	**Initial Approval:** 3 months **Renewal Approval:** 6 months ***Requires:***

Aetna Better Health of Illinois
Prior Authorization Guidelines

Austedo
Tetrabenazine
	• Provider has attempted an alternative method to manage condition
	  ○ For example, dose reduction, discontinuation of offending medication, or switching to alterative agent such as atypical antipsychotic
	  ▪ Documentation of atypical antipsychotic used
	  ▪ Time frame of stability on the atypical antipsychotic
	Additional Criteria for Austedo, tetrabenazine, and Ingrezza:
	• Member does not have any of the following:
	  ○ Active suicidal thoughts or behaviors
	  ○ Untreated or undertreated depression
	  ○ Austedo, tetrabenazine and Ingrezza are not prescribed concurrently with one another
	  ○ Hepatic impairment (for Austedo and tetrabenazine only)
	<u>Huntington's Chorea (Austedo, Tetrabenazine)</u>
	• Member is 18 years of age or older.
	• Prescribed by or in consultation with a neurologist
	• Diagnosis is confirmed by genetic testing of a targeted mutation analysis, demonstrating a cytosine-adenine-guanine (CAG) trinucleotide expansion of 36 or more repeats in the Huntington (HTT) gene
	• Member has a Unified Huntington's Disease Rating Scale (UHDRS), score ranging from 1 to 4 on any one of the Unified Huntington's Disease Rating Scale (UHDRS) chorea items 1 through 7
		• Austedo, tetrabenazine or Ingrezza are not prescribed concurrently with one another
		Tardive Dyskinesia
		• Documentation of improvement in AIMS score from baseline or maintained improvement thereafter
		• Provider is monitoring for all the following:
		  ○ Emergent or worsening depression
		  ○ Suicidal thoughts and behaviors
		  ○ Hepatic dysfunction (for Austedo only)
		Huntington's Chorea
		Requires:
		• Documentation of improvement in Total Maximal Chorea score from baseline or maintained improvement thereafter
		• Provider is monitoring all the following:
		  ○ Emergent or worsening depression
		  ○ Suicidal thoughts and behaviors

Last Update: 12.1.2020, 12.4.2020, 3.1.2021, 5.11.2021, 6.28.2021, 8.1.2021, 9.13.2021, 10.1.2021, 12.17.2021, 1.9.2022, 2.1.2022, 2.17.2022, 2.28.2022, 3.11.2022, 4.5.2022, 4.7.2022, 4.26.2022, 5.11.2022, 5.19.2022, 6.7.2022, 7.9.2022, 8.1.2022, 12.16.2022, 1.1.2023, 1.13.2023, 2.1.2023
,
Current Update: 2.10.2023

		○ Hepatic dysfunction **Quantity Level Limits:** • Ingrezza 30/30 • Austedo 120/30 • Tetrabenazine 120/30
Mulpleta[xlviii]	**Mulpleta may be authorized when all the following criteria are met:** • Member has diagnosis of thrombocytopenia with chronic liver disease and is scheduled to undergo an invasive procedure. • Member is 18 years of age or older • Medication is prescribed by or in consultation with a gastroenterologist or hepatologist • Documentation member has a baseline platelet count of less than 50 x 10^9/L within 14 days of the request • Provider attestation a platelet count will also be obtained no more than 2 days prior to the procedure • Documentation member is scheduled to undergo their procedure 2 – 8 days after the final dose • Member is not undergoing laparotomy, thoracotomy, open-heart surgery, craniotomy, or organ resection • Member does not have a history of splenectomy, partial splenic embolization, or thrombosis, Child-Pugh class C liver disease, absence of hepatoportal blood flow, or a prothrombotic condition other than chronic liver disease • Medication will not be used in combination with other thrombopoietin receptor agonists (for example, Doptelet, Promacta, Nplate) or Tavalisse NOTE: indications not in this guideline are not covered benefits and will not be approved.	**Approval Duration:** 30 days **Quantity Level Limits:** 7 tablets
Multaq[xlix]	**May be authorized when the following criteria are met:**	**Initial Approval:**

Aetna Better Health of Illinois
Prior Authorization Guidelines

	• Member is 18 years of age or older
	• Diagnosis of paroxysmal or persistent atrial fibrillation and
	  ○ Member is currently in normal sinus rhythm, or
	  ○ Member plans to undergo cardioversion to normal sinus rhythm
	• Prescribed by, or in consultation with a cardiologist
	• Attestation member does not have any contraindications as outlined per the prescribing information including, but not limited to the following:
	  ○ Symptomatic heart failure with recent decompensation requiring hospitalization
	  ○ New York Heart Association (NYHA) Class IV chronic heart failure
	• Member had inadequate response, intolerable side effect, or contraindication to one of the following formulary alternatives:
	  ○ amiodarone
	  ○ propafenone
	  ○ flecainide
	  ○ sotalol
		3 months
		
		<u>Renewal Approval</u>:
		6 months
		
		Requires:
		• Attestation that member has positive response to treatment
		• Monitoring of electrocardiogram (ECG) every 3 months to make sure atrial fibrillation (AF) has not become permanent
		
		<u>Quantity Level Limits</u>:
		60/30 days

Multiple Sclerosis	Multiple Sclerosis IL Final.doc.docx	
Oncology - Antineoplastic Agents	**Requests for antineoplastic agents will be reviewed based on the following criteria:** • Member is under the care of an Oncologist or Hematologist • Medication is prescribed for an Food and Drug Administration (FDA)-approved indication OR for a "medically accepted indication" as noted in the following Compendia: ○ National Comprehensive Cancer Network (NCCN) Drugs and Biologic Compendium or National Comprehensive Cancer	**<u>Initial Approval:</u>** 3 months **<u>Renewal Approval:</u>** 1 year ***Requires:***

Last Update: 12.1.2020, 12.4.2020, 3.1.2021, 5.11.2021, 6.28.2021, 8.1.2021, 9.13.2021, 10.1.2021, 12.17.2021, 1.9.2022, 2.1.2022, 2.17.2022, 2.28.2022, 3.11.2022, 4.5.2022, 4.7.2022, 4.26.2022, 5.11.2022, 5.19.2022, 6.7.2022, 7.9.2022, 8.1.2022, 12.16.2022, 1.1.2023, 1.13.2023, 2.1.2023
,
Current Update: 2.10.2023

	Network (NCCN) Clinical Practice Guidelines, category 1, 2a, or 2b. ○ Micromedex DrugDex ○ Clinical Pharmacology • The dose prescribed is within the Food and Drug Administration (FDA)-approved range for the indication and patient specific factors (for example., age, weight or Body Surface Area (BSA), renal function, liver function, drug interactions, etc) • Requests for non-preferred or non-formulary antineoplastics must meet one of the following: ○ Trials of formulary preferred agents (when available based on Food and Drug Administration (FDA) indication and National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines) for an adequate duration were not effective or were poorly tolerated ○ All other formulary preferred alternatives (when available based on Food and Drug Administration (FDA) indication and National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines) are contraindicated based on the member's other medical conditions or drug interactions ○ There are no formulary preferred medications for the patient's indication ○ Member has a genetic mutation that is resistant to the formulary preferred agents ○ All other formulary preferred agents are not alternatives supported by National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for the indication • Medical records, lab results, test results, and clinical markers supporting the diagnosis and treatment are submitted with the request	Attestation of clinically significant improvement or stabilization of disease state

	○ If a test with adequate ability to confirm a disease mutation exists, documentation that the test was performed to confirm the mutation ○ Documentation has been provided of the results of required genetic testing where required per the drug package insert) • Member does not have any contraindications to the medication • Member is not taking other medications that should be avoided with the requested drug based on the Food and Drug Administration (FDA)-approved labeling • Request is not for experimental / investigational use or for a clinical trial	

Aetna Better Health of Illinois
Prior Authorization Guidelines

Nexavar
(sorafenib)[l]
	General Criteria:
	• Prescribed by or in consultation with an oncologist
	• Member is 18 years of age or older
	
	In addition, Nexavar may be authorized when one of the following criteria are met:
	• Advanced renal cell carcinoma with clear cell histology:
	  ○ Trial of a preferred first-line Tyrosine Kinase Inhibitor (such as Sutent (sunitinib), Votrient (pazopanib))
	  ▪ **Note:** Sorafenib is no longer recommended for Non-Clear Cell Renal Cell Carcinoma
	• Hepatocellular carcinoma
	  ○ Disease is metastatic or member is otherwise not eligible for transplant
	• Treatment of differentiated thyroid carcinoma (for example, papillary, follicular, and Hürthle cell), that is refractory to radioactive iodine treatment
	• Metastatic medullary thyroid carcinoma that is persistent or recurrent:
	  ○ Member has symptomatic or progressive disease
	  ○ Trial of Caprelsa (vandetanib) or Cometriq (cabozantinib)
	• Bone Cancer
	  ○ Recurrent Chordoma
	  ▪ Trial of Gleevec (imatinib), Sutent (sunitinib), or Sprycel (dasatinib)
	  ○ Osteosarcoma, dedifferentiated chondrosarcoma, or high-grade Undifferentiated Pleomorphic Sarcoma
	  ▪ Member has relapsed/refractory or metastatic disease
	  ▪ Trial of a first-line regimen containing cisplatin and doxorubicin
		Initial Approval:
		1 year
		
		Renewal Approval:
		3 years
		
		Requires
		• Member does not show evidence of progressive disease while on therapy
		• Member does not have unacceptable toxicity from therapy

Last Update: 12.1.2020, 12.4.2020, 3.1.2021, 5.11.2021, 6.28.2021, 8.1.2021, 9.13.2021, 10.1.2021, 12.17.2021, 1.9.2022, 2.1.2022, 2.17.2022, 2.28.2022, 3.11.2022, 4.5.2022, 4.7.2022, 4.26.2022, 5.11.2022, 5.19.2022, 6.7.2022, 7.9.2022, 8.1.2022, 12.16.2022, 1.1.2023, 1.13.2023, 2.1.2023
,
Current Update: 2.10.2023

Aetna Better Health of Illinois
Prior Authorization Guidelines

	• Angiosarcoma
	• Advanced or unresectable desmoid tumors (aggressive fibromatosis)
	• Gastrointestinal stromal tumor (GIST)
	  ○ Disease progression occurred while on Gleevec (imatinib), Sutent (sunitinib), or Stivarga (regorafenib)
	• Solitary fibrous tumor/hemangiopericytoma
	• Relapsed or refractory acute myeloid leukemia (AML)
	  ○ Nexavar will be used in combination with Vidaza (azacitidine) or Dacogen (decitabine)
	  ○ Member is FLT3-ITD mutation positive	

Ondansetron Oral Solution[li]	**Ondansetron Oral Solution will pay at the point of sale (without requiring prior authorization) when the following criteria is met:** • Member is 3 years of age or younger **Prescriptions that do not pay at the point of sale require prior authorization and may be authorized for members who meet one of the following:** • Member is 3 years of age or younger • Trial of ondansetron tablet or ondansetron orally disintegrating tablet	**Initial Approval:** One year **Renewals:** One year
Opioids	Opioid Guideline IL_4.5.2022.docx	
Oral Liquids **Antidepressants:** Citalopram Solution 10mg/5ml	**May be authorized for members over 12 years of age when the following criteria is met:** • Medical necessity of an oral liquid is due to an inability to use an oral solid dosage form	**Initial Approval**: 1 year **Renewal Approval:** 1 year

Last Update: 12.1.2020, 12.4.2020, 3.1.2021, 5.11.2021, 6.28.2021, 8.1.2021, 9.13.2021, 10.1.2021, 12.17.2021, 1.9.2022, 2.1.2022, 2.17.2022, 2.28.2022, 3.11.2022, 4.5.2022, 4.7.2022, 4.26.2022, 5.11.2022, 5.19.2022, 6.7.2022, 7.9.2022, 8.1.2022, 12.16.2022, 1.1.2023, 1.13.2023, 2.1.2023
,
Current Update: 2.10.2023

Escitalopram Solution 5mg/5ml Nortriptyline Solution 10mg/5ml Sertraline Solution 20mg/ml **Antivirals:** Acyclovir Suspension 200/5ml Tamiflu/ Oseltamivir Suspension 6mg/ml **Corticosteroids:** Prednisone Solution 5mg/5ml **Ulcer Drugs:** Sucralfate Suspension 1gm/10ml Dicyclomine Solution 10mg/5ml Famotidine Suspension 40mg/5ml First-Lansoprazole Suspension 3mg/ml	○ For example, includes but not limited to dysphagia, ulcers, stomatitis, feeding tube	***Requires*:** Member is responding to treatment

Omeprazole + SyrSpend Sf Alka Oral Suspension 2 mg/ml First-Omeprazole Suspension 2mg/ml **Urinary Anti-infective:** Nitrofurantoin Suspension 25mg/5ml		
Overactive Bladder (OAB)[lii] Enablex Gemtesa Myrbetriq Toviaz Tolterodine IR/ER Trospium IR/ER	**Non-Formulary Agents may be authorized when the following criteria are met:** • Member has diagnosis of overactive bladder (OAB) due to urgency, frequency, incontinence, etc. • Age is 18 years or older • There was a trial and failure with two formulary alternatives ○ For example: oxybutynin ER/IR, solifenacin	**Initial Approval:** 1 year **Renewal Approval:** 1 year ***Requires:*** Response to treatment **Quantity Level Limits:** • Enablex - 1 tablet/day • Gemtesa – 1 tablet/day • Myrbetriq - 1 tablet/day • Toviaz - 1 tablet/day • Trospium – 1 tablet/day
Sickle Cell Disease Agents[liii] Endari	**Endari** **May be authorized when all the following criteria are met:** • Diagnosis is for Sickle Cell Disease	**Initial approval**: Endari – 12 months Oxbryta – 6 months

Aetna Better Health of Illinois
Prior Authorization Guidelines

Oxbryta	• Request is to reduce the acute complications experienced from Sickle Cell Disease • Member is 5 years of age or older • There was a previous trial and failure, intolerance, or a contraindication to hydroxyurea • Endari will be used concurrently with hydroxyurea • All other indications are considered experimental/investigational and not medically necessary **Oxbryta** **May be authorized with documentation of all the following:** • Diagnosis of sickle cell disease • Member is 12 years of age or older • Prescribed by or in consultation with a hematologist, or other specialist with expertise in the diagnosis and management of sickle cell disease • Failure of a 3-month trial of hydroxyurea or clinical rationale as to why it cannot be used • Baseline hemoglobin level between 5.5 and 10.5g/dL within the past 3 months • Member has had 1 or more vaso-occlusive crises in the past 12 months • Member is not receiving regular red-cell transfusion therapy, has not received a transfusion in the past 60 days, and has not been hospitalized for vaso-occlusive crisis within 14 days • Adakveo will not be used concurrently	**Renewal Approval:** 12 months ***Requires:*** **Endari** • Member experienced a reduction in acute complications of sickle cell disease (For example, reduction in number of sickle cell crises, acute chest syndrome episodes, fever, occurrences of priapism, splenic sequestration) **Oxbryta** • Documentation showing there has been a sustained hemoglobin increase from baseline of more than 1g/dL **Quantity Level Limits:** Oxbryta – 3 tablets per day
Platelet Inhibitors[liv] Zontivity	**May be approved when the following criteria are met:** • Member has a history of Myocardial Infarction, or Peripheral Artery Disease • Will be used with aspirin and/or clopidogrel	**Approve for members stabilized in hospital** **Initial Approval:** 12 months

Last Update: 12.1.2020, 12.4.2020, 3.1.2021, 5.11.2021, 6.28.2021, 8.1.2021, 9.13.2021, 10.1.2021, 12.17.2021, 1.9.2022, 2.1.2022, 2.17.2022, 2.28.2022, 3.11.2022, 4.5.2022, 4.7.2022, 4.26.2022, 5.11.2022, 5.19.2022, 6.7.2022, 7.9.2022, 8.1.2022, 12.16.2022, 1.1.2023, 1.13.2023, 2.1.2023
,
Current Update: 2.10.2023

	• Member does not have any of the following:
	  ○ History of stroke (Transient Ischemic Attack)
	  ○ Intracranial hemorrhage
	  ○ Active pathological bleeding (for example, peptic ulcer)
		Renewal Approval:
		12 months
		
		***Requires*:**
		Member is not at high risk of bleeding, or has significant overt bleeding
		
		Quantity Level Limit:
		Zontivity: 1 tablet per day

Promacta[lv]	**For all indications:**
	• Attestation that provider to monitor the following labs at baseline and regularly throughout therapy, per frequency outlined in package insert:
	  ○ Ocular examination
	  ○ Complete blood count with differentials
	  ○ Platelet count
	  ○ Liver function tests
	• Medication will not be used in combination with other thrombopoietin receptor agonists (for example, Doptelet, Mulpleta, Nplate) or Tavalisse
	Chronic immune thrombocytopenia (ITP) - Relapsed or Refractory:
	• Member is at least 1 year of age
	• Medication is prescribed by or in consultation with a hematologist
	• Member had insufficient response to corticosteroids, immunoglobulins, or splenectomy
	• Documentation that Promacta is being used to prevent major bleeding in member with platelet count less than 30,000/mm^3 and
		Initial Approval:
		4 weeks
		
		Dosing Restrictions by Indication:
		• Chronic ITP:
		  ○ 75mg/day
		• Hepatitis C-associated Thrombocytopenia:
		  ○ 100mg/day
		• Aplastic Anemia:
		  ○ 150mg/day
		
		Renewal Approval:
		• Chronic ITP (idiopathic thrombocytopenic purpura) with documented platelet increase to greater than

	NOT to achieve platelet counts in normal range (150,000-450,000/mm^3) **Hepatitis C-associated Thrombocytopenia:** • Member is at least 18 years of age • Medication is prescribed by or in consultation with a hepatologist, gastroenterologist, or infectious disease specialist • Member has chronic hepatitis C with baseline thrombocytopenia (documentation of platelet count less than 75,000/mm^3) that prevents initiation of interferon-based therapy when interferon is required NOTE: If member is not receiving interferon-based therapy for treatment of Hepatitis C, Promacta should NOT be approved **Severe Aplastic Anemia:** • Member meets one of the following: ○ Age is at least 17 years old for treatment of refractory aplastic anemia ○ Age is at least 2 years old for first-line treatment of severe aplastic anemia in combination with standard immunosuppressive therapy • Medication is prescribed by or in consultation with a hematologist • Diagnosis of severe aplastic anemia is confirmed by documentation of both the following: ○ Bone marrow cellularity less than 25% (or 25 to 50% if less than 30 percent of residual cells are hematopoietic) ○ At least two of the following: ▪ Absolute Neutrophil Count (ANC) less than 500/mm^3 ▪ Platelet count less than 20,000/mm^3 ▪ Absolute Reticulocyte Count (ARC) less than 20,000/mm^3 OR	50,000/mm^3 to less than 200,000/mm^3: ○ 6 months at current dose • Chronic ITP (idiopathic thrombocytopenic purpura) without documented platelet increase to greater than 50,000/mm^3: ○ 4 additional weeks with dose increase to 75mg/day • Hepatitis C-associated Thrombocytopenia with documented platelet increase to greater than 90,000/mm^3: ○ Duration of antiviral treatment • Hepatitis C-associated Thrombocytopenia without documented platelet increase to greater than 90,000/mm^3: ○ 4 additional weeks with dose increase of 25mg every 2 weeks up to a maximum of 100mg/day, until platelets are greater than 90,000mm^3 • Aplastic anemia with documented platelet increase

	• Anemia is refractory to previous first line treatment, including hematopoietic cell transplantation or immunosuppressive therapy with combination of cyclosporine A and antithymocyte globulin (ATG)
	  ○ Documentation member has a platelet count less than 30,000/mm^3
	
	Limitations of Use:
	• Promacta is not indicated for treatment of myelodysplastic syndrome and is not a covered benefit. Other indications not in this guideline will also not be approved.
		to greater than or equal to 50,000/mm^3:
		  ○ 6 months at current dose
		• Aplastic Anemia without documented platelet increase to greater than or equal to 50,000/mm^3:
		  ○ 4 additional weeks with dose increase up to maximum of 150mg/day

Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9 Inhibitors)[lvi]
 	
Repatha
Praluent
	Medical Records Required with Request
	
	Authorization Criteria for all indications:
	• Prescribed by, or in consultation with, a Cardiologist, Endocrinologist, or Lipid Specialist
	• Member had a trial and failure, or contraindication with Repatha
	• Current lipid panel results within the past 90 days
	• Member meets one of the following:
	  ○ Trial and failure of 2 high intensity statins for 90 days
	  ▪ For example, atorvastatin greater than or equal to 40 mg and rosuvastatin greater than or equal to 20 mg, at maximum tolerated doses and in combination with other lipid lowering therapies such as ezetimibe or bile acid sequestrants
	  ○ Member had intolerance to at least 2 different statins as defined by one of the following:
	  ▪ Documentation supporting skeletal muscle related symptoms
	  ➢ For example, myopathy, myositis or abnormal biomarkers such as alanine aminotransferase /
		Initial Approval:
		3 months
		
		Renewal Approval:
		6 months
		
		Requires:
		• Current Lipid Panel within past 3 months
		• Claims history to support compliance or adherence
		• Low-Density Lipoprotein reduction from baseline
		
		Quantity Level Limit:
		
		Praluent
		• **Atherosclerotic Cardiovascular Disease**
		  ○ 2 syringes per 28 days

	aspartate aminotransferase (ALT/AST) 3 times upper limit of normal, elevation of creatinine kinase 10 times upper limit of normal, or elevation of creatine kinase 4 times upper limit of normal with evidence of rhabdomyolysis ▪ Documentation that dose reduction was attempted for resolution of symptoms and for biomarker abnormalities rather than discontinuation of statin therapy altogether ▪ Documentation member has been re-challenged at lower dose or with different statin ▪ Member has condition that is contraindicated for statin therapy ➢ For example, chronic active liver disease, persistent elevation of serum transaminases **Additional Criteria based on Indication** **<u>Repatha or Praluent</u>** **Atherosclerotic Cardiovascular Disease:** • Member is 18 years of age or older • There is supporting evidence of high cardiovascular disease risk ○ For example, history of acute coronary syndrome, myocardial infarction, stable or unstable angina, coronary or other revascularization (percutaneous coronary intervention/coronary artery bypass grafting), stroke, transient ischemic attack, peripheral arterial disease presumed to be of atherosclerotic origin. • Will be used as an adjunct to diet, alone, or in combination with statin or other lipid lowering therapies such as ezetimibe or bile acid sequestrants	• **Heterozygous Familial Hypercholesterolemia** ○ 2 syringes per 28 days **<u>Repatha</u>** • **Atherosclerotic Cardiovascular Disease** ○ 2 syringes per 28 days • **Heterozygous Familial Hypercholesterolemia** ○ 2 syringes per 28 days ○ May be increased to 3 (140mg) syringes OR 1 (420mg) syringe per 28 days if LDL is >70 after initial trial **<u>Repatha</u>** • **Homozygous Familial Hypercholesterolemia** ○ 3 (140mg) syringes OR 1 (420mg) syringe per 28 days

	• Lab results to support a Low-Density Lipoproteins level greater than or equal to 70 mg/dL (treated)
	
	<u>Repatha or Praluent</u>
	Heterozygous Familial Hypercholesterolemia
	• Member is 18 years of age or older
	• Will be used as an adjunct to diet, alone, or in combination with statin or other lipid lowering therapies such as ezetimibe or bile acid sequestrants
	• There is evidence of one of the following:
	  ○ Low-Density Lipoprotein (LDL)-C is greater than 190 mg/dL either pretreatment or highest on treatment
	  ○ Physical evidence of tendon xanthomas or evidence of these signs in a 1st or 2nd degree relative Deoxyribonucleic acid (DNA) based evidence of a Low-Density Lipoprotein receptor mutation, Apolipoprotein B100 (APO-B100), or Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) mutation
	  ○ Who/Dutch Lipid Network Criteria result with a score of greater than 8 points
	• Lab results to support a current low-density lipoprotein level greater than or equal to 70 mg/dL on treatment.
	
	<u>Repatha</u>
	Homozygous Familial Hypercholesterolemia:
	• Member is 13 years of age or older
	• There is evidence of one of the following:
	  ○ Genetic confirmation of two mutant alleles at low-density lipoprotein receptor, or Apolipoprotein B100 (APO-B100), or Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)
	  ○ History of untreated Low-Density Lipoprotein level over 500mg/dL, or treated Low-Density Lipoprotein level over	

	300mg/dL and member is on maximum dosed statin with evidence of one of the following: ▪ Presence of cutaneous xanthoma before the age of 10 ▪ Evidence of Heterozygous Familial Hypercholesterolemia in both parents • Low-Density Lipoprotein reduction was less than 50% on current lipid lowering therapy o For example, high intensity statin + ezetimibe or bile acid sequestrants	
Increlex[lvii]	**For Members that Meet the Following Criteria:** • Prescribed by or in consultation with a pediatric endocrinologist • Member is 2 years of age and not older than 19 years of age • Documentation showing member has no evidence of the following: o Epiphyseal closure o Active or suspected neoplasia • Documentation supporting one of the following diagnoses: o Growth hormone (GH) gene deletion with development of neutralizing antibodies to Growth hormone (GH) o Severe, Primary Insulin-like growth factor 1 (IGF-1) deficiency ▪ Height standard deviation score less than or equal to -3 ▪ Basal Insulin-like growth factor 1 (IGF-1) standard deviation score less than or equal to -3 ▪ Normal or elevated growth hormone levels (greater than 10ng/mL on standard growth hormone stimulation tests) • Member shows no evidence of secondary forms of Insulin-like growth factor 1 (IGF-1) deficiency, such as growth hormone deficiency (GHD), malnutrition, hypothyroidism, or chronic treatment with pharmacologic doses of corticosteroids • Increlex will not be approved as a substitute to growth hormone for growth hormone indications	**Initial Approval:** 6 months **Renewal Approval:** 12 months ***Requires:*** • Documentation of growth charts • Growth velocity is greater than or equal to 2cm/year • Documentation showing epiphyses are open (confirmed by x-ray) • Member has no active or suspected neoplasia • Member is not on concurrent growth hormone therapy **Quantity Level Limit:** 0.24 mg/kg/day

Aetna Better Health of Illinois
Prior Authorization Guidelines

Nuedexta[lviii]	**May be authorized when all of the following criteria are met:** • Member is 18 years of age or older • Medication is prescribed by, or in consultation with, a specialist (for example, a psychiatrist, psychologist, neuropsychologist, or neurologist) • Diagnosis of pseudobulbar affect (PBA) • Documentation that member has at least one underlying neurologic condition associated with pseudobulbar affect (PBA) • Member has had a cognitive assessment to evaluate for the presence of pseudobulbar affect (PBA) (for example, Center for Neurologic Study-Lability Scale (CNS-LS) greater than or equal to 13 or The Pathological Laughter and Crying Scale (PLACS) greater than or equal to 13) • Member does not have any contraindications to therapy (for example, QT prolongation, Atrioventricular (AV) block, or monoamine oxidase inhibitor (MAOI) therapy in the previous 14 days) • Member has tried and failed selective serotonin reuptake inhibitors (SSRIs) or tricyclic antidepressants (TCAs) • Dose adjustments to desipramine, paroxetine, and digoxin will be made if co-administered with Nuedexta	**Initial Approval:** 3 months **Renewal Approval:** 1 year ***Requires***: Decreased frequency of pseudobulbar affect (PBA) episodes **Quantity Level Limit:** 2 capsules per day
Oxervate[lix]	**May be authorized when member meets the following criteria:** • Diagnosis is for treatment of stage 2 or Stage 3 neurotrophic keratitis • Member is 2 years of age or older • Member experienced persistent epithelial defects (PED), or corneal ulceration for at least 2 weeks • There was trial and failure with one or more conventional non-surgical treatments ○ For example: preservative free artificial tears	**Approval Duration:** 8 weeks total per eye **Recommended Dosing:** One drop in the affected eye(s), 6 times per day at 2-hour intervals, for 8 weeks

Last Update: 12.1.2020, 12.4.2020, 3.1.2021, 5.11.2021, 6.28.2021, 8.1.2021, 9.13.2021, 10.1.2021, 12.17.2021, 1.9.2022, 2.1.2022, 2.17.2022, 2.28.2022, 3.11.2022, 4.5.2022, 4.7.2022, 4.26.2022, 5.11.2022, 5.19.2022, 6.7.2022, 7.9.2022, 8.1.2022, 12.16.2022, 1.1.2023, 1.13.2023, 2.1.2023
,
Current Update: 2.10.2023

	• Documentation of decreased corneal sensitivity (less than or equal to 4 cm using the Cochet-Bonnet aesthesiometer) within the area of epithelial defects (PED) or corneal ulcer, and outside the area of the defect in at least one corneal quadrant • The member has not received a previous 8-week course of Oxervate in the affected eye • All other indications are considered experimental/investigational and not medically necessary	

Idiopathic Pulmonary Fibrosis Agents[lx]
 	
Non-Preferred Agents:
Esbriet
Ofev
	Documentation is required to support approval, when all the following criteria are met:
	• Member is 18 years of age or older
	• Prescribed by, or in consultation with, a pulmonologist or rheumatologist
	• Member meets one of the following:
	  ○ Diagnosis of idiopathic pulmonary fibrosis (IPF) confirmed by:
	  ▪ High resolution computed tomography (HRCT) demonstrating usual interstitial pneumonia (UIP), OR
	  ▪ Surgical lung biopsy with usual interstitial pneumonia (UIP)
	  ○ Diagnosis of chronic fibrosing of interstitial lung disease (Ofev only) with:
	  ▪ Relevant fibrosis (greater than 10% fibrotic features), AND
	  ▪ Clinical signs of progression (forced vital capacity (FVC) decline greater than or equal to 10%, FVC decline greater than or equal to 5% and less than 10% with worsening symptoms or imaging, or worsening symptoms and worsening imaging all in the 24 months prior to screening)
	  ○ Diagnosis of systemic sclerosis-associated interstitial lung disease (Ofev only) with:
	  ▪ Onset of disease (first non-Raynaud symptom) of less than 7 years, AND
		Initial Approval:
		3 months
		
		Renewal Approval:
		6 months
		
		Requires:
		Documentation of all the following:
		• Stable Forced Vital Capacity (FVC) (recommend discontinuing if there is greater than 10% decline in Forced Vital Capacity (FVC) over 12-month period)
		• Liver function tests (LFTs) are being monitored
		• Member is not a current smoker
		• Compliance and adherence to treatment
		
		Quantity Level Limit:

	▪ Greater than or equal to 10% fibrosis on a chest high resolution computed tomography (HRCT) scan conducted within the previous 12 months • Forced vital capacity (FVC) greater than or equal to 40% predicted • Carbon Monoxide Diffusion Capacity (DLCO) greater than or equal to 30% • Baseline liver function tests (LFTs) prior to initiating treatment • Member is not a current smoker • Other known causes of interstitial lung disease have been ruled out o For example, domestic and occupational environmental exposures, connective tissue disease, or drug toxicity • Negative pregnancy test result for females of reproductive potential o Ofev only	**Ofev:** 2 capsules per day **Esbriet:** 9 capsules per day or 3 tablets per day
Pulmonary Arterial Hypertension[lxi] **PREFERRED AGENTS** **Oral:** sildenafil tadalafil 20mg Revatio Suspension Tracleer Letairis **Injectable:** Epoprostenol Flolan	**Authorization Guideline for All Agents:** • Prescribed by, or in consultation with pulmonologist or cardiologist • Evidence of right heart catheterization with mean Pulmonary Arterial Pressure (mPAP) greater than or equal to 25 mmHg • Medical records supporting diagnosis of Pulmonary Arterial Hypertension World Health Organization Group I with Functional Class II to IV symptoms • Member meets one of the following criteria: o Negative vasoreactivity test o Contraindication to vasoreactivity test ▪ For example, low blood pressure, low cardiac index, or presence of severe Functional Class IV symptoms o Positive vasoreactivity test with inadequate response, or intolerance, to one calcium channel blocker: ▪ For example, amlodipine, nifedipine ER, or diltiazem o Contraindication to use of calcium channel blockers	**Initial Approval**: 6 months **Renewal Approval**: 1 year ***Requires*:** • Medical records and lab results to support response to therapy; maintaining or achieving a low risk profile o For example, improvement in 6-minute walk distance, functional class, or reducing time to clinical worsening

Aetna Better Health of Illinois
Prior Authorization Guidelines

NON-PREFERRED AGENTS:
 	
Oral:
Adempas
Opsumit
Orenitram
Revatio
Uptravi
 	
Inhaled:
Tyvaso
Ventavis
 	
Injectable:
Remodulin
treprostinil
Veletri
	Note: Adempas may include World Health Organization Group IV and does not require trial of calcium channel blocker
	
	Additional Drug Specific Criteria:
	
	Brand Revatio oral suspension
	• Documentation to support inability to swallow, and necessity of brand suspension formulation
	Adempas
	• Member meets one of the following diagnoses:
	  ○ Diagnosis of Pulmonary Arterial Hypertension, World Health Organization Group I with Functional Class II to IV symptoms
	  ○ Member tried and failed all preferred oral agents from each of the following class:
	  ▪ Phosphodiesterase 5 Inhibitors: sildenafil, tadalafil
	  ▪ Endothelin Receptor Antagonists: Tracleer, Letairis
	  ○ Diagnosis of Chronic Thromboembolic Pulmonary Hypertension, World Health Organization Group IV and one of the following:
	  ▪ Recurrent or persistent Chronic Thromboembolic Pulmonary Hypertension, after surgical treatment
	  ▪ Inoperable Chronic Thromboembolic Pulmonary Hypertension
	Uptravi, **Orenitram, Revatio, Opsumit**
	• Member does not have severe hepatic impairment (Child-Pugh class C)
	• For members with World Health Organization Functional Class II and III symptoms:
	  ○ There was a trial and failure with all preferred oral agents from each of the following classes:
	  ▪ Phosphodiesterase 5 Inhibitors: sildenafil, tadalafil
		Quantity Level Limit:
		Adempas:
		90 tablets per 30 days
		
		Opsumit:
		30 tablets per 30 days
		
		Orenitram: Determine by tolerability:
		90 tablets per 30 days
		
		Sildenafil:
		90 tablets per 30 days
		
		Brand Revatio oral suspension:
		180 mL per 30 days
		
		Tadalafil:
		60 tablets per 30 days
		
		Tracleer:
		60 tablets per 30 days
		
		Letairis:
		30 tablets per 30 days
		
		Uptravi:
		60 tablets per 30 days
		(may be higher during titration phase)
		
		Tyvaso:
		54 mcg (9 breaths) per treatment session, 4 times daily
		
		Flolan/Veletri:

Last Update: 12.1.2020, 12.4.2020, 3.1.2021, 5.11.2021, 6.28.2021, 8.1.2021, 9.13.2021, 10.1.2021, 12.17.2021, 1.9.2022, 2.1.2022, 2.17.2022, 2.28.2022, 3.11.2022, 4.5.2022, 4.7.2022, 4.26.2022, 5.11.2022, 5.19.2022, 6.7.2022, 7.9.2022, 8.1.2022, 12.16.2022, 1.1.2023, 1.13.2023, 2.1.2023
,
Current Update: 2.10.2023

	▪ Endothelin Receptor Antagonists: Tracleer, Letairis • For members with World Health Organization Functional Class IV symptoms: o There was a trial and failure with one Prostacyclin Analog such as epoprostenol **Tyvaso**, **Veletri, Ventavis**, **Remodulin**, **treprostinil** • Member has World Health Organization Functional Class III-IV symptoms (for example, Tyvaso, Veletri, and Ventavis), or Functional Class II-IV symptoms (for example, Remodulin, treprostinil) • For members with World Health Organization Functional Class II and III symptoms: o There was a trial and failure with all preferred oral agents from each of the following classes: ▪ Phosphodiesterase Type 5 Inhibitors: sildenafil, tadalafil ▪ Endothelin Receptor Antagonists: Tracleer, Letairis • For members with World Health Organization Functional Class IV symptoms: o There was a trial and failure with one Prostacyclin Analog such as epoprostenol **<u>Coverage Limitation:</u>** **Any contraindications to treatment including but not limited to the following:** • Pregnancy: o Endothelin Receptor Antagonists and Adempas • Concurrent use of nitrate or nitric oxide donors (for example, isosorbide mononitrate, isosorbide dinitrate, nitroglycerin): o Phosphodiesterase Type 5 Inhibitors and Adempas • Child Pugh class C hepatic impairment:	56 vials per 28 days <u>Remodulin/treprostinil:</u> 1 vial per 30 days

	○ Orenitram, Uptravi • Heart Failure with severe left ventricular dysfunction: ○ Veletri/epoprostenol • Pulmonary veno-occlusive disease: ○ tadalafil, sildenafil, Letairis, Opsumit, epoprostenol, Tracleer **Coverage Exclusions:** • Requests for Viagra (sildenafil) for Pulmonary Arterial Hypertension must be redirected to Revatio (sildenafil) • Requests for Cialis (tadalafil) for Pulmonary Arterial Hypertension must be redirected to tadalafil. **Additional Information:** • Pediatric case requests have an accepted off-label use and will require to further be sent to medical director for review **WHO Functional Classification of Pulmonary Hypertension** **Class I:** • No limitation of physical activity. Ordinary physical activity does not cause undue dyspnea or fatigue, chest pain, or near syncope. **Class II:** • Slight limitation of physical activity. Comfortable at rest, but ordinary physical activity causes undue dyspnea or fatigue, chest pain, or near syncope. **Class III:** • Marked limitation of physical activity. Comfortable at rest, but less than ordinary activity causes undue dyspnea or fatigue, chest pain, or near syncope. **Class IV:** • Inability to carry out any physical activity without symptoms. Dyspnea and/or fatigue may be present at rest and discomfort is increased by any physical activity.	

Aetna Better Health of Illinois
Prior Authorization Guidelines

Rectiv	**Rectiv may be authorized when the following criteria are met:** • Member has a diagnosis of pain associated with anal fissures.	**Initial Approval:** 6 months **Renewal Approval:** 1 year

Revlimid[lxii] **(lenalidomide)**	**General Criteria:**
	• Prescribed by or in consultation with an oncologist
	• Member is 18 years of age or older
	In addition, Revlimid may be authorized when one of the following criteria is met:
	• Multiple myeloma
	• Mantle cell lymphoma, after relapse or progression with two prior therapies, one of which includes Velcade (bortezomib)
	• Myelodysplastic Syndrome, member meets one of the following:
	  ○ Symptomatic anemia associated with the 5q-deletion cytogenetic abnormality
	  ○ Symptomatic anemia without the 5q-deletion, and serum erythropoietin levels greater than 500 mU/mL or history of failure, contraindication, or intolerance to a preferred erythropoietin
	• Diffuse Large B-cell Lymphoma with one of the following:
	  ○ Used as maintenance therapy for ages 60 – 80 years
	  ○ Used as second-line therapy or as therapy for relapsed/refractory disease
	• Follicular lymphoma
	• Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma with one of the following:
	  ○ Used for post first-line chemoimmunotherapy maintenance
	  ○ Used for relapsed or refractory disease
		Initial Approval:
		1 year
		
		Renewal Approval:
		1 year
		
		Requires
		• Member does not show evidence of progressive disease while on therapy
		• Member does not have unacceptable toxicity from therapy

Last Update: 12.1.2020, 12.4.2020, 3.1.2021, 5.11.2021, 6.28.2021, 8.1.2021, 9.13.2021, 10.1.2021, 12.17.2021, 1.9.2022, 2.1.2022, 2.17.2022, 2.28.2022, 3.11.2022, 4.5.2022, 4.7.2022, 4.26.2022, 5.11.2022, 5.19.2022, 6.7.2022, 7.9.2022, 8.1.2022, 12.16.2022, 1.1.2023, 1.13.2023, 2.1.2023
,
Current Update: 2.10.2023

	• Systemic light chain amyloidosis, in combination with dexamethasone • Hodgkin's Lymphoma, as subsequent therapy for relapsed/refractory disease • Adult T-cell leukemia/lymphoma, second-line, or subsequent therapy • Peripheral T-cell lymphoma, second-line, or subsequent therapy for relapsed or refractory disease • Marginal Zone Lymphoma, including Mucosa-Associated Lymphoid Tissue Lymphoma, nodal marginal zone lymphoma, and splenic marginal zone lymphoma ○ Disease has been previously treated and therapy will be given in combination with rituximab • Myelofibrosis-associated anemia with serum erythropoietin levels greater than or equal to 500 mU/mL, or failure with a preferred erythropoiesis stimulating agent • Acquired Immune Deficiency Syndrome (AIDS)-Related B-cell lymphoma, as second-line or subsequent therapy • Castleman's Disease, as second-line or subsequent therapy for disease that has progressed following therapy for relapsed/refractory or progressive disease • Mycosis fungoides/Sezary syndrome	
Rybelsus[lxiii]	**Rybelsus will be covered with prior authorization when the following criteria are met:** • Member has a diagnosis of type 2 diabetes mellitus • Provider attests that medication will be administered as adjunct to diet and exercise • Member meets one of the following: ○ There was inadequate response, intolerance, or contraindication to metformin	**Approval Duration:** One year

	○ Member requires combination therapy due to a hemoglobin A1c of 7.5 or greater	
Second/Third Generation Tyrosine Kinase Inhibitors (TKI) for Chronic Myeloid Leukemia (CML) and Acute Lymphoblastic Leukemia (ALL)[lxiv] **<u>Second Generation</u>:** Sprycel (dasatinib) Tasigna (nilotinib) Bosulif (bosutinib) **<u>Third Generation</u>:** Iclusig (ponatinib)	Imatinib, a first-generation Tyrosine Kinase Inhibitor (TKI), is the preferred agent for Chronic Myeloid Leukemia (CML) and Acute Lymphoblastic Leukemia (ALL) with prior authorization Imatinib should NOT be used in patients who had treatment failure with a second or third generation Tyrosine Kinase Inhibitor (TKI) Tasigna and Sprycel - Second generation Tyrosine Kinase Inhibitors (TKIs), are formulary preferred with prior authorization **General Criteria:** • Prescribed by or in consultation with an oncologist • Member is 18 years of age or older ○ Exception for Tasigna: Diagnosis of Chronic myeloid leukemia (CML) in chronic phase for 1 year of age or older ○ Exception for Sprycel: Diagnosis of Philadelphia Chromosome Positive (Ph+) Chronic myeloid leukemia (CML) in chronic phase and newly diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) in those 1 year of age or older **In addition, Tasigna or Sprycel may be authorized when one the following criteria is met:** • Newly diagnosed Chronic Myeloid Leukemia (CML) in chronic phase: ○ Low to intermediate risk group determined by EUTOS, Euro [Hasford], or Sokal scores, requires trial of imatinib; or ○ High risk group determined by EUTOS, Euro [Hasford], or Sokal scores • Newly diagnosed Philadelphia chromosome positive (Ph+), or BCR-ABL1 positive Acute Lymphoblastic Leukemia (ALL)	**<u>Initial Approval:</u>** 1 year **<u>Renewal Approval:</u>** 3 years ***Requires*** • Member does not show evidence of progressive disease while on therapy • Member does not have unacceptable toxicity from therapy

	• Chronic Myeloid Leukemia (CML) in chronic or advanced phase, or Philadelphia chromosome positive (Ph+), or BCR-AB1 positive Acute Lymphoblastic Leukemia: Intolerance, disease progression, or resistance to prior therapy of imatinib • Follow-up treatment for Chronic Myeloid Leukemia (CML) with allogeneic hematopoietic cell transplant **In addition, Bosulif may be authorized when ONE the following criteria is met:** • Newly diagnosed Philadelphia chromosome positive (Ph+) Chronic Myeloid Leukemia (CML) in chronic phase: o Low or intermediate risk group determined by EUTOS, Euro [Hasford], or Sokal scores, requires trial of imatinib, AND Tasigna or Sprycel o High risk group determined by EUTOS, Euro [Hasford], or Sokal scores, requires trial of Tasigna or Sprycel • Chronic Myeloid Leukemia (CML) in chronic phase or in advanced phase, or Philadelphia chromosome positive (Ph+), or BCR-ABL1 positive Acute Lymphoblastic Leukemia (ALL), and intolerance, disease progression, or resistance to imatinib and Tasigna or Sprycel • Follow-up treatment for Chronic Myeloid Leukemia after allogeneic hematopoietic cell transplant **In addition, Iclusig may be authorized when one of the following criteria is met:** • Chronic Myeloid Leukemia (CML) in chronic phase, or advanced phase, or Philadelphia chromosome positive (Ph+), or BCR-ABL1 positive Acute Lymphoblastic Leukemia (ALL) *(note: not indicated in newly diagnosed chronic phase CML)* o T315I-positive OR	

	○ Disease has not responded to 2 or more Tyrosine Kinase Inhibitor (TKI) therapies (for example, imatinib, Tasigna, Sprycel, or Bosulif), or other Tyrosine Kinase Inhibitor (TKI) therapy is not indicated. • Follow-up treatment for Chronic Myeloid Leukemia (CML) after allogeneic hematopoietic cell transplant	
Soliris[lxv]	**Atypical hemolytic uremic syndrome** • Medical records/lab results indicating the following: ○ ADAMTS 13 activity level above 5% ○ Absence of Shiga toxin **Paroxysmal nocturnal hemoglobinuria** • Medical records/lab results indicating the following: ○ Diagnosis of Paroxysmal nocturnal hemoglobinuria was confirmed by detecting a deficiency of glycosylphosphatidylinositol-anchored proteins (GPI-APs) as demonstrated by either of the following: ▪ At least 5% PNH cells ▪ At least 51% of GPI-anchored protein deficient poly-morphonuclear cells ○ Flow cytometry is used to demonstrate GPI-anchored proteins deficiency **Generalized myasthenia gravis (gMG)** • Medical records/lab results indicating the following: ○ Anti-acetylcholine receptor (AchR) antibody positive ○ Myasthenia Gravis Foundation of America (MGFA) clinical classification II to IV ▪ MG activities of daily living (MG-ADL) total score ≥6 ▪ Meets both of the following: • Member had inadequate response to at least two immunosuppressive therapies listed below:	**Initial Approval:** Atypical hemolytic uremic syndrome: 6 months Paroxysmal nocturnal hemoglobinuria: 6 months Generalized myasthenia gravis (gMG): 6 months Neuromyelitis Optica Spectrum Disorder (NMOSD): 6 months **Renewal Approval:** ***Requires:*** Medical records/lab results indicating the following: Atypical hemolytic uremic syndrome: 12 months

	i. azathioprine ii. cyclosporine iii. mycophenolate mofetil iv. tacrolimus v. methotrexate vi. cyclophosphamide • Member has inadequate response to chronic IVIG AND rituximab **Neuromyelitis Optica Spectrum Disorder (NMOSD)** • Medical records/lab results indicating the following: o Anti-aquaporin-4 (AQP4) antibody positive o Member exhibits one of the following core clinical characteristics: ▪ Optic neuritis ▪ Acute myelitis ▪ Area postrema syndrome • For example, episode of otherwise unexplained hiccups or nausea and vomiting) ▪ Acute brainstem syndrome ▪ Symptomatic narcolepsy or acute diencephalic clinical syndrome with Neuromyelitis Optica Spectrum Disorder - typical diencephalic MRI lesions ▪ Symptomatic cerebral syndrome with Neuromyelitis Optica Spectrum Disorder -typical brain lesions o Member will not be treated with rituximab and Soliris concomitantly	• There is no evidence of unacceptable toxicity or disease progression while on current regimen • Member demonstrates a positive response to therapy o For example, normalization of lactate dehydrogenase levels, platelet counts <u>Paroxysmal nocturnal hemoglobinuria:</u> 12 months • There is no evidence of unacceptable toxicity or disease progression while on current regimen • Member demonstrates a positive response to therapy o For example, improvement in hemoglobin levels, normalization of lactate dehydrogenase levels <u>Generalized myasthenia gravis (gMG):</u> 12 months • There is no evidence of unacceptable toxicity or disease progression while on current regimen • Member demonstrates a positive response to therapy

		○ For example, improvement in MG-ADL score, changes compared to baseline in Quantitative Myasthenia Gravis total score Neuromyelitis optica spectrum disorder (NMOSD): 12 months • There is no evidence of unacceptable toxicity or disease progression while on current regimen • Member demonstrates a positive response to therapy ○ For example, reduction in the number of relapses
Somatostatin Analogs[lxvi] **Non-Preferred Agents:** Octreotide Sandostatin Long-Acting Release Signifor Signifor Long-Acting Release Somatuline Depot	**General Authorization Criteria for ALL Indications:** • Member is 18 year of age or older (unless prescribed for pediatric chemotherapy-induced diarrhea) • Sandostatin Long-Acting Release and Somatuline Depot: ○ Baseline testing for the following: ▪ A1c or fasting glucose ▪ Thyroid-stimulating hormone ▪ Electrocardiography • Signifor and Signifor Long-Acting Release: ○ Baseline testing for the following: ▪ A1c, or fasting plasma glucose ▪ Electrocardiography ▪ Potassium ▪ Magnesium ▪ Thyroid-stimulating hormone	**Initial Approval:** 6 months **Renewal Approval:** • Acromegaly, Cushing's, Carcinoid and VIPomas: One year • All other indications: 6 months ***Requires:*** Documentation of the following for all indications for somatostatin analogs: • A1c or fasting glucose

	▪ Liver function tests ▪ Attestation that gallbladder ultrasound has been completed **Additional Criteria Based on Indication:** • **Acromegaly** Octreotide, Sandostatin Long-Acting Release, Somatuline Depot, Signifor Long-Acting Release, Somavert: ○ Prescribed by, or in consultation with, an endocrinologist ○ Member has one of the following: ▪ Persistent disease following radiotherapy and/or pituitary surgery ▪ Surgical resection is not an option as evidenced by one of the following: ➢ Majority of tumor cannot be resected ➢ Member is a poor surgical candidate based on comorbidities ➢ Member prefers medical treatment over surgery, or refuses surgery ○ Baseline insulin-like growth factor-1 (IGF-1) meets one of the following criteria: ▪ Greater than or equal to 2.5 times the upper limit of normal for age ▪ Remains elevated despite a 6-month trial of maximally tolerated dose of cabergoline (unless member cannot tolerate, or has contraindication to cabergoline) • **Carcinoid Tumor or Vasoactive Intestinal Polypeptide Secreting Tumor (VIPomas)** Octreotide, Sandostatin Long-Acting Release, Somatuline Depot - To reduce frequency of short-acting somatostatin analog	• Electrocardiography • Monitor for cholelithiasis and discontinue if complications of cholelithiasis are suspected • Thyroid-stimulating hormone • Response to therapy **Documentation of additional requirements per indication or drug:** • Acromegaly: ○ Decreased or normalized insulin-like growth factor-1 (IGF-1) levels • Cushing's: ○ Decreased or normalized cortisol levels • Signifor: ○ Liver function tests **Quantity Level Limits:** • Octreotide: Max dose 1500mcg/day • Sandostatin (LAR): Maximum dose 40mg every 4 weeks ○ 10mg and 30mg vials: 1 vial per 28 days ○ 20mg vials: 2 vials per 28 days

	rescue therapy: ○ Prescribed by, or in consultation with, an oncologist or endocrinologist • **Cushing's Syndrome** Signifor, Signifor Long-Acting Release: ○ Member has persistent disease after pituitary surgery, or surgery is not an option ○ Member had inadequate response, intolerable side effects, or contraindication to cabergoline ○ NOTE: Member does not need a trial of octreotide or Sandostatin Long-Acting Release for approval • **Hepato-renal syndrome** Octreotide: ○ Prescribed by hepatologist or nephrologist ○ Must be used in combination with midodrine and albumin • **Gastro-entero-pancreatic neuroendocrine tumor** Octreotide, Sandostatin Long-Acting Release, Somatuline Depot: ○ Prescribed by, or in consultation with, an oncologist or endocrinologist ○ Member has persistent disease after surgical resection, or is not a candidate for surgery **Octreotide may be reviewed for medical necessity and approved for the following:** • Chemotherapy-induced diarrhea in pediatrics, when prescribed by, or in consultation with, oncologist • Dumping Syndrome in adults 18 years of age or older • Enterocutaneous fistula in adults 18 years of age or older • Hyperthyroidism due to thyrotropinoma in adults 18 years of age or older	• Signifor: 2 vials per day • Signifor (LAR): 1 vial per 28 days • Somatuline Depot: 1 syringe per 28 days

	• Short bowel syndrome (associated diarrhea) in adults 18 years of age or older • Portal hypertension and/or upper gastrointestinal bleed related to variceal bleeding, in adult members with esophageal varices that are 18 years of age or older • Other, medically accepted indications per compendia	

Spinraza[lxvii]	**May be authorized when all the following criteria are met:**
	• Member has a diagnosis of spinal muscular atrophy confirmed by genetic testing
	• Prescribed by, or in consultation with a neurologist
	• Documentation that member has Type I, Type II, or Type III Spinal Muscular Atrophy
	• Member is 15 years of age or younger at initiation of treatment
	• Member is confirmed to have at least 2 copies of the Survival Motor Neuron-2 (SMN2) gene
	• Genetic test confirms presence of one of the following chromosome 5q mutations or deletions:
	  ○ Homozygous deletions of Survival Motor Neuron-1 (SMN1) gene
	  ○ Homozygous mutation in the Survival Motor Neuron-1 (SMN1) gene
	  ○ Compound heterozygous mutation in the Survival Motor Neuron-1 (SMN1) gene (deletion of Survival Motor Neuron-1 (SMN1) exon 7 (allele 1), and mutation of Survival Motor Neuron-1 (SMN1) (allele 2))
	• Member is not dependent on any of the following:
	  ○ Invasive ventilation for more than 16 hours per day, or tracheostomy
	  ○ Non-invasive ventilation for at least 12 hours per day
	• Baseline motor milestone score is obtained using one of the following assessments:
		Initial Approval:
		2 months
		
		Renewal Approval:
		4 months
		
		Requires:
		• Response to therapy as demonstrated by medical records of one of the following:
		  ○ Maintained, or improved motor milestone score, using the same exam as performed at baseline (refer to specific exam below)
		  ○ Achieved, and maintained any new motor milestones, when otherwise would be unexpected to do so, using the same exam as performed at baseline
		Additional Requirements per Exam Performed:

	○ Hammersmith Functional Motor Scale Expanded (HFMSE) ○ Hammersmith Infant Neurologic Exam Part 2 (HINE-2) ○ Revised Upper Limb Module (RULM) test ○ Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) ○ Six-minute walk test • Baseline labs to rule out coagulation abnormalities and thrombocytopenia: ○ Platelet count ○ Prothrombin time (PT), and activated partial thromboplastin time (aPTT) • Baseline labs to rule out renal toxicity: ○ Quantitative spot urine protein testing <u>Exclusion Criteria:</u> • There is currently insufficient evidence to support initiation of Spinraza after the age of 15 years. • Spinraza will not be approved for spinal muscular atrophy without confirmation of the chromosome 5q mutation or deletion testing. • Medication is not concurrently prescribed with Evrysdi or Zolgensma	• **Hammersmith Infant Neurologic Exam Part 2 (HINE-2)** ○ One of the following: ▪ Improvement, or maintenance of previous improvement, of at least a 2-point increase in ability to kick ▪ Improvement, or maintenance of previous improvement, of at least a 1-point increase, in any other milestone (for example, head control, rolling, sitting, crawling), excluding voluntary grasp • **Hammersmith Functional Motor Scale Expanded (HFMSE)** ○ Improvement, or maintenance of previous improvement, of at least a 3-point increase in score from baseline • **Revised Upper Limb Module (RULM)**

		○ Improvement, or maintenance of previous improvement, of at least a 2-point increase in score from baseline • **Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND)** ○ Improvement, or maintenance of previous improvement, of at least a 4-point increase in score from baseline • **6-Minute Walk Test (6MWT)** ○ Maintained, or improved score from baseline • The following laboratory tests showing improvement from pretreatment baseline status: ○ Platelet count ○ Coagulation tests such as prothrombin time (PT), activated partial thromboplastin time (aPTT) ○ Quantitative spot urine protein test **Quantity Level Limit:** *Initial:*

		• 12 mg (5 mL) per administration ➢ Total of 4 loading doses. First 3 doses are given at 14-day intervals. The 4th dose is given 30 days after the 3rd dose. *Maintenance:* • Given once every 4 months
Spiriva Respimat[lxviii] (Long-acting Muscarinic Agents [LAMA])	**Incruse Ellipta** is the formulary preferred agent for the treatment of chronic obstructive pulmonary disease (COPD) and does not require prior authorization **Spiriva Respimat may be authorized when:** • Member is 6 years of age or older with a diagnosis of asthma • Member is currently taking an inhaled corticosteroid (ICS), and will continue with an inhaled corticosteroid (ICS) when Spiriva is initiated • There was a trial and failure with at least two formulary agents: o Inhaled corticosteroid o Inhaled corticosteroid with a long-acting beta-2 agonist o Montelukast or zafirlukast NOTE: Spiriva HandiHaler, and Incruse Ellipta are not Food and Drug Administration (FDA) approved for asthma	**Initial Approval:** 12 months **Renewal Approval:** 12 months ***Requires:*** Member is currently taking an inhaled corticosteroid (ICS), and will continue to take the inhaled corticosteroid (ICS) along with Spiriva Respimat
Synagis[lxix]	**May be authorized for members in the following groups when the criteria are met:** **Preterm Infants without Chronic Lung Disease (CLD):** • Gestational Age less than 29 weeks, 0 days • 12 months of age or younger at start of Respiratory Syncytial Virus (RSV) season	**Approval Duration:** 1 dose per month for maximum of 5 doses per season **Note:** Infants born during Respiratory Syncytial Virus (RSV)

	Preterm Infants with Chronic Lung Disease (CLD):
	• Gestational Age less than 32 weeks, 0 days
	• Member meets one of the following:
	  ○ Less than 12 months of age at start of Respiratory Syncytial Virus (RSV) season, and required greater than 21% oxygen for greater than or equal to 28 days after birth
	  ○ Between 12 and 24 months of age at start of Respiratory Syncytial Virus (RSV) season, and continues to require medical support within 6 months of start of Respiratory Syncytial Virus (RSV) season
	  ▪ for example, supplemental oxygen, chronic systemic corticosteroid therapy, diuretic therapy, or bronchodilator therapy
	Infants with Hemodynamically Significant Congenital Heart Disease:
	• Member meets one of the following:
	  ○ Between 12 and 24 months of age at start of Respiratory Syncytial Virus (RSV) season, and has undergone cardiac transplantation during Respiratory Syncytial Virus (RSV) season
	  ○ Less than 12 months of age at start of Respiratory Syncytial Virus (RSV) season and meets one of the following:
	  ▪ Diagnosis of acyanotic heart disease that will require cardiac surgery and currently receiving medication to control heart failure
	  ▪ Diagnosis of cyanotic heart disease and prophylaxis is recommended by Pediatric Cardiologist
	  ▪ Diagnosis of moderate to severe pulmonary hypertension
	Children with Anatomic Pulmonary Abnormalities or Neuromuscular Disorder:
		season may require fewer than 5 doses
		
		Requires:
		Current weight to confirm correct vial size at 15mg/kg dose

	• 12 months of age or younger at start of Respiratory Syncytial Virus (RSV) season
	• Disease or congenital anomaly impairs ability to clear secretions from upper airway because of ineffective cough
	Immunocompromised Children:
	• 24 months of age or younger at start of Respiratory Syncytial Virus (RSV) season
	• Child is profoundly immunocompromised during Respiratory Syncytial Virus (RSV) season
	Children with Cystic Fibrosis
	• Member meets one of the following:
	  ○ 12 months of age or younger with clinical evidence of chronic lung disease (CLD) and/or nutritional compromise in first year of life
	  ○ 24 months of age or younger with manifestations of severe lung disease, (previous hospitalization for pulmonary exacerbation in first year of life, or abnormalities on chest radiography or chest computed tomography that persist when stable), or weight for length less than 10th percentile.
	The following groups are not at increased risk of Respiratory Syncytial Virus (RSV) and should NOT receive Synagis:
	• Infants and children with hemodynamically insignificant heart disease (for example, secundum atrial septal defect, small ventricular septal defect, pulmonic stenosis, uncomplicated aortic stenosis, mild coarctation of aorta, and patent ductus arteriosus)
	• Infants with lesions adequately corrected by surgery, unless continue to require medication for congestive heart failure
	• Infants with mild cardiomyopathy who are not receiving medical therapy for condition
	• Children with cystic fibrosis (unless above criteria is met)	

	• Children with Down Syndrome (unless qualifying heart disease or prematurity) • Children who had met criteria above but experienced break through Respiratory Syncytial Virus (RSV) hospitalization during current season.	

Tadalafil (Cialis)[lxx]	**Tadalafil 5mg may be approved for members who meet all the following:**
	• Diagnosis of benign prostatic hyperplasia (BPH)
	• Inadequate response, intolerable side effects or contraindication to both of the following:
	  ○ Two alpha blockers
	  ▪ For example, alfuzosin, tamsulosin, doxazosin, terazosin
	  ○ Finasteride for at least 6 months
	• Member is not using any form of organic nitrate (for example, nitroglycerin, isosorbide dinitrate, isosorbide mononitrate or amyl nitrate) or Adempas
	
	NOTE: Use of tadalafil for treatment of erectile dysfunction including penile rehabilitation is not a covered benefit
		Initial Approval:
		3 months
		
		Renewal Approval:
		12 months
		
		Requires:
		• Demonstration of improvement in symptoms
		  ○ Improvement of International Prostate Symptom Score (I-PSS), or American Urological Association (AUA) Symptom Index score from baseline
		• Member continues to not use organic nitrates or Adempas
		
		Quantity Level Limit:
		30/30 days

Tarceva[lxxi] (erlotinib)	**General Criteria:** • Prescribed by or in consultation with an oncologist • Member is 18 years of age or older **In addition, Tarceva may be authorized when one the following criteria is met:**	**Initial Approval:** 1 year **Renewal Approval**: 3 years

	• Locally advanced or metastatic pancreatic cancer in combination with gemcitabine (Gemzar)
	• Advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) with one of the following:
	  ○ Epidermal Growth Factor Receptor (EGFR) exon 19 deletion
	  ○ Exon 21 (L858R) substitution mutation
	• Central Nervous System Cancer
	  ○ Member is positive for the sensitizing Epidermal Growth Factor Receptor (EGFR) exon 19 deletion or exon 21 (L858R) substitution mutation, and meets one of the following:
	  ▪ Brain metastases as result of recurrent Non-Small Cell Lung Cancer (NSCLC)
	  ▪ Leptomeningeal or spinal metastases from Non-Small Cell Lung Cancer (NSCLC)
	• Advanced Renal Cell Carcinoma (RCC):
	  ○ Disease is relapsed or stage IV
	  ○ Non-clear cell histology
	• Advanced, recurrent, or metastatic vulvar cancer when used as a single agent
	• Recurrent chordoma
	  ○ Trial of Gleevec (imatinib), Sutent (sunitinib), or Sprycel (dasatinib)
		***Requires*:**
		• Member does not show evidence of progressive disease while on therapy
		• Member does not have unacceptable toxicity from therapy

Tavalisse[lxxii]	**May be authorized when the following criteria are met:** • Member is 18 years of age or older • Diagnosis of chronic, refractory immune thrombocytopenia (ITP) • Medication is prescribed by or in consultation with a hematologist • Insufficient response to at least one previous treatment such as corticosteroid, splenectomy, immunoglobulin, Thrombopoietin (TPO) Receptor Agonists (Promacta, Nplate), or Rituxan • Documentation of a baseline platelet count less than 30 x 10^9/L	**<u>Initial Approval</u>:** 4 months **<u>Renewal Approval</u>:** 6 months ***Requires*:** • Documentation showing that

	• After obtaining baseline assessments, provider attests to the following:
	  ○ Monitor complete blood counts (CBCs), including platelet counts, monthly until a stable platelet count (at least 50 x 10^9/L) is achieved.
	  ○ Monitor liver function tests (LFTs) (for example, alanine aminotransferase [ALT], aspartate aminotransferase [AST] and bilirubin) monthly
	  ○ Monitor blood pressure every 2 weeks until establishment of a stable dose, then monthly thereafter
	• Medication will not be used in combination with thrombopoietin receptor agonists (for example, Doptelet, Mulpleta, Promacta, Nplate)
		after 12 weeks, platelet counts have increased to a level sufficient to avoid clinically important bleeding
		• Provider attestation of continuation of monitor complete blood counts (CBCs), neutrophils, blood pressure, and liver function tests (LFTs)
		
		Quantity Level Limit:
		2 tablets per day

Tepezza[lxxiii]	**May be approved when all the following criteria are met:**
	• Diagnosis is for moderate to severe Graves' disease associated with thyroid eye disease (TED)
	• Member is 18 years of age or older
	• Prescribed by or in consultation with an ophthalmologist, or endocrinologist
	• Thyroid Eye Disease (TED) is associated with one of the following:
	  ○ Lid retraction ≥ 2 mm
	  ○ Moderate or severe soft tissue involvement
	  ○ Exophthalmos ≥ 3 mm above normal for race and gender
	  ○ Diplopia
	• There was a trial and failure with glucocorticoids (cumulative dose less than 1000mg methylprednisolone or equivalent), or glucocorticoids are contraindicated or cannot be tolerated
	• Member has not been on a high dose (greater than 1000mg methylprednisolone or equivalent) steroid therapy in the past 4 weeks
		Approval Duration:
		6 months

	• Documentation that Thyroid Eye Disease (TED) Clinical Activity Score (CAS) is greater than or equal to 4 • Member does not require immediate surgical ophthalmological intervention and is not planning corrective surgery/irradiation • Documentation that member is euthyroid or mildly hypo/hyper-thyroid with free thyroxine (FT4) and free triiodothyronine (FT3) levels less than 50% above or below normal limits • Females of reproductive potential will be using effective contraception prior to starting therapy, during treatment, and for 6 months following the last dose of Tepezza • Tepezza will not be used in combination with another biologic immunomodulator such as rituximab, Actemra, or Kevzara • Member has not exceeded the maximum limit of 8 doses per lifetime	
Transmucosal Immediate Release Fentanyl (TIRF) Agents[lxxiv] Abstral (fentanyl) sublingual tablets fentanyl citrate lozenge Fentora (fentanyl) buccal tablets Lazanda (fentanyl citrate) nasal spray Subsys (fentanyl) sublingual spray	Transmucosal immediate release fentanyl (TIRF) agents are opioid analgesics that are approved for the management of breakthrough cancer pain in members who are receiving and are tolerant to opioid therapy for underlying persistent cancer pain. Transmucosal immediate release fentanyl (TIRF) agents are available only through a restricted TIRF Risk Evaluation and Mitigation Strategy (REMS) Access program. The preferred formulary product is the generic fentanyl citrate with prior authorization (PA). **May be authorized for members when all of the following criteria are met:** • Member is at least 16 years old for Actiq or generic fentanyl citrate lozenge and at least 18 years old for Abstral, Fentora, Lazanda, and Subsys	**Initial Approval:** 1 year **Renewal Approval:** 1 year ***Requires:*** • Improvement in breakthrough cancer pain • Continued use of a long-acting opioid around-the-clock while on treatment • Documentation showing member has been confirmed to be opioid tolerant prior to each prescription

	• Prescribed by, or in consultation with, an oncologist or pain specialist • Documentation to support diagnosis of cancer and that treatment will be used for breakthrough cancer pain • Member is on a long-acting opioid around-the-clock for treatment of cancer pain • Attestation member is not on a benzodiazepine or gabapentinoids (gabapentin or pregabalin), but if concomitant use is deemed necessary therapy will be tapered and/or member will be monitored closely for adverse effects • Provider has considered naloxone for the emergency treatment of opioid overdose, especially for members concomitantly prescribed benzodiazepines, other central nervous system (CNS) depressants, or muscle relaxants • Documentation showing member has been confirmed to be opioid-tolerant prior to each prescription • Member must be considered opioid-tolerant and is considered opioid-tolerant if the member has received at least <u>one week</u> of treatment on <u>one</u> of the following medications: o Oral morphine sulfate at doses of at least 60 mg/day o Fentanyl transdermal patch at doses of at least 25 mcg/hour o Oral oxycodone at doses of at least 30 mg/day o Oral hydromorphone at doses of at least 8 mg/day o Oral oxymorphone at doses of at least 25 mg/day o Oral hydrocodone at doses of at least 60 mg/day o An alternative opioid at an equianalgesic dose for at least one week (for example, oral methadone at doses of at least 20 mg/day) And	**<u>Quantity Level Limit</u>:** Abstral: 4 tablets/day Actiq: 4 lozenges/day Fentora: 4 tablets/day Lazanda: 1 bottle/day Subsys: 8 sprays/day

	• For all non-formulary agents, member had inadequate response or intolerable side effects with generic fentanyl citrate lozenge. **Note: transmucosal immediate release fentanyl (TIRF) products are not covered for the management of acute or postoperative pain including migraine headaches or for members who are not tolerant to opioids and who are not currently on opioid therapy.	

Tykerb (lapatinib)[lxxv]	**General Criteria:**
	• Prescribed by or in consultation with an oncologist
	• Member is 18 years of age or older
	
	In addition, Tykerb may be authorized when one of the following criteria is met:
	• Recurrent or metastatic breast cancer, human epidermal growth factor receptor 2 positive (HER2+) in combination with an aromatase inhibitor (for example, anastrozole, letrozole, or exemestane)
	  ○ Member meets one of the following:
	  ▪ Postmenopausal or premenopausal, and receiving ovarian ablation or suppression
	  ▪ Will receive testicular steroidogenesis suppression (for male members)
	• Recurrent or metastatic breast cancer that is human epidermal growth factor receptor 2 positive (HER2+)
	  ○ Used in combination with capecitabine (Xeloda) or trastuzumab (Herceptin)
	  ▪ Disease progression while on trastuzumab prior to initiation of either combination regimen
	• Recurrent chordoma
	  ○ Trial of Gleevec (imatinib), Sutent (sunitinib), or Sprycel (dasatinib)
		Initial Approval:
		1 year
		
		Renewal Approval:
		3 years
		
		***Requires*:**
		• Member does not show evidence of progressive disease while on therapy
		• Member does not have unacceptable toxicity from therapy

	○ Disease is epidermal growth factor receptor positive (EGFR+) • Subsequent therapy of advanced or metastatic colon or rectal cancer: ○ Disease is not appropriate for or has progressed on intensive therapy ○ Treatment will be in combination with trastuzumab • Central Nervous System cancers meet one of the following: ○ Recurrence of tumors in adult intracranial and spinal ependymoma (excluding subependymoma) ▪ Treatment is in combination with temozolomide ○ Brain metastases in recurrent HER2-positive breast cancer ▪ Treatment is in combination with capecitabine	
Verquvo	https://www.aetnabetterhealth.com/illinois-medicaid/providers/index.html	
Viscosupplements[lxxvi] **Gel-One** **Visco-3**	**Agents other than Visco-3 and Gel-One will not be covered** **Authorization Criteria:** • Member had inadequate response, intolerable side effects, or contraindications to all the following: ○ Conservative non-pharmacologic therapy ▪ For example, physical therapy, land based or aquatic based exercise, resistance training, or weight loss ○ Adequate trial of pharmacologic therapy, one of which must be oral or topical non-steroidal anti-inflammatory drugs (NSAIDs) ▪ For example, acetaminophen, duloxetine, or topical capsaicin ○ Intra-articular steroid injections • Member reports pain which interferes with functional activities	**Initial Approval:** 1 series **Renewal Approval:** 1 series ***Requires:*** • 6 months has elapsed since previous treatment • Documentation to support improved response to previous series ○ For example, dose reduction with non-

	○ For example, ambulation, or prolonged standing • Pain is not attributed to other forms of joint disease • Member has not had surgery on the same knee in the past 6 months • Treatment is not requested for any of the following indications: ○ Temporomandibular joint disorders ○ Chondromalacia of patella (chondromalacia patellae) ○ Pain in joint, lower leg (patellofemoral syndrome) ○ Osteoarthrosis and allied disorders (joints other than knee) ○ Diagnosis of osteoarthritis of the hip, hand, shoulder, etc. • Documentation to meet one of the following criteria: ○ Radiographic evidence of mild to moderate osteoarthritis of the knee ▪ For example, severe joint space narrowing, subchondral sclerosis, osteophytes ○ Symptomatic osteoarthritis of the knee according to the American College of Rheumatology clinical and laboratory criteria, which requires knee pain, and at least **five** of the following: ▪ Bony enlargement ▪ Bony tenderness ▪ Crepitus (noisy, grating sound) on active motion ▪ Erythrocyte sedimentation rate (ESR) less than 40 mm/hour ▪ Less than 30 minutes of morning stiffness ▪ No palpable warmth of synovium ▪ Over 50 years of age ▪ Rheumatoid factor less than 1:40 titer (agglutination method) ▪ Synovial fluid signs (clear fluid of normal viscosity, and white blood cells less than 2000/mm3)	steroidal anti-inflammatory drugs (NSAIDs), or other analgesics

Aetna Better Health of Illinois
Prior Authorization Guidelines

Votrient[lxxvii]	**General Criteria:**
	• Prescribed by or in consultation with an oncologist
	• Member is 18 years of age or older
	
	In addition, Votrient may be authorized when one of the following criteria is met:
	• Advanced Renal Cell Carcinoma (RCC)
	• Advanced or metastatic Soft Tissue Sarcoma (STS) and one of following:
	  ○ Desmoid Tumors (Aggressive Fibromatosis)
	  ○ Angiosarcoma
	  ○ Alveolar Soft Part Sarcoma (ASPS)
	  ○ Solitary Fibrous Tumor
	  ○ Pleomorphic rhabdomyosarcoma
	  ○ Retroperitoneal/intra-abdominal soft tissue sarcoma
	  ○ Soft tissue sarcoma of the extremity/body wall or head/neck
	  ○ Gastrointestinal stromal tumor (GIST) and disease progression after imatinib (Gleevec), sunitinib (Sutent), and regorafenib (Stivarga)
	• Metastatic Dermatofibrosarcoma Protuberans (DFSP)
	• Recurrent or metastatic uterine sarcoma that has progressed with prior cytotoxic therapy (for example doxorubicin, docetaxel/gemcitabine, doxorubicin/ifosfamide)
	• Epithelial, ovarian, Fallopian tube, or primary peritoneal cancer must meet the following:
	  ○ Disease is stage 2 to 4
	  ○ Member received primary treatment with chemotherapy (for example carboplatin with paclitaxel) and/or surgery and achieved complete response
		Initial Approval:
		1 year
		
		Renewal Approval:
		3 years
		
		Requires:
		• Member does not show evidence of progressive disease while on therapy
		• Member does not have unacceptable toxicity from therapy

Last Update: 12.1.2020, 12.4.2020, 3.1.2021, 5.11.2021, 6.28.2021, 8.1.2021, 9.13.2021, 10.1.2021, 12.17.2021, 1.9.2022, 2.1.2022, 2.17.2022, 2.28.2022, 3.11.2022, 4.5.2022, 4.7.2022, 4.26.2022, 5.11.2022, 5.19.2022, 6.7.2022, 7.9.2022, 8.1.2022, 12.16.2022, 1.1.2023, 1.13.2023, 2.1.2023
,
Current Update: 2.10.2023

	• Differentiated thyroid carcinoma (for example, papillary, follicular, and Hürthle cell) meets all the following:
	  ○ Unresectable recurrent, persistent locoregional, or distant metastatic disease
	  ○ Progressive and/or symptomatic iodine-refractory disease
	  ○ Nexavar (sorafenib) and Lenvima (lenvatinib) are not available or are not clinically appropriate
	• Metastatic medullary thyroid carcinoma (MTC) that is persistent or recurrent:
	  ○ Member has symptomatic or progressive disease
	  ○ Trial of Caprelsa (vandetanib) or Cometriq (cabozantinib)	

Wakefulness Agents[lxxviii]
 	
Armodafinil
Modafinil
Sunosi
Wakix
	***Excessive* daytime sleepiness associated with narcolepsy:**
	• Members is at least 17 years of age
	• Prescribed by, or in consultation with a sleep specialist
	• Multiple sleep latency test (MSLT) or maintenance of wakefulness test (MWT) performed after polysomnography supports diagnosis of narcolepsy
	Excessive daytime sleepiness associated with Obstructive Sleep Apnea:
	• Members is at least 17 years of age
	• Prescribed by, or in consultation with a sleep specialist
	• Polysomnography has confirmed the diagnosis of Obstructive Sleep Apnea
	• Member remains symptomatic despite optimization of Continuous Positive Airway Pressure (CPAP) or Bilevel Positive Airway Pressure (BIPAP) therapy, with compliance for at least 1 month
	• Continuous Positive Airway Pressure (CPAP) or Bilevel Positive Airway Pressure (BIPAP) is continued after modafinil or armodafinil is started
		Initial Approval:
		6 months
		
		Renewal Approval:
		1 year
		
		Requires:
		• Response to treatment
		• Obstructive Sleep Apnea:
		  ○ Member is compliant with Continuous Positive Airway Pressure (CPAP) or Bilevel Positive Airway Pressure (BIPAP)
		• Shift-Work Disorder:
		  ○ Member is still a shift-worker

Last Update: 12.1.2020, 12.4.2020, 3.1.2021, 5.11.2021, 6.28.2021, 8.1.2021, 9.13.2021, 10.1.2021, 12.17.2021, 1.9.2022, 2.1.2022, 2.17.2022, 2.28.2022, 3.11.2022, 4.5.2022, 4.7.2022, 4.26.2022, 5.11.2022, 5.19.2022, 6.7.2022, 7.9.2022, 8.1.2022, 12.16.2022, 1.1.2023, 1.13.2023, 2.1.2023
,
Current Update: 2.10.2023

	• Daytime fatigue is significantly impacting, impairing, or compromising member's ability to function normally **Note: Wakix is NOT indicated for Obstructive Sleep Apnea **Excessive daytime sleepiness associated with Shift-Work Disorder:** • Members is at least 17 years of age • Prescribed by, or in consultation with a sleep specialist • A sleep log and actigraphy monitoring have been completed for at least 14 days and show a disrupted sleep and wake pattern • Disruption is not due to another sleep disorder, medical condition, poor sleep hygiene, or substance abuse disorder • Symptoms have been present for 3 or more months • Sleepiness is significantly impacting, impairing, or compromising member's ability to function normally **Note: Sunosi and Wakix are NOT indicated for Shift-Work Disorder	
Xolair[lxxix]	**May be authorized for the following indications:** **Diagnosis for moderate to severe persistent asthma** • Member 6 years of age or older • Prescribed by, or in consult with pulmonologist or allergist/immunologist specialist • Positive skin test or in vitro reactivity to perennial allergen • For example, dust mite, animal dander, cockroach, etc. • Documentation to support baseline Immunoglobulin E (IgE) is at least 30 IU/mL • Member has been compliant with medium to high dose Inhaled Corticosteroids (ICS) + Long-Acting Beta Agonist (LABA) for at least 3 months, or other controller medication such as Leukotriene Receptor Antagonists (LTRA), or theophylline, if intolerant to a Long-Acting Beta Agonist (LABA)	**Initial Approval:** **Asthma:** 6 months **Nasal Polyps:** 3 months **Chronic urticaria:** 3 months **Renewal Approval:** **Asthma:** 1 year ***Requires***

	• Asthma symptoms are poorly controlled on one of the above regimens as defined by any one of the following:
	  ○ Daily use of rescue medications (Short-Acting Beta-2 Agonists (SABA))
	  ○ Nighttime symptoms occurring more than once per week
	  ○ At least 2 exacerbations in the last 12 months requiring additional medical treatment
	  ○ Systemic corticosteroids, emergency department visits, or hospitalization
	• Member will not use Xolair concomitantly with other biologics indicated for asthma
	  ○ For example, Nucala, Fasenra, Cinqair, or Dupixent
	• Xolair is not indicated for the relief of acute bronchospasm or status asthmaticus
	Diagnosis for Nasal Polyps:
	• Member is 18 years of age or older
	• Documentation for both of the following:
	  ○ Bilateral polyps as determined by a Nasal Polyp Score (NPS) of 5 or greater, with a score of 2 or greater in each nostril
	  ○ An average weekly Nasal Congestion Score (NCS) greater than 1
	• Prescribed by, or in consult with an allergist/immunologist, otolaryngologist, or pulmonologist specialist
	• Documentation to support baseline Immunoglobulin E (IgE) is at least 30 IU/mL
	• Member had trial and failure with a nasal corticosteroid for at least 2 weeks, or there was a history of intolerance, or contraindication to nasal corticosteroids
	  ○ For example, mometasone, fluticasone, or budesonide
		Documentation of clinical improvement:
		○ Decreased use of rescue medications or systemic corticosteroids,
		○ Reduction in number of emergency department visits or hospitalizations
		○ Compliance with asthma controller medications
		
		Nasal Polyps:
		6 months
		
		Requires
		Documentation of clinical improvement
		○ Reduction in polyp size, decreased congestion, and improved sense of smell
		
		Chronic urticaria:
		6 months
		
		Requires
		Documentation of positive clinical response
		Decreased exacerbations, itch severity, or hives
		Dosing:

	• Request is for use as an add-on therapy to members' current maintenance treatment
	• Member will not use Xolair concomitantly with other biologics indicated for nasal polyps
	  ○ For example, Nucala or Dupixent
	Diagnosis for chronic spontaneous urticaria (CSU):
	• Member is 12 years of age or older
	• Prescribed by an allergist/immunologist, or dermatology specialist
	• Currently receiving therapy with an H1 antihistamine
	  ○ For example, hydroxyzine, diphenhydramine, loratadine, etc.
	• Failure of a 4-week, compliant trial of a high dose second generation H1 antihistamine
	  ○ For example, cetirizine, levocetirizine, loratadine, or fexofenadine
	• Failure of a 4-week, compliant trial with at least three of the following combinations:
	  ○ H1 antihistamine + Leukotriene inhibitor (montelukast or zafirlukast)
	  ○ H1 antihistamine + H2 antihistamine (ranitidine or cimetidine)
	  ○ H1 antihistamine + Doxepin
	  ○ First generation antihistamine + second generation antihistamine
	• Xolair is not indicated for other allergic conditions, or other forms of urticaria
	Note: Off-label use for Allergic Rhinitis or food allergy is not covered
		Asthma:
		75mg to 375mg subcutaneously every 2 to 4 weeks, and not exceeding 375mg every 2 weeks.
		Nasal Polyps:
		75mg to 600mg subcutaneously every 2 to 4 weeks.
		Chronic Spontaneous Urticaria:
		150mg or 300mg subcutaneously every 4 weeks.

Xyrem **Xywav**[lxxx]	**Documentation of progress notes, lab results, or other clinical information is required** • Diagnosis is for one of the following:	**Initial Approval:** 6 months

	○ Narcolepsy with cataplexy ○ Narcolepsy with excessive daytime sleepiness • Member is 7 years of age or older • Member experiences daily periods of irrepressible need to sleep, or daytime lapses into sleep, for at least three months • Member does not have succinic semialdehyde dehydrogenase deficiency ○ Inborn error of metabolism variably characterized by mental retardation, hypotonia, and ataxia • Prescribed by, or in consultation with a neurologist, or a sleep specialist that is board-certified by the American Board of Sleep Medicine • No concurrent fills for Central Nervous System (CNS) depressants ○ Central Nervous System (CNS) depressant drugs may include, but are not limited to the following: ▪ Alcohol ▪ Sedative hypnotics ▪ Narcotic analgesics ▪ Benzodiazepines ▪ Sedating antidepressants ▪ Sedating antipsychotics ▪ Sedating antiepileptic drugs ▪ General anesthetics ▪ Muscle relaxants • Polysomnography indicates the following: ○ At least 6 hours of sleep time occurred during overnight polysomnogram ○ Other conditions of sleepiness have been ruled out • Multiple sleep latency test (MSLT) indicates the following: ○ Mean sleep latency is 8 minutes or less	**Renewal Approval:** 12 months ***Requires:*** • No concomitant fills for Central Nervous System (CNS) depressants • Adherence to medication as demonstrated by prescription claims history • Response to therapy is indicated by the following: • Decrease in symptoms as demonstrated by a reduction in the frequency of cataplexy attacks, Epworth Sleepiness Scale (ESS) and/or Maintenance of Wakefulness Test (MWT)

	○ There are 2 or more sleep onset rapid eye movement periods (SOREMPs) • A sleep onset rapid eye movement period (SOREMP) (within 15 minutes of sleep onset), on the preceding polysomnography may replace one of the sleep onset rapid eye movement periods (SOREMP) on the Multiple sleep latency test (MSLT) • Prescriber and member are both enrolled in the Xywav and Xyrem Risk Evaluation and Mitigation Strategy (REMS) Program **Cataplexy:** • Member experiences more than one episode of sudden loss of muscle tone with retained consciousness • Members 17 years of age or older require trial and failure, intolerance, or contraindication to Modafinil and Wakix ○ Prior authorization is required **Excessive Daytime Sleepiness:** • Trial and failure, intolerance, or contraindication with two Central Nervous System (CNS) stimulants for 60 days at maximum tolerated dose ○ Amphetamine, dextroamphetamine, or methylphenidate • Members 17 years of age or older had trial and failure, intolerance, or contraindication to Modafinil, Sunosi, and Wakix ○ Prior authorization required	
Zeposia for UC[lxxxi]	**For Members that Meet the Following Criteria:** • Prescribed by or in consultation with a gastroenterologist • Member is 18 years of age or older • Diagnosis of moderately to severely active ulcerative colitis • Documented inadequate response or contraindication to oral aminosalicylates, or corticosteroids, immunomodulators (for example, 6-mercaptopurine and azathioprine) • Member is stable on either oral aminosalicyclates or corticosteroids,	**Initial Approval:** 3 months **Renewal Approval:** 12 months ***Requires:***

	or has documented contraindication to both • Documented inadequate response or contraindication to a biologic indicated for ulcerative colitis (for example a TNF blocker (such as Humira) or Entyvio) • Member does not have any of the following: ○ History (within the last 6 months) of myocardial infarction, unstable angina, stroke, transient ischemic attack, decompensated heart failure requiring hospitalization, or NYHA Class III/IV heart failure ○ History or presence of Mobitz Type II second- or third-degree AV block, sick sinus syndrome, or sino-atrial block (unless member has a functioning pacemaker) ○ Severe untreated sleep apnea • Medication will not be used concurrently with immunomodulators, biologics, or targeted synthetic drugs	• Member is stable or has experienced response to therapy (for example, clinical remission, improvement in rectal bleeding score, stool frequency score, etc.) **Quantity Level Limit:** 30 tablets every 30 days
Zolgensma	**See detailed document:** https://www.aetnabetterhealth.com/illinois-medicaid/providers/pharmacy-guidelines	

[i] **Afinitor References:**

1. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomized placebo-controlled phase III trial. *The Lancet*. 2008
2. National Comprehensive Cancer Network (NCCN) Clinical Practice Guideline in Oncology: Thyroid Carcinoma. https://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf. Version 2.2019. Accessed November 8, 2019.
3. National Comprehensive Cancer Network (NCCN) Clinical Practice Guideline in Oncology: Central Nervous System. https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf. Version 3.2019. Accessed November 8, 2019.
4. National Comprehensive Cancer Network (NCCN) Clinical Practice Guideline in Oncology: Kidney Cancer. https://www.nccn.org/professionals/physician_gls/PDF/kidney.pdf. Version 2.2020. Accessed November 8, 2019.
5. National Comprehensive Cancer Network (NCCN) Clinical Practice Guideline in Oncology: Breast Cancer. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf . Version 3.2019. Accessed November 8, 2019.
6. National Comprehensive Cancer Network (NCCN) Clinical Practice Guideline in Oncology: Waldenstrom's Macroglobulinemia/Lymphoplasmacytic lymphoma. https://www.nccn.org/professionals/physician_gls/pdf/waldenstroms.pdf . Version 2. 2019. Accessed November 8, 2019.

Last Update: 12.1.2020, 12.4.2020, 3.1.2021, 5.11.2021, 6.28.2021, 8.1.2021, 9.13.2021, 10.1.2021, 12.17.2021, 1.9.2022, 2.1.2022, 2.17.2022, 2.28.2022, 3.11.2022, 4.5.2022, 4.7.2022, 4.26.2022, 5.11.2022, 5.19.2022, 6.7.2022, 7.9.2022, 8.1.2022, 12.16.2022, 1.1.2023, 1.13.2023, 2.1.2023
,
Current Update: 2.10.2023

7. National Comprehensive Cancer Network (NCCN) Clinical Practice Guideline in Oncology: Soft Tissue Sarcoma. https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf . Version 4.2019. Accessed November 8, 2019.
8. National Comprehensive Cancer Network (NCCN)Clinical Practice Guideline in Oncology: Hodgkin Lymphoma. https://www.nccn.org/professionals/physician_gls/pdf/hodgkins.pdf . Version 2.2019. Accessed November 8, 2019.
9. National Comprehensive Cancer Network (NCCN Clinical Practice Guideline in Oncology: Thymomas and Thymic Carcinomas. https://www.nccn.org/professionals/physician_gls/pdf/thymic.pdf . Version 2.2019. Accessed November 8, 2019.
10. National Comprehensive Cancer Network (NCCN): Clinical Practice Guidelines in Oncology: Uterine Neoplasms. https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf. Version 4.2019. Accessed November 8, 2019.
11. National Comprehensive Cancer Network (NCCN) Clinical Practice Guideline in Oncology: Bone Cancer. https://www.nccn.org/professionals/physician_gls/pdf/bone.pdf . Version 1.2020. Accessed November 8, 2019.
12. Besalga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012 Feb 9;366(6):520-9.
13. National Guideline Clearinghouse (NGC). Guideline summary: Guidelines on renal cell carcinoma. In: National Guideline Clearinghouse (NGC). http://www.guideline.gov/content.aspx?id=45321&search=advanced+renal+cell+carcinoma#Section420. Rockville (MD): Agency for Healthcare Research and Quality (AHRQ); cited 2015 August 10. Available: http://www.guideline.gov.
14. Owens, James. Tuberous sclerosis complex: Management. In UpToDate, Post TW (Ed.), Waltham, MA, (accessed on August 10,2015).
15. Torres, Vicente. Renal angiomyolipomas. In UpToDate, Post TW (Ed.), Waltham, MA, (accessed on August 10, 2015).
16. Chan Ang, Jennifer. Metastatic pancreatic neuroendocrine tumors and poorly differentiated gastroenteropancreatic neuroendocrine carcinomas: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion. In UpToDate, Post TW (Ed.), Waltham, MA, (accessed August 10, 2015).
17. Ellis, Matthew. Treatment approach to metastatic hormone receptor-positive breast cancer: Endocrine therapy. In UpToDate, Post TW (Ed.), Waltham, MA, (accessed August 10, 2015).
18. National Comprehensive Cancer Network (NCCN) Clinical Practice Guideline in Oncology: Neuroendocrine Tumors. http://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf. Version 1.2019. Accessed November 8, 2019.
19. Afinitor (everolimus) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; April 2018. https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/afinitor.pdf. Accessed November 8, 2019.
20. Afinitor. Clinical Pharmacology. Clinical Pharmacology Website. www.clinicalpharmacology.com. Accessed November 8, 2019.

[ii] **Anthelmintics references**

1. Biltricide [package insert]. Bayer Healthcare Pharmaceuticals, Inc., Whippany, NJ; 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/018714s018lbl.pdf. Accessed Sept 12, 2019.
2. Lexicomp [database online]. Available at: https://online.lexi.com/lco/action/home. Accessed September 12, 2019
3. Center of Disease Control and Prevention – Parasites. https://www.cdc.gov/parasites/ Accessed November 15, 2019
4. Praziquantel prescribing information. Par Pharmaceutical Chestnut Ridge, NY 10977 U.S.A. last revised 2017
5. Albendazole prescribing information. Amedra Pharmaceuticals LLC Horsham, PA 19044 U.S.A last revised 2016
6. Gold Standard, Inc. Clinical Pharmacology [database online]. Available at: http://www.clinicalpharmacology.com. Accessed November 15, 2019.

[iii] **Antidepressant References:**

1. American Psychiatric Association: Practice guideline for the treatment of patients with major depressive disorder, Third Edition. *Am J Psychiatry*. 2010;167(supply):1-104.

2. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. *Am J Psychiatry*. 2006;163:1905-1917.
3. Depression Guideline Panel. Depression in Primary Care: Treatment of Major Depression: Clinical Practice Guideline. U.S. Department of Health and Human Services
4. ACOG Practice Bulletin No. 141: management of menopausal symptoms. Obstet Gynecol. 2014 Jan;123(1):202-16. doi: 10.1097/01.AOG.0000441353.20693.78
5. Goodman NF, Cobin RH, Ginzburg SB, et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of menopause. Endocr Pract 2011;17:1-25.
6. North American Menopause Society. Non-hormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society. Menopause. 2015;22:1155-1172.
7. Avery D. Seasonal affective disorder: Treatment. Waltham, MA: UptoDate; Last modified August 23, 2019. https://www.uptodate.com/contents/seasonal-affective-disorder-treatment?search=seasonal%20affective%20disorder&source=search_result&selectedTitle=1~23&usage_type=default&display_rank=1#H209889. Accessed 9/25/19.
8. Simpson HB. Pharmacotherapy for obsessive-compulsive disorder in adults. Waltham, MA: UptoDate; Last modified June 22, 2017. https://www.uptodate.com/contents/pharmacotherapy-for-obsessive-compulsive-disorder-in-adults?search=obsessive%20compulsive%20disorder%20treatment&source=search_result&selectedTitle=1~139&usage_type=default&display_rank=1. Accessed September 25, 2019.
9. American Psychiatric Association: Practice guideline for the treatment of patients with obsessive-compulsive disorder. 2007. https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/ocd.pdf. Accessed September 25, 2019 , .
10. American Psychiatric Association: Practice guideline for the treatment of patients with obsessive-compulsive disorder (Guideline Watch). 2013. https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/ocd-watch.pdf. Accessed September 25, 2019.
11. American Psychiatric Association: Practice guideline for the treatment of patients with panic disorder. 2009. https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/panicdisorder.pdf. Accessed September 25, 2019.
12. Casper RF, Yonkers KA. Treatment of premenstrual syndrome and premenstrual dysphoric disorder. Waltham, MA: UptoDate; Last modified June 14, 2019. https://www.uptodate.com/contents/treatment-of-premenstrual-syndrome-and-premenstrual-dysphoric-disorder?search=premenstrual%20dysphoric%20disorder&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1. Accessed September 25, 2019.
13. Selective Serotonin Reuptake Inhibitors and Serotonin Norepinephrine Reuptake Inhibitors. In: Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.; http://www.clinicalpharmacology-ip.com/Forms/AdvSearch/msearch.aspx?s=c&id=298. Accessed September 25, 2019.
14. APLENZIN (bupropion hydrobromide extended-release) Prescribing Information. Valeant Pharmaceuticals, Inc. Bridgewater, New Jersey. May 2017.
15. Forfivo XL Prescribing Information. Edgemont Pharmaceuticals LLC. Austin, TX. August 2016.
16. Pexeva Prescribing Information. Norwich Pharmaceuticals, Inc. Norwich, NY. July 2014.
17. Trintellix Prescribing Information. Takeda Pharmaceuticals America, Inc. Deerfield, IL. April 2017.
18. Fetzima Prescribing Information. Allergan USA, Inc. Irvine, CA. January 2017.

1. Lovenox® [package insert]. Bridgewater, NJ: Sanofi-Aventis US LLC; May 2020. http://products.sanofi.us/Lovenox/Lovenox.pdf. Accessed September 3, 2020.
2. Arixtra [package insert]. Rockford, IL: Mylan Institutional LLC; June 2020. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8a27f341-f612-de72-8c1f-3fd977905de0. Accessed September 3, 2020.
3. Fragmin® [package insert]. New York, NY: Pfizer Labs; June 2020. http://labeling.pfizer.com/ShowLabeling.aspx?id=2293. Accessed April 17, 2019.
4. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. *CHEST*. 2016;149(2):315-352.
5. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed. *CHEST*. 2012: 141(2 Suppl):e419S-e494S.
6. Kahn SR., Lim W., Dunn AS., et al. Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines), Chest 2012; 141 (Suppl 2): e195S-e226S
7. Gould MK., Garcia DA., Wren SM,, et al. Prevention of VTE in Nonorthopedic Surgical Patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (Suppl 2): e227S-e277S
8. Falck-Ytter Y., Francis CW., Johanson NA,, et al. Prevention of VTE in Orthopedic Surgery Patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (Suppl 2): e278S-e325S
9. Douketis JD., Spyropoulos AC., Spencer FA., et al. Perioperative Management of Antithrombotic Therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (Suppl 2): e326S-e350S
10. You JJ., Singer DE., Howard PA., et al. Antithrombotic Therapy for Atrial Fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2_suppl):e531S-e575S
11. Lansberg MG., O'Donnell MJ., Khatri P., et al. Antithrombotic and Thrombolytic Therapy for Ischemic Stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2_suppl):e601S-e636S.
12. Bates SM., Greer IA., Middeldorp S., et al. VTE, Thrombophilia, Antithrombotic Therapy, and Pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2_suppl):e691S-e736S.
13. Guyatt GH, Norris SL, Schulman S, et al. Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):53S-70S.
14. Jaff MR, McMurtry MS, Archer SL, et al. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association [published correction appears in Circulation. 2012 Aug 14;126(7):e104] [published correction appears in Circulation. 2012 Mar 20;125(11):e495]. Circulation. 2011;123(16):1788-1830

[v] **Anticoagulants - Oral References**

1. Xarelto® [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; August 2021. http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf. Accessed November 4, 2021.
2. Eliquis® [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; April 2021. https://packageinserts.bms.com/pi/pi_eliquis.pdf. Accessed November 4, 2021.
3. Pradaxa® [package insert]. Ridgefiled, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; June 2021. https://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf. Accessed November 4, 2021.
4. Savaysa® [package insert]. Basking Ridge, NJ: Daiichi Sankyo, Inc.; March 2021. https://dsi.com/prescribing-information-portlet/getPIContent?productName=Savaysa&inline=true. Accessed November 4, 2021

Last Update: 12.1.2020, 12.4.2020, 3.1.2021, 5.11.2021, 6.23.2021, 8.1.2021, 9.13.2021, 10.1.2021, 12.17.2021, 1.9.2022, 2.1.2022, 2.17.2022, 2.28.2022, 3.11.2022, 4.5.2022, 4.7.2022, 4.26.2022, 5.11.2022, 5.19.2022, 6.7.2022, 7.9.2022, 8.1.2022, 12.16.2022, 1.1.2023, 1.13.2023, 2.1.2023
,
Current Update: 2.10.2023

5. Oral Anticoagulants: Drug Class Review. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc. 2021. Retrieved from https://www.clinicalkey.com/pharmacology/resources/overviews?id=1479109. Accessed November 4, 2021.
6. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients with Atrial Fibrillation; Guidelines Made Simple – Focused Update Edition. Journal of the American College of Cardiology. https://www.acc.org/~/media/Non-Clinical/Files-PDFs-Excel-MS-Word-etc/Guidelines/2019/2019-Afib-Guidelines-Made-Simple-Tool.pdf. Accessed July 20, 2020.
7. Lip GYH, Banjeree A, Boriani G, et al. Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report. *Chest*. https://journal.chestnet.org/article/S0012-3692(18)32244-X/fulltext. Accessed July 20, 2020.
8. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. *Chest*. https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext. Accessed July 20, 2020.
9. Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in Orthopedic Surgery Patients: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012; 141(Suppl 2):e2788-e325S.
10. Streiff MB, Agnelli G, Connors JM, et al. Guidance for the Treatment of Deep Vein Thrombosis and Pulmonary Embolism. Journal of Thrombosis and Thrombolysis. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4715858/. Accessed July 20, 2020.
11. Guyatt GH, Akl EA, Crowther M, et al. Executive summary: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-based Clinical Practice Guidelines. Chest. 2012; 141(Suppl 2):e7S-e47S.
12. Walter A, Gallus A, et al. Oral Anticoagulant Therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(Suppl 2): e44s-e88s..

[vi] **Antihistamines**

1. XYZAL Levocetirizine dihydrochloride [package insert]. April 2016. Sanofi-Aventis U.S. LLC Bridgewater, NJ; https://gskpro.com/content/dam/global/hcpportal/en_NG/PDF/Home/Products/xyzal/xyzal_prescribing_information.pdf. Accessed October 3, 2019.
2. ALLEGRA (fexofenadine hydrochloride) [prescribing information]. 2003. Aventis Pharmaceuticals Inc. Kansas City, MO; https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/20786se8-014,20872se8-011,20625se8-012_allegra_lbl.pdf. Accessed October 3, 2019.

[vii] **Balversa References:**

1. Balversa® [package insert]. Horsham, PA: Janssen Product, LP; Revised April 2020. http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/BALVERSA-pi.pdf. Accessed July 12, 2021.
2. National Comprehensive Cancer Network (NCCN). *NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer. Version 3.2021.* 2021 Apr 22; National Comprehensive Cancer Network. Available from: https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf. Accessed July 12, 2021.

[viii] **Diclegis & Bonjesta References**

1. Nausea and vomiting of pregnancy. Practice Bulletin No. 189. American College of Obstetricians and Gynecologists. Obstet Gynecol 2018; 131(1):e15-e30. https://journals.lww.com/greenjournal/Fulltext/2018/01000/ACOG_Practice_Bulletin_No__189___Nausea_And.39.aspx
2. Diclegis® (doxylamine succinate and pyridoxine hydrochloride). [Prescribing Information]. Bryn Mawr, PA. Duchesnay Inc; Revised September 2018.
3. Bonjesta® (doxylamine succinate and pyridoxine hydrochloride). [Prescribing Information]. Bryn Mawr, PA. Duchesnay Inc; Revised June 2018.
4. Gold Standard, Inc. Diclegis. Clinical Pharmacology [database online]. Available at: http://www.clinicalpharmacology.com. Accessed October 15, 2019.
5. Gold Standard, Inc. Bonjesta. Clinical Pharmacology [database online]. Available at: http://www.clinicalpharmacology.com. Accessed October 15,[t],

6. Facts & Comparisons eAnswers. Drug Facts and Comparisons. Indianapolis, IN: Wolters Kluwer Health; 2013. http://online.factsandcomparisons.com/. Accessed October 15, 2019

[ix] **Cablivi**

1. Cablivi [package insert]. Genzyme Corporation. Cambridge, MA 02142. February 2019
2. Clinical Pharmacology® Gold Standard Series [Internet database]. Tampa FL. Elsevier 2019. Updated periodically
3. George JN et al. Acquired TTP: Clinical manifestations and diagnosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com.
7. Accessed on May 9, 2019.
1. National Heart, Lung, and Blood Institute. U.S. Department of Health & Human Services. Available at https://www.nhlbi.nih.gov/health-topics/thrombotic-thrombocytopenic-purpura. Accessed September 11, 2019
2. Scully M et al., Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura. NEJM. 2019;380:335-346. Available at https://www.nejm.org/doi/10.1056/NEJMoa1806311. Accessed September 11, 2019.
3. Coppo P, Schwarzinger M, Buffet M, et al. Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA Reference Center experience. PLoS One 2010;5(4):e10208-e10208.

x**Calcipotriene References**

1. Calcipotriene 0.005% Cream [package insert]. Mahwah, NJ: Glenmark Pharmaceuticals Ltd; Revised December 2018. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1bc020e0-b5ae-4cda-aa5b-87fa0452a6bc. Accessed March 2, 2020.
2. Feldman, S.R. (2019) Treatment of psoriasis in adults. In R.P. Dellavalle (Ed.), *UpToDate*. Retrieved May 20, 2021 from: https://www.uptodate.com/contents/treatment-of-psoriasis-in-adults.

[xi] **Calcitonin Gene-Related Peptide (CGRP) Receptor Agents References**

1. Aimovig® [package insert]. Amgen Inc. Thousand Oaks, CA 91320-1799; Revised May 2021. https://www.pi.amgen.com/~/media/amgen/repositorysites/pi-amgen-com/aimovig/aimovig_pi_hcp_english.ashx. Accessed October 11, 2021
2. Emgality® [package insert]. Indianapolis, IN: Eli Lilly and Company; Revised December 2019. http://uspl.lilly.com/emgality/emgality.html#pi. Accessed October 11, 2021.
3. Ajovy® [package insert]. North Wales, PA: Teva Pharmaceuticals USA, Inc; Revised June 2021. https://www.ajovy.com/globalassets/ajovy/ajovy-pi.pdf. Accessed October 11, 2021.
4. Vyepti™ [package insert]. Lundbeck Seattle Pharmaceuticals, Inc; Revised February 2020. https://www.lundbeck.com/upload/us/files/pdf/Products/Vyepti_PI_US_EN.pdf. Accessed October 11, 2021.
5. Ubrelvy™ [package insert]. Allergan USA, Inc; Revised March 2021. https://media.allergan.com/products/Ubrelvy_pi.pdf. Accessed October 11, 2021.
6. Nurtec™ ODT [package insert]. Biohaven Pharmaceuticals Inc; Revised May 2021. https://www.nurtec.com/pi. Accessed October 11, 2021.
7. Qulipta [prescribing information]. Forest Laboratories; Revised October 2021. https://www.rxabbvie.com/pdf/qulipta_pi.pdf. Accessed October 11, 2021
8. E.W. Loder and M.S. Robbins. Monoclonal antibodies for migraine prevention: Progress, but not a panacea. JAMA. Vol. 319, August 15, 2019, p.1985. doi: 10.1001/jama.2018.4852. https://www.ncbi.nlm.nih.gov/pubmed/29800193
9. L.H. Lassen et al. CGRP may play a causative role in migraine. Cephalalgia. Vol. 22, February 1, 2002, p. 54. doi:10.1046/j. 1468-2982.2002.00310.x http://journals.sagepub.com/doi/abs/10.1046/j.1468-2982.2002.00310.x?journalCode=cepa
10. Smith, J.H., (2021). Preventive treatment of episodic migraine in adults, In J.W. Swanson (Ed.), UpToDate. Retrieved October 11, 2021 from https://www.uptodate.com/contents/preventive-treatment-of-episodic-migraine-in-adults

Last Update: 12.1.2020, 12.4.2020, 3.1.2021, 5.11.2021, 6.28.2021, 8.1.2021, 9.13.2021, 10.1.2021, 12.17.2021, 1.9.2022, 2.1.2022, 2.17.2022, 2.28.2022, 3.11.2022, 4.5.2022, 4.7.2022, 4.26.2022, 5.11.2022, 5.19.2022, 6.7.2022, 7.9.2022, 8.1.2022, 12.16.2022, 1.1.2023, 1.13.2023, 2.1.2023

,

Current Update: 2.10.2023

11. May, A. Cluster Headache: Treatment and Prognosis. Waltham, MA. UpToDate. Last Modified February 25, 2021. https://www.uptodate.com/contents/cluster-headache-treatment-and-prognosis. Accessed July 7, 2021.
12. Smith, J.H. (2020). Acute treatment of migraine in adults. In J.W. Swanson (Ed.), UpToDate. Retrieved March 25, 2020 from: https://www.uptodate.com/contents/acute-treatment-of-migraine-in-adults.
13. Headaches in over 12s: diagnosis and management. National Institute for Health and Care Excellence (NICE). Last updated May 12, 2021. https://www.nice.org.uk/guidance/cg150. Accessed July 9, 2021.
14. (2019), The American Headache Society Position Statement on Integrating New Migraine Treatments into Clinical Practice. Headache: The Journal of Head and Face Pain, 59: 1-18. doi:10.1111/head.13456.

[xii] **Xeloda References**

1. Xeloda® [capecitabine] prescribing information. South San Francisco, CA: Genentech, Inc. Revised February 2019. https://www.gene.com/download/pdf/xeloda_prescribing.pdf. Accessed May 21, 2021.
2. National Comprehensive Cancer Network (NCCN). *Clinical Practice Guideline in Oncology. Colon Cancer* version 2.2021 - January 21, 2021; National Comprehensive Care Network. Available from https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf . Accessed May 21, 2021.
3. National Comprehensive Cancer Network (NCCN). *Clinical Practice Guideline in Oncology. Rectal Cancer* version 1.2021 - December 22, 2020; National Comprehensive Care Network. Available from https://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf. Accessed May 20, 2021.
4. National Comprehensive Cancer Network (NCCN). *Clinical Practice Guideline in Oncology. Pancreatic Adenocarcinoma* version 2.2021 - February 25, 2021; National Comprehensive Care Network. Available from https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf. Accessed May 20, 2021.
5. National Comprehensive Cancer Network (NCCN). *Clinical Practice Guideline in Oncology. Breast Cancer* version 4.2021 - April 28, 2021; National Comprehensive Care Network. Available from: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed January 30, 2020.
6. National Comprehensive Cancer Network (NCCN). *Clinical Practice Guideline in Oncology. Esophageal and Esophagogastric Junction Cancers* Version 2. 2021 - March 9, 2021; National Comprehensive Cancer Network. Available from: https://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf. Accessed May 21, 2021.
7. National Comprehensive Cancer Network (NCCN). *Clinical Practice Guideline in Oncology. Gastric Cancer version 2.2021 - March 9, 2021*; National Comprehensive Cancer Network. Available from: https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf. Accessed May 24, 2021
8. National Comprehensive Cancer Network (NCCN). *Clinical Practice Guideline in Oncology. Head and Neck Cancers version 3.2021 - April 27, 2021*; National Comprehensive Cancer Network. Available from: https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf. Accessed May 24, 2021.
9. National Comprehensive Cancer Network (NCCN). *Clinical Practice Guideline in Oncology. Hepatobiliary Cancers version 2.2021 - April 16, 2021*; National Comprehensive Cancer Network. Available from: https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf. Accessed May 24, 2021.
10. National Comprehensive Cancer Network (NCCN). *Clinical Practice Guideline in Oncology: Neuroendocrine and Adrenal Tumors version 1.2021 - April 14, 2021*; National Comprehensive Care Network. Available from https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf. Accessed May 24, 2021.
11. National Comprehensive Cancer Network (NCCN). *Clinical Practice Guideline in Oncology. Occult Primary version 2.2021 - February 8, 2021*; National Comprehensive Cancer Network. Available from: https://www.nccn.org/professionals/physician_gls/pdf/occult.pdf. Accessed May 24, 2021.

12. National Comprehensive Cancer Network (NCCN). *Clinical Practice Guideline in Oncology. Ovarian Cancer version 1.2021 - February 26, 2021*; National Comprehensive Cancer Network. Available from: https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf. Accessed May 24, 2021.
13. National Comprehensive Cancer Network (NCCN). *Clinical Practice Guideline in Oncology. Penile Cancer version 1.2021 - January 13, 2021*; National Comprehensive Cancer Network. Available from: https://www.nccn.org/professionals/physician_gls/pdf/penile.pdf. Accessed May 24, 2021.
14. National Comprehensive Cancer Network (NCCN). *Clinical Practice Guideline in Oncology. Kidney Cancer version 4.2021 - April 19, 2021*; National Comprehensive Cancer Network. Available from: https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf . Accessed May 24, 2021.

[xiii] **Celecoxib References**

1. Celebrex® [package insert]. New York, NY: Pfizer Revised April 2021. http://labeling.pfizer.com/ShowLabeling.aspx?format=PDF&id=793.Accessed May 24, 2021.
2. Solomon, D.H. (2019) Overview of selective COX-2 selective NSAIDs. In D.E. Furst (Ed.), *UpToDate.* Retrieved from: https://www.uptodate.com/contents/overview-of-cox-2-selective-nsaids. Accessed May 24, 2021.
3. Feldman, M. (2019) COX-2 inhibitors and gastroduodenal toxicity: Major clinical trials. J.T. Lamont (Ed.), *UpToDate.* Retrieved from: https://www.uptodate.com/contents/cox-2-inhibitors-and-gastroduodenal-toxicity-major-clinical-trials. Accessed May 24, 2021.

[xiv] **CNS Stimulant References:**

1. Vyvanse® [package insert]. Lexington, MA: Shire Pharmaceuticals; Revised January 1,2018. http://pi.shirecontent.com/PI/PDFs/Vyvanse_USA_ENG.pdf. Accessed January 16, 2020.
2. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 5th Edition. Arlington, VA, American Psychiatric Association, 2013.
3. Mao AR, Findling RL. Comorbidities in adult attention-deficit/hyperactivity disorder: a practical guide to diagnosis in primary care. Postgrad Med. 2014 Sep;126(5):42-51. doi: 10.3810/pgm.2014.09.2799. Review. PubMed PMID: 25295649.
4. Post RE, Kurlansik SL. Diagnosis and Management of Attention-Deficit/Hyperactivity Disorder in Adults. Am Fam Physician. 2012;85(9):890-896.
5. American Academy of Pediatrics. ADHD: Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics.2011;128;1007-1028;
6. National Eating Disorder Foundation. https://www.nationaleatingdisorders.org/binge-eating-disorder. Accessed January 2, 2018.
7. APA: American Psychiatric Association. Practice Guideline for the Treatment of Patients with Eating Disorders. http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/eatingdisorders.pdf. Third Edition. Accessed January 2, 2018.
8. Bukstein, O. (2018). Attention deficit hyperactivity disorder in adults: Epidemiology, pathogenesis, clinical features, course, assessment, and diagnosis. In D. Brent (Ed.), *UpToDate.* Retrieved November 8, 2018, from https://www.uptodate.com/contents/attention-deficit-hyperactivity-disorder-in-adults-epidemiology-pathogenesis-clinical-features-course-assessment-and-diagnosis.
9. Bukstein, O. (2019). Pharmacotherapy for adult attention deficit hyperactivity disorder. In D. Brent (Ed.), *UpToDate.* Retrieved December 23, 2019, from https://www.uptodate.com/contents/pharmacotherapy-for-adult-attention-deficit-hyperactivity-disorder.
10. Sysko, R., & Devlin, M. (2019). Binge eating disorder in adults: Overview of treatment. In J. Yager (Ed.), *UpToDate*. Retrieved December 23, 2019, from https://www.uptodate.com/contents/binge-eating-disorder-in-adults-overview-of-treatment.

Last Update: 12.1.2020, 12.4.2020, 3.1.2021, 5.11.2021, 6.28.2021, 8.1.2021, 9.13.2021, 10.1.2021, 12.17.2021, 1.9.2022, 2.1.2022, 2.17.2022, 2.28.2022, 3.11.2022, 4.5.2022, 4.7.2022, 4.26.2022, 5.11.2022, 5.19.2022, 6.7.2022, 7.9.2022, 8.1.2022, 12.16.2022, 1.1.2023, 1.13.2023, 2.1.2023
,
Current Update: 2.10.2023

11. Wolraich ML, Hagan, JF, Allan, C, et al, American academy of Pediatrics, Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. Pediatrics Volume 144, number 4, October 2019: e20192528. https://pediatrics.aappublications.org/content/pediatrics/144/4/e20192528.full.pdf

[xv] **Sensipar References**

1. Sensipar® [package insert]. Thousand Oaks, CA: Amgen Inc.; Revised December 2019. https://www.pi.amgen.com/~/media/amgen/repositorysites/pi-amgen-com/sensipar/sensipar_pi_hcp_english.pdf. Accessed May 24, 2021.
2. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD). *Kidney International Supplements (2017) 7, 1–59 1.*
3. Quarles, L.D., & Berkoben, M. (2018). Management of secondary hyperparathyroidism in adult dialysis patients. In S. Goldfarb (Ed.), *UpToDate*. Retrieved May 24, 2021, from: https://www.uptodate.com/contents/management-of-secondary-hyperparathyroidism-in-adult-dialysis-patients.

[xvi] **Continuous Glucose Monitoring System References:**

1. American diabetes association, checking your blood pressure, http://www.diabetes.org/living-with-diabetes/treatment-and-care/blood-glucose-control/checking-your-blood-glucose.html Accessed May 22, 2019
2. American Diabetes Association. Standards of Medical Care in Diabetes 2019. Diabetes Care. January 2019, 42(Supplement 1). https://professional.diabetes.org/content-page/practice-guidelines-resources. Accessed July 2, 2019.
3. Dexcom CGM. Dexcom. https://s3-us-west-2.amazonaws.com/dexcompdf/G6-CGM-Users-Guide.pdf Accessed July 3, 2019.
4. American Diabetes Association Diabetes Care 2019 Jan; 42(Supplement 1): S71-S80. https://care.diabetesjournals.org/content/42/Supplement_1/S71 Accessed April 10, 2020

[xvii] **Corlanor References**

1. Yancy CW et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure Circulation: 2017. http://www.onlinejacc.org/content/accj/70/6/776.full.pdf?_ga=2.179733604.1964533065.1574204551-936785029.1560984365. Accessed November 19, 2019.
2. Corlanor (ivabradine) [package insert]. Thousand Oaks, CA; Amgen Inc.; Revised April, 2019. Retrieved from https://www.pi.amgen.com/~/media/amgen/repositorysites/pi-amgen-com/corlanor/corlanor_pi.pdf. Accessed November 19, 2019.
3. Corlanor. Clinical Pharmacology [Internet]. Tampa (FL): Elsevier.c2018 [cited 2018 October 29] Available from: http://www.clinicalpharmacology.com

[xviii] **Cystic Fibrosis Medications References**

1. Pulmozyme [package insert]. San Francisco, CA: Genentech, Inc; 2014, https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/103532s5175lbl.pdf, Accessed July 7, 2021.
2. Tobi Podhaler [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2015, https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/tobipodhaler.pdf. Accessed July 7, 2021.
3. Tobi-tobramycin solution [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2015, https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/tobi.pdf, Accessed July 7, 2021.
4. Bethkis - tobramycin solution [package insert]. Cary, NC: Chiesi USA, Inc. Revised May 2021, https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201820s000lbl.pdf. Accessed July 7, 2021.

Last Update: 12.1.2020, 12.4.2020, 3.1.2021, 5.11.2021, 6.28.2021, 8.1.2021, 9.13.2021, 10.1.2021, 12.17.2021, 1.9.2022, 2.1.2022, 2.17.2022, 2.28.2022, 3.11.2022, 4.5.2022, 4.7.2022, 4.26.2022, 5.11.2022, 5.19.2022, 6.7.2022, 7.9.2022, 8.1.2022, 12.16.2022, 1.1.2023, 1.13.2023, 2.1.2023
,
Current Update: 2.10.2023

5. Kitabis – tobramycin solution [package insert]. Woodstock, IL: Catalent Pharma Solutions, LLC. 2019, https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205433s000lbl.pdf, Accessed July 7, 2021.
6. Cayston [package insert]. Foster City, CA: Gilead Sciences, Inc; Revised November 2019, https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050814s007lbl.pdf, Accessed July 7, 2021.
7. Kalydeco [package insert].]. Boston, MA: Vertex Pharmaceuticals Incorporated; Revised December 2020, https://pi.vrtx.com/files/uspi_ivacaftor.pdf, Accessed on July 7, 2021.
8. Orkambi [package insert]. Boston, MA: Vertex Pharmaceuticals Inc; 2019, https://pi.vrtx.com/files/uspi_lumacaftor_ivacaftor.pdf, Accessed July 13, 2021
9. Symdeko [package insert]. Boston, MA: Vertex Pharmaceuticals inc; 2020, https://pi.vrtx.com/files/uspi_tezacaftor_ivacaftor.pdf, Accessed on July 13, 2021.
10. Trikafta [prescribing information]. Vertex Pharmaceuticals Inc. Boston, MA Revised June 2021. https://pi.vrtx.com/files/uspi_elexacaftor_tezacaftor_ivacaftor.pdf. Accessed July 23, 2021.
11. Simon R, Mallory G. Cystic fibrosis: Treatment with CFTR modulators. In AG Hoppin (Ed.), UpToDate, Waltham, MA June 2021. https://www.uptodate.com/contents/cystic-fibrosis-treatment-with-cftr-modulators?search=CFTR%20gating%20mutations%20approved%20by%20the%20FDA%20for%20ivacaftor&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1#H1336420855. Accessed July 13, 2021.
12. Katkin, JP. Cystic fibrosis: Clinical manifestations and diagnosis. UpToDate, Mallory, GB (Ed), UpToDate, Waltham, MA. https://www.uptodate.com/contents/cystic-fibrosis-clinical-manifestations-and-diagnosis?search=Cystic%20fibrosis:%20Clinical%20manifestations%20and%20diagnosis&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1, Accessed on July 25, 2018.
13. Nadig, TR, Flume PA. Aerosolized Antibiotics for Patients with Bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2016; 193(7). . https://www.atsjournals.org/doi/full/10.1164/rccm.201507-1449LE. Accessed July 13, 2021.
14. Polverino E, Pieter C. Goeminne MJ. European Respiratory Society guidelines for the management of adult bronchiectasis. European Respiratory Journal. 2017; 50: 1700629. doi 10.1183/13993003.00629-2017. http://erj.ersjournals.com/content/50/3/1700629#sec-27. Accessed July 13, 2021.
15. McShane PJ, Naureckas ET, Tino G. Non-Cystic Fibrosis Bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2013; 188(6). https://www.atsjournals.org/doi/full/10.1164/rccm.201303-0411CI/. Accessed July 13, 2021.

[xix] **Dalfampridine (Ampyra) References**

1. Ampyra® [package insert]. Acorda Therapeutics Inc., Ardsley, NY; Revised February 2021. https://ampyra.com/prescribing-information.pdf. Accessed November 11, 2021.
2. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983 Nov;33(11):1444-52. https://n.neurology.org/content/neurology/33/11/1444.full.pdf. Accessed September 9, 2019.
3. Olek MJ, Narayn RN, et al. Symptom Management of Multiple Sclerosis in Adults. Waltham, MA. UpToDate. Last Modified: March 3, 2021. https://www.uptodate.com/contents/symptom-management-of-multiple-sclerosis-in-adults. Accessed November 11, 2021.
4. Schachter, SC., Evaluation and management of the first seizure in adults (2021). UpToDate. In JF Dashe (Ed.), retrieved from https://www.uptodate.com/contents/evaluation-and-management-of-the-first-seizure-in-adults. Accessed November 11, 2021.
5. Baird J, Sandroff B, Motl, R. Therapies for mobility disability in persons with multiple sclerosis. PMC 2019, 2018 Jun; 18(6): 493–502. Doi: 10.1080/14737175.2018.1478289 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291756/ Accessed July 7, 2020

[xx] **Direct Renin Inhibitors References**

Last Update: 12.1.2020, 12.4.2020, 3.1.2021, 5.11.2021, 6.28.2021, 8.1.2021, 9.13.2021, 10.1.2021, 12.17.2021, 1.9.2022, 2.1.2022, 2.17.2022, 2.28.2022, 3.11.2022, 4.5.2022, 4.7.2022, 4.26.2022, 5.11.2022, 5.19.2022, 6.7.2022, 7.9.2022, 8.1.2022, 12.16.2022, 1.1.2023, 1.13.2023, 2.1.2023
,
Current Update: 2.10.2023

1. James PA, Oparil S, Carter BL, et al. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507-520. doi:10.1001/jama.2013.284427.
2. Tekturna [package insert]. Noden Pharma USA Inc, Boston, MA; November 2017. http://www.tekturna.com/wp-content/uploads/2017/11/Tekturna_PCR-1.pdf.Accessed October 17, 2019
3. Tekturna HCT [package insert]. Noden Pharma USA Inc, Boston, MA; November 2016. http://www.tekturna.com/wp-content/uploads/2017/11/TekturnaHCT_PCR-1.pdf. Accessed October 17, 2019.
4. Flynn JT, Kaelber DC, Baker-Smith CM, et al. Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents. Pediatrics. September 2017, Volume 140 Issue 3. 10.1542/peds.2017-1904. http://pediatrics.aappublications.org/content/early/2017/08/21/peds.2017-1904#T47.
5. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2018; 71(19):127-248. doi:10.1016/j.jacc.2017.11.006.
6. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc., URL: http://www.clinicalpharmacology-ip.com/. Updated 2017. Accessed October 17, 2019.
7. Aliskiren, Jacobs, TF, Terrell, JM. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK507868/. Accessed November 20, 2019.

[xxi]**Dupixent References**

1. Dupixent® (dupliumab). [Prescribing information]. Tarrytown, NY. Regeneron. Revised June 2020. https://www.regeneron.com/sites/default/files/Dupixent_FPI.pdf. Accessed August 3, 2020.
2. Eichenfield LF, Tom WL, Berger TG, Krol A, Paller AS, Schwarzenberger K, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014 Jul;71(1):116-32. https://www.aad.org/practicecenter/quality/clinical-guidelines/atopic-dermatitis. Accessed . August 3, 2020
3. Eli Lily and Company. Validated Investigator Global Assessment scale for Atopic Dermatitis. vIGA-AD™. https://www.eczemacouncil.org/wp-content/uploads/2018/02/Validated-Investigator-Global-Assessment-Scale_vIGA-AD_2017.pdf. Accessed August 3, 2020
4. CR Charman,1 AJ Venn,2 JC Ravenscroft,3 and HC Williams3. The British Journal of Dermatology. Translating Patient-Oriented Eczema Measure (POEM) scores into clinical practice by suggesting severity strata derived using anchor-based methods. http://europepmc.org/articles/pmc3920642. Accessed August 3, 2020.
5. Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma (GINA) 2020.. https://ginasthma.org/gina-reports/. Accessed August 4, 2020.
6. National Asthma Education and Prevention Program: Expert panel report III: Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Heart, Lung, and Blood Institute, 2007. (NIH publication no. 08-4051). https://www.nhlbi.nih.gov/files/docs/guidelines/asthgdln.pdf. Accessed August 4, 2020
7. Rabe KF, Nair P, Brusselle ., et al, Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma. N Engl J Med. 2018;378(26):2475 https://www.nejm.org/doi/full/10.1056/NEJMoa1804093. Accessed . August 4, 2020.
8. Wenzel S. Treatment of severe asthma in adolescents and adults. Waltham, MA. UpToDate. Last modified July 6, 2020. https://www.uptodate.com/contents/treatment-of-severe-asthma-in-adolescents-and-adults. Accessed August 3, 2020
9. Hamilos DL, Holbrook, EH. Chronic rhinosinusitis: Management. Waltham, MA. UpToDate. Last modified May 27, 2020 https://www.uptodate.com/contents/chronic-rhinosinusitis-management. Accessed . August 3, 2020

[xxii] **Egrifta References:**

1. Egrifta® [package insert]. Theratechnologies, Inc., Montreal, Quebec, Canada; July, 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022505s011lbl.pdf. Accessed September 6, 2019.

Last Update: 12.1.2020, 12.4.2020, 3.1.2021, 5.11.2021, 6.28.2021, 8.1.2021, 9.13.2021, 10.1.2021, 12.17.2021, 1.9.2022, 2.1.2022, 2.17.2022, 2.28.2022, 3.11.2022, 4.5.2022, 4.7.2022, 4.26.2022, 5.11.2022, 5.19.2022, 6.7.2022, 7.9.2022, 8.1.2022, 12.16.2022, 1.1.2023, 1.13.2023, 2.1.2023
,
Current Update: 2.10.2023

2. Clinical Pharmacology. http://www.clinicalpharmacology-ip.com/Default.aspx. Accessed September 6, 2019.
3. Treatment of HIV-associated lipodystrophy. UpToDate. https://www.uptodate.com. Accessed September 11, 2019.
4. Stanley T, Falutz J, Marsolais C, et al. Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin. Clin Infect Dis. 2012 Jun;54(11):1642-51. Accessed September 12,2019
5. Clinical Review Report: Tesamorelin (Egrifta) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2016 Aug. https://www.ncbi.nlm.nih.gov/books/NBK539131/ Accessed September 6, 2019

[xxiii] **Emflaza References**

1. Emflaza® (deflazacort) [package insert]. *South Plainfield, NJ:* PTC Therapeutics Inc*;* Revised June 2021. https://emflaza.com/wp-content/uploads/2020/10/prescribing-information.pdf. Accessed August 25, 2021.
2. Matthews E, Brassington R, Kuntzer T, et al. Corticosteroids for the treatment of Duchenne muscular dystrophy. Cochrane Database of Systematic Reviews 2016, Issue 5. https://www.cochrane.org/CD003725/NEUROMUSC_corticosteroid-therapy-duchenne-muscular-dystrophy. Accessed December 4, 2019.
3. Darras, B.T., Duchenne and Becker muscular dystrophy: Clinical features and diagnosis, (2018). In J.F. Dashe (Ed), UpToDate, retrieved October 19, 2019 from https://www.uptodate.com/contents/duchenne-and-becker-muscular-dystrophy-clinical-features-and-diagnosis
4. Gloss D., Moxley T.R., Ashwal S., Oskoui M., February 1, 2016. Practice guideline update summary: Corticosteroid treatment of Duchenne muscular dystrophy; Report of the Guideline Development Subcommittee of the American Academy of Neurology; https://n.neurology.org/content/86/5/465. Accessed August 25, 2021
5. Darras, B.T., Duchenne and Becker muscular dystrophy: Glucocorticoid and disease-modifying treatment (2021) In J.F. Dashe (Ed), UpToDate, Retrieved August 25, 2021 from https://www.uptodate.com/contents/duchenne-and-becker-muscular-dystrophy-glucocorticoid-and-disease-modifying-treatment?search=emflaza&source=search_result&selectedTitle=2~5&usage_type=default&display_rank=1#H3411948572
6. Muscular Dystrophy UK. North Star Ambulatory Assessment. https://www.physio-pedia.com/North_Star_Ambulatory_Assessment. Accessed December 4, 2019.
7. McDonald CM, Henricson EK, RT Abresch, et al. The 6-minute walk test and other clinical endpoints in Duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study. Muscle Nerve**.** 2013b Sep;48(3):357- 368.
8. Ramsey D, Scoto M, Mayhew A, et al. Revised Hammersmith Scale for spinal muscular atrophy; A SMA specific clinical outcome assessment tool. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5319655/. Accessed December 4, 2019.
9. Berard C, Payan C, Hodgkinson I, et al. A motor function measure scale for neuromuscular diseases. Construction and validation study. http://www.motor-function-measure.org/upload/File/MFM%20article%20Neuro%20muscular%20disorders%202005.pdf. Accessed December 4, 2019.

[xxiv] **Epidiolex®**

1. Epidiolex® [package insert]. Greenwich Biosciences, Inc, Carlsbad, CA; Revised December 2018. https://www.epidiolex.com/sites/default/files/EPIDIOLEX_Full_Prescribing_Information.pdf. Accessed Novermber 14, 2019.
2. Gold Standard, Inc. Epidiolex. Clinical Pharmacology [database online]. Available at: http://www.clinicalpharmacology.com. Accessed November 14, 2019.
3. Wilfong A. Epilepsy Syndromes in Children. Waltham, MA: UpToDate. Last modified: September 27, 2019. https://www.uptodate.com/contents/epilepsy-syndromes-in-children. Accessed December 10, 2019.
4. Nascimento FA, Andrade DM. Dravet Syndrome: Management and Prognosis. Waltham, MA. UpToDate. Last modified February 1, 2019. https://www.uptodate.com/contents/dravet-syndrome-management-and-prognosis. Accessed December 10, 2019.

[xxv] **Erythromycin Ethylsuccinate Suspension References**

Last Update: 12.1.2020, 12.4.2020, 3.1.2021, 5.11.2021, 6.28.2021, 8.1.2021, 9.13.2021, 10.1.2021, 12.17.2021, 1.9.2022, 2.1.2022, 2.17.2022, 2.28.2022, 3.11.2022, 4.5.2022, 4.7.2022, 4.26.2022, 5.11.2022, 5.19.2022, 6.7.2022, 7.9.2022, 8.1.2022, 12.16.2022, 1.1.2023, 1.13.2023, 2.1.2023
,
Current Update: 2.10.2023

8. E.E.S. ® [package insert]. Arbor Pharmaceuticals, Inc., Atlanta, GA; January 2012. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050207s071lbl.pdf. Accessed May 3, 2021.
9. Gold Standard, Inc. Erythromycin. Clinical Pharmacology [database online]. Available at: http://www.clinicalpharmacology.com. Accessed April 1, 2020.
10. Camilleri, M. Treatment of Gastroparesis. Waltham, MA. UpToDate. Last modified February 21, 2019. https://www.uptodate.com/contents/treatment-of-gastroparesis. Accessed May24, 2021.
11. Camilleri, M, Parkman, HP, Shafi, MA, Abell TL, Gerson, L. Management of Gastroparesis. American Journal of Gastroenterology: January 2013;108(1):18-37doi: 10.1038/ajg.2012.373.

[xxvi] **Erythropoiesis Stimulating Agent References**

1. Epogen® [package insert]. Thousand Oaks, CA: Amgen Inc.; Revised July 2018. https://www.pi.amgen.com/~/media/amgen/repositorysites/pi-amgen-com/epogen/epogen_pi_hcp_english.pdf. Accessed August 9, 2020November 15, 2021.
2. Procrit® [package insert]. Thousand Oaks, CA: Amgen Inc.; Revised July 2018. http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/PROCRIT-pi.pdf. Accessed August 7, 2019November 1, 2021.
3. Retacrit™ [package insert]. Lake Forest, IL: Pfizer Inc.; Revised January 2019August 2020. http://labeling.pfizer.com/ShowLabeling.aspx?id=10738#S2.6http://labeling.pfizer.com/ShowLabeling.aspx?id=10738. Accessed August 7, 2019November 15, 2021.
4. Aranesp® [package insert]. Thousand Oaks, CA: Amgen Inc.; Revised January 2019. https://www.pi.amgen.com/~/media/amgen/repositorysites/pi-amgen-com/aranesp/ckd/aranesp_pi_hcp_english.pdf. Accessed August 9, 2020November 15, 2021.
5. Mircera® [package insert]. Switzerland: Vifor Pharma; Revised June 2018August 2019. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=22c56f2a-f73c-60e7-e054-00144ff88e88https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125164s078lbl.pdf. Accessed August 9, 2020November 15, 2021.
6. Gold Standard, Inc. Clinical Pharmacology [database online]. http://www.clinicalpharmacology.com. Accessed August 9, 2020.
7. National Comprehensive Cancer Network. Myelodysplastic Syndromes (Version 2.20201). NCCN. https://www.nccn.org/professionals/physician_gls/pdf/mds.pdf. Updated October 18, 2018November 15, 2021. Accessed August 9, 2019November 15, 2021.
8. Estey EH, Schrier SL. Management of the complications of the myelodysplastic syndromes. UpToDate. https://www.uptodate.com/contents/management-of-the-hematologic-complications-of-myelodysplastic-syndromes?search=Management%20of%20the%20complications%20of%20the%20myelodysplastic%20syndromes&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1 http://www.uptodate.com. Updated July 17, 2015August 6, 2021. Accessed August 1, 2016November 15, 2021.
9. Rizzo JD, Brouwers M, Hurley P, et al. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Onc. 2010;28(33):4996-5010.
10. Bohlius J, Bohlke K, Castelli R, et al. American Society of Clinical Oncology/American Society of Hematology. Management of Cancer-Associated Anemia with Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update. Journal of Clinical Oncology 2019 37:15, 1336-1351.
11. Volberding PA, Levine AM, Dieterich D, et al. Anemia in HIV Working Group, Anemia in HIV Infection: Clinical Impact and Evidence-Based Management Strategies, Clinical Infectious Diseases, Volume 38, Issue 10, 15 May 2004, Pages 1454–1463.
12. KDIGO Anemia Work Group. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney Int Suppl. 2012;2(4):279-335.

Last Update: 12.1.2020, 12.4.2020, 3.1.2021, 5.11.2021, 6.28.2021, 8.1.2021, 9.13.2021, 10.1.2021, 12.17.2021, 1.9.2022, 2.1.2022, 2.17.2022, 2.28.2022, 3.11.2022, 4.5.2022, 4.7.2022, 4.26.2022, 5.11.2022, 5.19.2022, 6.7.2022, 7.9.2022, 8.1.2022, 12.16.2022, 1.1.2023, 1.13.2023, 2.1.2023
,
Current Update: 2.10.2023

13. Afdhal NH, Dieterich DT, Pockros PJ, et al. Epoetin Alfa Maintains Ribavirin Dose in HCV-infected Patients: a Prospective, Double-blind, Randomized Controlled Study. Gastroenterology, Volume 126, Issue 5, 1302 – 1311.
14. Berns JS. Treatment of Anemia in Non-dialysis Chronic Kidney Disease. UpToDate. https://www.uptodate.com/contents/treatment-of-anemia-in-nondialysis-chronic-kidney-disease. Updated October 12, 2018November 11, 2021. Accessed August 9, 2019November 15, 2021.
15. National Comprehensive Cancer Network. Management of Cancer and Chemotherapy Induced Anemia (Version 2.2020). NCCN. Accessed August 9, 2020November 15, 2021
16. Lee A. Fleisher, Kirsten E. Fleischmann, et al. 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;130:e278-e333.

iv **Erythropoiesis Stimulating Agent References**

1. Epogen® [package insert]. Thousand Oaks, CA: Amgen Inc.; Revised July 2018. https://www.pi.amgen.com/~/media/amgen/repositorysites/pi-amgen-com/epogen/epogen_pi_hcp_english.pdf. Accessed August 9, 2020November 15, 2021.
2. Procrit® [package insert]. Thousand Oaks, CA: Amgen Inc.; Revised July 2018. http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/PROCRIT-pi.pdf. Accessed August 7, 2019November 1, 2021.
3. Retacrit™ [package insert]. Lake Forest, IL: Pfizer Inc.; Revised January 2019August 2020. http://labeling.pfizer.com/ShowLabeling.aspx?id=10738#S2.6http://labeling.pfizer.com/ShowLabeling.aspx?id=10738. Accessed August 7, 2019November 15, 2021.
4. Aranesp® [package insert]. Thousand Oaks, CA: Amgen Inc.; Revised January 2019. https://www.pi.amgen.com/~/media/amgen/repositorysites/pi-amgen-com/aranesp/ckd/aranesp_pi_hcp_english.pdf. Accessed August 9, 2020November 15, 2021.
5. Mircera® [package insert]. Switzerland: Vifor Pharma; Revised June 2018August 2019. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=22c56f2a-f73c-60e7-e054-00144ff88e88https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125164s078lbl.pdf. Accessed August 9, 2020November 15, 2021.
6. Gold Standard, Inc. Clinical Pharmacology [database online]. http://www.clinicalpharmacology.com. Accessed August 9, 2020.
7. National Comprehensive Cancer Network. Myelodysplastic Syndromes (Version 2.20201). NCCN. https://www.nccn.org/professionals/physician_gls/pdf/mds.pdf. Updated October 18, 2018November 15, 2021. Accessed August 9, 2019November 15, 2021.
8. Estey EH, Schrier SL. Management of the complications of the myelodysplastic syndromes. UpToDate. https://www.uptodate.com/contents/management-of-the-hematologic-complications-of-myelodysplastic-syndromes?search=Management%20of%20the%20complications%20of%20the%20myelodysplastic%20syndromes&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1 http://www.uptodate.com. Updated July 17, 2015August 6, 2021. Accessed August 1, 2016November 15, 2021.
9. Rizzo JD, Brouwers M, Hurley P, et al. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Onc. 2010;28(33):4996-5010.
10. Bohlius J, Bohlke K, Castelli R, et al. American Society of Clinical Oncology/American Society of Hematology. Management of Cancer-Associated Anemia with Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update. Journal of Clinical Oncology 2019 37:15, 1336-1351.
11. Volberding PA, Levine AM, Dieterich D, et al. Anemia in HIV Working Group, Anemia in HIV Infection: Clinical Impact and Evidence-Based Management Strategies, Clinical Infectious Diseases, Volume 38, Issue 10, 15 May 2004, Pages 1454–1463.
12. KDIGO Anemia Work Group. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney Int Suppl. 2012;2(4):279-335.

Last Update: 12.1.2020, 12.4.2020, 3.1.2021, 5.11.2021, 6.28.2021, 8.1.2021, 9.13.2021, 10.1.2021, 12.17.2021, 1.9.2022, 2.1.2022, 2.17.2022, 2.28.2022, 3.11.2022, 4.5.2022, 4.7.2022, 4.26.2022, 5.11.2022, 5.19.2022, 6.7.2022, 7.9.2022, 8.1.2022, 12.16.2022, 1.1.2023, 1.13.2023, 2.1.2023
,
Current Update: 2.10.2023

13. Afdhal NH, Dieterich DT, Pockros PJ, et al. Epoetin Alfa Maintains Ribavirin Dose in HCV-infected Patients: a Prospective, Double-blind, Randomized Controlled Study. Gastroenterology, Volume 126, Issue 5, 1302 – 1311.
14. Berns JS. Treatment of Anemia in Non-dialysis Chronic Kidney Disease. UpToDate. https://www.uptodate.com/contents/treatment-of-anemia-in-nondialysis-chronic-kidney-disease. Updated October 12, 2018November 11, 2021. Accessed August 9, 2019November 15, 2021.
15. National Comprehensive Cancer Network. Management of Cancer and Chemotherapy Induced Anemia (Version 2.2020). NCCN. Accessed August 9, 2020November 15, 2021
16. Lee A. Fleisher, Kirsten E. Fleischmann, et al. 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;130:e278-e333.

[xxvii] **Entresto References**

1. Entresto® [package insert]. East Hanover, NJ: Novartis Pharmaceutical Corporation. Revised February 2021. https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/entresto.pdf. Accessed November 11, 2021.
2. Maddox TM, Januzzi JL, Allen LA, et al. 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. Published online January 2021. Available at: https://www.jacc.org/doi/10.1016/j.jacc.2020.11.022**.** Accessed November 11, 2021.
3. Yancy CW, Jessup M, Bozkurt B, et. al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation.* 2016;134: DOI: 10.1161/CIR.0000000000000435.
4. Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Journal of the American College of Cardiology. August 8, 2017; 70(6): 776-803.

[xxviii] **Eucrisa References**

1. Eucrisa™ (crisaborole). [Prescribing information]. New York, New York. Pfizer, Inc.; Revised April 2020. http://labeling.pfizer.com/ShowLabeling.aspx?id=5331. Accessed November 15, 2021.
2. Eichenfield LF, Tom WL, Berger TG, Krol A, Paller AS, Schwarzenberger K, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014 Jul;71(1):116-32. https://www.aad.org/practicecenter/quality/clinical-guidelines/atopic-dermatitis. Accessed November 15, 2021.
3. Eli Lily and Company. Validated Investigator Global Assessment scale for Atopic Dermatitis. vIGA-AD™. https://www.eczemacouncil.org/wp-content/uploads/2018/02/Validated-Investigator-Global-Assessment-Scale_vIGA-AD_2017.pdf. Accessed November 15, 2021.
4. CR Charman,1 AJ Venn,2 JC Ravenscroft,3 and HC Williams3. The British Journal of Dermatology. Translating Patient-Oriented Eczema Measure (POEM) scores into clinical practice by suggesting severity strata derived using anchor-based methods. http://europepmc.org/articles/pmc3920642. Accessed November 15, 2021.
5. Tollefson M, Bruckner. Atopic Dermatitis: Skin-Directed Management. American Academy of Pediatrics. 2014. 134 (6) e1735-e1744; DOI: 10.1542/peds.2014-2812
6. Howe W; Treatment of atopic dermatitis (eczema); November 2021, UpToDate; In R Corona (Ed.), https://www.uptodate.com/contents/treatment-of-atopic-dermatitis-eczema?search=eucrisa&source=search_result&selectedTitle=2~6&usage_type=default&display_rank=1#H1022550. Accessed November 15, 2021

Last Update: 12.1.2020, 12.4.2020, 3.1.2021, 5.11.2021, 6.28.2021, 8.1.2021, 9.13.2021, 10.1.2021, 12.17.2021, 1.9.2022, 2.1.2022, 2.17.2022, 2.28.2022, 3.11.2022, 4.5.2022, 4.7.2022, 4.26.2022, 5.11.2022, 5.19.2022, 6.7.2022, 7.9.2022, 8.1.2022, 12.16.2022, 1.1.2023, 1.13.2023, 2.1.2023

,

Current Update: 2.10.2023

[xxix] **EVRYSDI references:**

1. EVRYSDI [package insert]. San Francisco, CA 94080. Genentech, Inc., Revised April 2021. https://www.gene.com/download/pdf/evrysdi_prescribing.pdf. Accessed November 15, 2021.
2. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2016 Sept 21 - . Identifier NCT02908685, A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants (SUNFISH); 2020 Jul 22 [cited 2020 Aug 8]; [about 4 screens]. Available from: https://clinicaltrials.gov/ct2/show/NCT02908685.
3. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 02016 Sept 23 - . Identifier: CT02913482, Investigate Safety, Tolerability, PK, PD and Efficacy of Risdiplam (RO7034067) in Infants with Type1 Spinal Muscular Atrophy (FIREFISH); 2020 Aug 24 [cited 2020 Aug 26]; [about 5 screens]. Available from: https://clinicaltrials.gov/ct2/show/NCT02913482.
4. Yonezawa A, Inui KI. Importance of the multidrug and toxin extrusion MATE/SLC47A family to pharmacokinetics, pharmacodynamics/toxico-dynamics and pharmacogenomics. British Journal of Pharmacology; Br J Pharmacol. 2011 Dec; ;164(7): 1817-1825. doi: 10.1111/j.1476-5381.2011.01394.x. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3246706/.
5. Vuillerot C, Payan C. Responsiveness of the Motor Function Measure in Patients with Spinal Muscular Atrophy Archives of Physical Medicine and Rehabilitation journal. Archives of Physical Medicine and Rehabilitation 2013;94:1555-61. https://www.archives-pmr.org/article/S0003-9993(13)00098-1/pdf.
6. ClinicalTrials.gov. [Internet]. Bethesda (MD): National Library of Medicine (US). 0217 Jan26 -. Identifier: NCT03032172, A Study of Risdiplam (RO7034067) in Adult and Pediatric Participants with Spinal Muscular Atrophy (JEWELFISH); 0220 Jul 21 [cited 2020 Sept 18]; [about 5 screens]. Available from: https://clinicaltrials.gov/ct2/show/NCT03032172.

[xxx] **Exondys References:**

1. Exondys 51 [package insert]. Cambridge, MA: Sarepta Therapeutics, Inc.; October 2018.
2. Mendell JR, Rodino-Klapac LR, Sahenk Z, et al. Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol. 2013;74(5):637-47.
3. Cirak S, Arechavala-Gomeza V, Guglieri M, et al. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet. 2011;378(9791):595-605.
4. Mendell JR, Goemans N, Lowes LP, et al; Eteplirsen Study Group and Telethon Foundation DMD Italian Network. Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy. Ann Neurol. 2016;79(2):257-271.
5. Randeree L, Eslick GD. Eteplirsen for paediatric patients with Duchenne muscular dystrophy: A pooled-analysis. J Clin Neurosci. 2018;49:1

[xxxi] **GnRH Agonists References**

1. Fensolvi® [package insert]. Fort Collins: Tolmar Pharmaceuticals Inc. Revised May 2020. https://www.tolmar.com/sites/default/files/resources/FEN_Full_PI.pdf. Accessed December 7, 2021.
2. Eligard® [package insert]. Fort Collins: Tolmar Pharmaceuticals Inc. Revised April 2019. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=b78d1919-9dee-44fa-90f9-e0a26d32481d&type=display. Accessed December 7, 2021.
3. Leuprolide acetate [package insert]. Princeton, NJ: Sandoz Inc. Revised June 2021. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8bd72c1e-2751-4498-a346-bc5e3acbba0b&type=display. Accessed December 7, 2021.

4. Lupron Depot[package insert]. North Chicago, IL: AbbVie Inc. Revised February 2021. https://www.rxabbvie.com/. Accessed December 7, 2021.
5. Lupron Depot-PED [package insert]. North Chicago, IL: AbbVie Inc. Revised March 2021. https://www.rxabbvie.com/. Accessed December 7, 2021.
6. Supprelin LA® (histrelin acetate) [package insert]. Malvern, PA: Endo Pharmaceuticals Solutions. Revised November 2019. https://www.endo.com/File%20Library/Products/Prescribing%20Information/SUPPRELINLA_prescribing_information.html. Accessed December 7, 2021.
7. Synarel® [package insert]. New York, NY: Pfizer Inc. Revised December 2020. https://www.pfizermedicalinformation.com/en-us/synarel. Accessed December 7, 2021.
8. Trelstar® (triptorelin pamoate) [package insert]. Wayne, PA: Verity Pharmaceuticals, Inc. Revised October 2020. https://trelstar.com/wp-content/uploads/2021/11/Trelstar%C2%AE-triptorelin-pamoate-for-injectable-suspension-PI_October2020.pdf. Accessed December 7, 2021.
9. Vantas® (histrelin acetate) [package insert]. Malvern, PA: Endo Pharmaceuticals Solutions. Revised November 2019. http://www.endo.com/File%20Library/Products/Prescribing%20Information/Vantas_prescribing_information.html. Accessed December 7, 2021.
10. Triptodur® [package insert]. Atlanta, GA: Arbor Pharmaceuticals LLC. Revised October 2018. http://triptodur.com/assets/pdf/Triptodur-PI-Rev.-10.2018.pdf. Accessed December 7, 2021.
11. Orilissa™ [package insert]. North Chicago, IL: AbbVie Inc. Revised February 2021. https://www.rxabbvie.com/pdf/orilissa_pi.pdf. Accessed December 7, 2021.
12. Lupaneta® 3.75mg [package insert]. North Chicago, IL: AbbVie Inc. Revised June 2015. https://www.rxabbvie.com/pdf/lupaneta_3_75_pi.pdf. Accessed December 7, 2021.
13. Lupaneta® 11.25mg [package insert]. North Chicago, IL: AbbVie Inc. Revised June 2015. https://www.rxabbvie.com/pdf/lupaneta_11_25_pi.pdf. Accessed December 7, 2021.
14. Chirico V, Lacquaniti A, Salpietro V, Buemi M, Salpietro C, Arrigo T. Central precocious puberty: from physiopathological mechanisms to treatment. *J Biolog Regul Homeo Agents*. 2014;28(3):367-375.
15. Kletter GB, Klein KO, Wong YY. A pediatrician's guide to central precocious puberty. *Clin Ped*. 2015;54(5):414-424.
16. Harrington J, Palmert MR. Treatment of Precocious Puberty. UpToDate. https://www.uptodate.com/contents/treatment-of-precocious-puberty. Updated October 22, 2021. Accessed December 7, 2021.
17. Schenken RS. Endometriosis: Treatment of Pelvic Pain. UpToDate. https://www.uptodate.com/contents/endometriosis-treatment-of-pelvic-pain. Updated September 20, 2021. Accessed December 8, 2021.
18. Armstrong C. ACOG updates guideline on diagnosis and treatment of endometriosis. *Am Fam Physician*. 2011;83(1):84-85.
19. Dunselman GA, Vermeulen N, Becker C. ESHRE guideline: management of women with endometriosis. *Hum Reprod.* 2014;29(3):400-412.
20. Stewart EA. Overview of Treatment of Uterine Leiomyomas (Fibroids). UpToDate. https://www.uptodate.com/contents/overview-of-treatment-of-uterine-leiomyomas-fibroids. Updated August 6, 2021. Accessed December 8, 2021.
21. National Comprehensive Cancer Network. Breast Cancer (Version 1.2022). NCCN. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Updated November 24, 2021. Accessed December 8, 2021.
22. National Comprehensive Cancer Network. Prostate Cancer (Version 2.2022). NCCN. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Updated November 30, 2021 Accessed December 8, 2021.
23. National Comprehensive Cancer Network. Ovarian Cancer (Version 3.2021). NCCN. https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf. Updated September 9, 2021. Accessed December 8, 2021.

Last Update: 12.1.2020, 12.4.2020, 3.1.2021, 5.11.2021, 6.28.2021, 8.1.2021, 9.13.2021, 10.1.2021, 12.17.2021, 1.9.2022, 2.1.2022, 2.17.2022, 2.28.2022, 3.11.2022, 4.5.2022, 4.7.2022, 4.26.2022, 5.11.2022, 5.19.2022, 6.7.2022, 7.9.2022, 8.1.2022, 12.16.2022, 1.1.2023, 1.13.2023, 2.1.2023
,
Current Update: 2.10.2023

24. National Comprehensive Cancer Network. Head and Neck Cancers (Version 1.2022). NCCN. https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf. Updated December 8, 2021. Accessed December 8, 2021.
25. Hembree WC, Cohen-Kettenis PT, Gooren L et al; Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline, *The Journal of Clinical Endocrinology & Metabolism*. https://academic.oup.com/jcem/article/doi/10.1210/jc.2017-01658/4157558/Endocrine-Treatment-of-Gender-Dysphoric-Gender. Updated Sept 13, 2017. Accessed December 8, 2021.

[xxxii] **Hemophilia Factor References**

1. NovoSeven® RT. [package insert]. Plainsboro NJ: Novo Nordisk; Revised July 2020. https://www.novo-pi.com/novosevenrt.pdf. Accessed May 4, 2021.
2. Alphanate® [package insert]. Los Angeles, CA: Grifols Biologicals LLC; Revised June 2018. https://www.alphanate.com/documents/32867717/32868353/alphanate+prescribing+information+patient/0b7a6c1a-af96-40ed-b534-5a06cec9a5ce. Accessed May 4, 2021.
3. Feiba NF. [package insert]. Westlake Village, CA: Baxter Healthcare Corporation; Revised February 2020. https://www.shirecontent.com/PI/PDFs/FEIBA_USA_ENG.pdf. Accessed May 4, 2021.
4. Hemlibra® [package insert]. South San Francisco, CA: Genentech, Inc.; Revised March 2021. https://www.gene.com/download/pdf/hemlibra_prescribing.pdf. Accessed May 4, 2021.
5. Obizur [package insert]. Lexington, MA: Baxalta US Inc.; Revised July 2020. https://www.shirecontent.com/PI/PDFs/OBIZUR_USA_ENG.pdf. Accessed May 4, 2021.
6. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.; Retrieved from https://www.clinicalkey.com/pharmacology/. Accessed February 24, 2020.
7. Guidelines for the management of hemophilia. 2nd ed. Montreal (Quebec): World Federation of Hemophilia; 2012; 1-74. Medical and Scientific Advisory Council (MASAC). MASAC Recommendation Regarding the Use of Bypassing Agents in Patients with Hemophilia A or B and Inhibitors. MASAC Document #167. Adopted by the NHF Board of Directors on June 3, 2006. Accessed May 4, 2021. Available from http://www.hemophilia.org/sites/default/files/document/files/167.pdf
8. Hoots W.K., Shapiro A.D. (2020). Hemophilia A and B: Routine management including prophylaxis. *UpToDate*. (Inc. L.K. Leung, D.H. Mahoney, J.S. Tirnauer, Eds.) Retrieved May 4, 2021 from https://www.uptodate.com/contents/hemophilia-a-and-b-routine-management-including-prophylaxis.
9. Medical and Scientific Advisory Council (MASAC) Recommendations Regarding the Treatment of von Willebrand Disease. MASAC document #244. Accessed January 25, 2018 at https://www.hemophilia.org/Researchers-Healthcare-Providers/Medical-and-Scientific-Advisory-Council-MASAC/MASAC-Recommendations/MASAC-Recommendations-Regarding-the-Treatment-of-von-Willebrand-Disease
10. Valentino LA, Kempton CL, Kruse-Jarres R, Mathew P, Meeks SL, Reiss UM on Behalf of the International Immune Tolerance Induction Study Investigators. US Guidelines for immune tolerance induction in patients with hemophilia A and inhibitors. *Hemophilia* 2015. DOI: 10.1111/hae.12730.
11. Medical-and-Scientific-Advisory-Council-MASAC/MASAC-Recommendations/MASAC-Recommendations-on-Standardized-Testing-and-Surveillance-for-Inhibitors-in-Patients-with-Hemophilia-A-and-B. Accessed January 25, 2018 at https://www.hemophilia.org/Researchers-Healthcare-Providers/Medical-and-Scientific-Advisory-Council-MASAC/MASAC-Recommendations/MASAC-Recommendations-on-Standardized-Testing-and-Surveillance-for-Inhibitors-in-Patients-with-Hemophilia-A-and-B
12. Selected available factor VIII products for patients with hemophilia A, (2019). Retrieved from https://www.uptodate.com/contents/image?imageKey=HEME%2F109838&topicKey=HEME%2F107911&search=treatment%20of%20hemophilia&rank=1~150&source=see_link. Accessed February 14, 2019.
13. National Hemophilia Foundation for all bleeding disorders. https://www.hemophilia.org/Bleeding-Disorders/What-is-a-Bleeding-Disorder
14. Selected available factor IX products for patients with hemophilia B. (2019). Retrieved from https://www.uptodate.com/contents/image?imageKey=HEME%2F109839&topicKey=RHEUM%2F4675&search=treatment%20of%20hemophilia&rank=1~150&source=see_link. Accessed May 4, 2021.

Last Update: 12.1.2020, 12.4.2020, 3.1.2021, 5.11.2021, 6.28.2021, 8.1.2021, 9.13.2021, 10.1.2021, 12.17.2021, 1.9.2022, 2.1.2022, 2.17.2022, 2.28.2022, 3.11.2022, 4.5.2022, 4.7.2022, 4.26.2022, 5.11.2022, 5.19.2022, 6.7.2022, 7.9.2022, 8.1.2022, 12.16.2022, 1.1.2023, 1.13.2023, 2.1.2023
,
Current Update: 2.10.2023

15. Medical and Scientific Advisory Council (MASAC) Recommendations Concerning Products Licensed for the Treatment of Hemophilia and Other Bleeding Disorders. (2018). https://www.hemophilia.org/Researchers-Healthcare-Providers/Medical-and-Scientific-Advisory-Council-MASAC/MASAC-Recommendations/MASAC-Recommendations-Concerning-Products-Licensed-for-the-Treatment-of-Hemophilia-and-Other-Bleeding-Disorders. Accessed February 14, 2019.
16. Treatment of von Willebrand disease. Rick ME, (2018). In Tirnauer JS, (Ed). https://www.uptodate.com/contents/treatment-of-von-willebrand-disease. Accessed May 4, 2021.
17. Recombinant factor VIIa: Clinical uses, dosing, and adverse effects, Hoffman M, (2017). Tirnauer JS (Ed), Retrieved from https://www.uptodate.com/contents/recombinant-factor-viia-clinical-uses-dosing-and-adverse-effects. Accessed May 4, 2021.
18. Researchers-Healthcare-Providers/Medical-and-Scientific-Advisory-Council-MASAC/MASAC-Recommendations/Guidelines-for-Emergency-Department-Management-of-Individuals-with-Hemophilia-and-Other-Bleeding-Disorders. Accessed May 4, 2021. https://www.hemophilia.org/Researchers-Healthcare-Providers/Medical-and-Scientific-Advisory-Council-MASAC/MASAC-Recommendations/Guidelines-for-Emergency-Department-Management-of-Individuals-with-Hemophilia-and-Other-Bleeding-Disorders.
19. Researchers-Healthcare-Providers/Medical-and-Scientific-Advisory-Council-MASAC/MASAC-Recommendations/Recommendation-on-the-Use-and-Management-of-Emicizumab-kxwh-Hemlibra-for-Hemophilia-A-with-and-without-Inhibitors. Accessed May 4, 2021. https://www.hemophilia.org/Researchers-Healthcare-Providers/Medical-and-Scientific-Advisory-Council-MASAC/MASAC-Recommendations/Recommendation-on-the-Use-and-Management-of-Emicizumab-kxwh-Hemlibra-for-Hemophilia-A-with-and-without-Inhibitors.
20. Hoots, KW, Shapiro AD. (2020). Treatment of bleeding and perioperative management in hemophilia A and B. Retrieved from In J. A. Melin (Ed.), UpToDate. Retrieved May 4, 2021. https://www.uptodate.com/contents/treatment-of-bleeding-and-perioperative-management-in-hemophilia-a-and-b.

[xxxiii] **HP Acthar References**

1. Acthar® Gel (corticotropin) [package insert]. Bedminster, NJ; Mallinckrodt ARD Inc; Revised February 2021. https://www.acthar.com/pdf/Acthar-PI.pdf. Accessed July 29, 2021.
2. Go, C.Y., Mackay, M.T., Weiss, S.K. et al. Evidence-based guideline update: Medical treatment of infantile spasms: Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2012;78;1974-1980. https://n.neurology.org/content/78/24/1974. July 29, 2021.

[xxxiv] **Hetlioz References**

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc., URL: http://www.clinicalpharmacology-ip.com/. Updated periodically. Accessed November 1, 2019
2. Hetlioz™ [package insert]. Vanda Pharmaceuticals Inc., Washington, D.C.; December 2014. http://www.hetliozpro.com/Content/Pdfs/HetliozPI.pdf. Accessed Novemeber 1, 2019
3. Vanda Pharmaceuticals. Efficacy and Safety of Tasimelteon Compared With Placebo in Totally Blind Subjects With Non-24-Hour Sleep-Wake Disorder. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2014 Mar 20]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01163032 NLM Identifier: NCT01163032.
4. Auger RR, Burgess HJ, Emens JS, et al. Clinical Practice Guideline for the Treatment of Intrinsic Circadian Rhythm Sleep-Wake Disorders: Advanced Sleep-Wake Phase Disorder (ASWPD), Delayed Sleep-Wake Phase Disorder (DSWPD), Non-24-Hour Sleep-Wake Rhythm Disorder (N24SWD), and Irregular Sleep-Wake Rhythm Disorder (ISWRD). An Update for 2015. Journal of Clinical Sleep Medicine. 2015; 11(10): 1199–1236. doi: [10.5664/jcsm.5100].
5. Daly A, Coppenrath V. Non-24-Hour Sleep-Wake Disorder: Disease Overview and Treatment Options. U.S. Pharmacist. 2015;40(6):48-52. https://www.uspharmacist.com/article/non-24-hour-sleep-wake-disorder-disease-overview-and-treatment-options

6. Abbott SM, Goldstein CA, Eichler AF. Non-24-Hour Sleep-Wake Rhythm Disorder. Waltham, MA: UpToDate. Last modified August 10, 2018. https://www.uptodate.com/contents/non-24-hour-sleep-wake-rhythm-disorder. Accessed November 4, 2019.

[xxxv] **Gleevec References**

1. Gleevec® [package insert]. East Hanover, NJ: Novartis U.S.; Revised August 2020. https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/gleevec_tabs.pdf. May 20, 2021.
2. National Comprehensive Cancer Network (NCCN). *NCCN Clinical Practice Guidelines in Oncology: Chronic Myeloid Leukemia. Version 3.2021 - January 13, 2021*; National Comprehensive Care Network. Available from http://www.nccn.org/professionals/physician_gls/pdf/cml.pdf. Accessed May 25, 2021.
3. National Comprehensive Cancer Network (NCCN). *Clinical Practice Guidelines in Oncology: Acute Lymphoblastic Leukemia. Version 1.2021 - April 6, 2021*; National Comprehensive Care Network. Available from http://www.nccn.org/professionals/physician_gls/pdf/all.pdf. Accessed May 25, 2021.
4. National Comprehensive Cancer Network (NCCN). *Clinical Practice Guidelines in Oncology: Myelodysplastic Syndromes. Version 3.2021 - January 15, 2021*; National Comprehensive Care Network. Available from https://www.nccn.org/professionals/physician_gls/pdf/mds.pdf. Accessed May 25, 2021.
5. National Comprehensive Cancer Network (NCCN). *Clinical Practice Guidelines in Oncology: Soft Tissue Sarcoma. Version 2.2021 - April 28, 2021*; National Comprehensive Care Network. Available from https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf. Accessed May 25, 2021.
6. National Comprehensive Cancer Network (NCCN). *Clinical Practice Guidelines in Oncology: Cutaneous Melanoma. Version 2.2021 - February 19, 2021*; National Comprehensive Care Network. Available from https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf. Accessed May 25, 2021.
7. National Comprehensive Cancer Network (NCCN). *Clinical Practice Guidelines in Oncology: AIDS-Related Kaposi Sarcoma. Version 2.2019.* 2018 Nov 29; National Comprehensive Care Network. Available from https://www.nccn.org/professionals/physician_gls/pdf/kaposi.pdf. Accessed February 5, 2020
8. Chao, N.J. (2018). Treatment of chronic graft-versus-host disease. In R. S. Negrin (Ed.), *UpToDate.* Retrieved February 5, 2020, from https://www.uptodate.com/contents/treatment-of-chronic-graft-versus-host-disease.
9. Antineoplastics - Pharmacy Clinical Policy Bulletins Aetna Non-Medicare Prescription Drug Plan. Aetna Clinical Pharmacy Bulletins. http://www.aetna.com/products/rxnonmedicare/data/2021/Specialty/Gleevec.html. Accessed May 20, 2021

[xxxvi] **Intravaginal Progesterone Products References**

1. Crinone [package insert]. Actavis Pharma, Inc., Parsippany, NJ; Revised November 2017. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7def92fe-d521-41c0-b419-48e028f59f15. Accessed December 13, 2019.
2. Endometrin [package insert]. Ferring Pharmaceuticals., Parsippany, NJ; Revised September 12, 2019. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2ba50fa9-b349-40cb-9a4b-1af8faa4ec09. Accessed December 13, 2019.
3. First-progesterone suppositories [package insert]. Cutis Pharm, Wilmington, MA; May 2015.
4. The American College of Obstetricians and Gynecologists. Committee on Practice Bulletins – Obstetrics, Practice Bulletin: Prediction and Prevention of Preterm Birth. *Obstetrics & Gynecology*. Oct 2012; 120;4: 964-973.
5. National Institute for Health and Care Excellence. Preterm labour and birth (NG25): NICE guideline. Aug. 2019.
6. O'brien, J.M., DeFranco, E.A., Adair, C.D., Lewis, D.F., Hall, D.R., How, H., Bsharat, M., and Creasy, G.W. Effect of progesterone on cervical shortening in women at risk for preterm birth: secondary analysis from a multinational, randomized, double-blind, placebo-controlled trial. *Ultrasound Obstet Gynecol* 2009; 34:653-659.

Last Update: 12.1.2020, 12.4.2020, 3.1.2021, 5.11.2021, 6.28.2021, 8.1.2021, 9.13.2021, 10.1.2021, 12.17.2021, 1.9.2022, 2.1.2022, 2.17.2022, 2.28.2022, 3.11.2022, 4.5.2022, 4.7.2022, 4.26.2022, 5.11.2022, 5.19.2022, 6.7.2022, 7.9.2022, 8.1.2022, 12.16.2022, 1.1.2023, 1.13.2023, 2.1.2023
,
Current Update: 2.10.2023

7. Coomarasamy, A., Williams, H., Truchanowicz, E., et al. A randomized trial of progesterone in women with recurrent miscarriages. *N Engl J Med*. 2015;373:2141-8.
8. Gold Standard, Inc. Progesterone. Clinical Pharmacology [database online]. Available at: http://www.clinicalpharmacology.com. Accessed December 13, 2019.
9. Norwitz, E.R. (2019). Progesterone supplementation to reduce the Risk of spontaneous preterm birth. In C.J. Lockwood (Ed), *UpToDate*. Retrieved December 13, 2019 from https://www.uptodate.com/contents/progesterone-supplementation-to-reduce-the-risk-of-spontaneous-preterm-birth.
10. Corrine, K.W., & Barbieri, R.L. (2018). Evaluation and management of secondary amenorrhea. In W.F. Crowley & M.E. Geffner (Ed), *UpToDate*. Retrieved December 13, 2019, from https://www.uptodate.com/contents/evaluation-and-management-of-secondary-amenorrhea.

[xxxvii] **Inlyta References:**

3. Inlyta® [package insert]. New York, NY: Pfizer Inc; Revised June 2020. http://labeling.pfizer.com/ShowLabeling.aspx?id=759. Accessed May 21, 2021.
4. National Comprehensive Cancer Network (NCCN). *NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer. version 4.2021 - April 19, 2021*; National Comprehensive Cancer Network. Available from: http://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf. Accessed May 21, 2021.
5. National Comprehensive Cancer Network (NCCN). *NCCN Clinical Practice Guidelines in Oncology: Thyroid Carcinoma. version 1.2021 - April 9, 2021*; National Comprehensive Cancer Network. Available from: https://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf. Accessed May 21, 2021.

[xxxviii] **Interferon References**

1. Intron A (interferon alfa-2b) [package insert]. August 2019. Kenilworth, NJ; Merck Sharp & Dohme Corp. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=30789790-8317-49f9-b97b-8c5ba17b53d2&type=display Accessed May 21, 2021
2. Actimmune (interferon gamma-1b) [package insertRevised March 2021. Roswell, GA; HZNP USA, Inc. https://www.hzndocs.com/ACTIMMUNE-Prescribing-Information.pdf Accessed May 21, 2021.
3. National Comprehensive Cancer Network. Hairy Cell Leukemia version 2.2021 - March 11, 2021. NCCN. https://www.nccn.org/professionals/physician_gls/pdf/hairy_cell.pdf. Accessed May 21, 2021.
4. National Comprehensive Cancer Network. Cutaneous Melanoma version 2.2021 - February 19, 2021. NCCN. https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf. Accessed May 21, 2021.
5. National Comprehensive Cancer Network. T-cell Lymphomas version 1.2021 - October 5, 2020. NCCN. https://www.nccn.org/professionals/physician_gls/pdf/t-cell.pdf. Accessed May 21, 2021.
6. Terrault, N. A., Bzowej, N. H., Chang, K.-M., Hwang, J. P., Jonas, M. M. and Murad, M. H. (2018), Update on Preventon, Diagnosis and Treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance. https://www.aasld.org/sites/default/files/2019-06/HBVGuidance_Terrault_et_al-2018-Hepatology.pdf Hepatology, 67: 261–283. Accessed May 21, 2021.

[xli] **Janus Associated Kinase Inhibitors**

1. Jakafi® (ruxolitinib) [package insert]. Wilmington, DE: Incyte, Corporation; Revised Jan 2020. https://www.jakafi.com/pdf/prescribing-information.pdf. Accessed August 20, 2020.
2. National Comprehensive Cancer Network. Myeloproliferative Neoplasms. (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mpn.pdf. Updated October 29, 2018. Accessed August 20, 2019.
3. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-2405.
4. Tefferi, A. Overview of the myeloproliferative neoplasms: UpToDate, Waltham, MA. https://www.uptodate.com/contents/overview-of-the-myeloproliferative-neoplasms?source=history_widget Accessed August 13, 2018
5. Harris AC, Young R, Devine S, et al. International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium. Biol Blood Marrow Transplant. 2016;22(1):4–10. doi:10.1016/j.bbmt.2015.09.001
6. Inrebic (fedratinib) [package insert]. Celgene Corporation. Revised August 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212327s000lbl.pdf. Accessed September 25, 2019
7. Inrebic (fedratinib) [package insert]. Summit, NJ: Celgene Corporation; 2019. https://media2.celgene.com/content/uploads/inrebic-pi.pdf. Accessed August 20, 2020.
8. National Comprehensive Cancer Network. Hematopoietic Cell Transplantation. (Version 2.2020). https://www.nccn.org/professionals/physician_gls/pdf/hct.pdf. Updated March 23, 2020. Accessed August 20, 2020.

[xlii] **Juxtapid/Kynamro References**

1. Gidding SS, Champagne MA, Ferranti SD, et al. on behalf of the American Heart Association Atherosclerosis, Hypertension, and Obesity in the Young Committee of the Council on Cardiovascular Disease in the Young, Council on Cardiovascular and Stroke Nursing, Council on Functional Genomics and Translational Biology, and Council on Lifestyle and Cardiometabolic Health Circulation. 2015; 132:2167-2192. doi: 10.1161/CIR.0000000000000297.
2. Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association of Clinical Endocrinologists And American College Of Endocrinology Guidelines For Management Of Dyslipidemia And Prevention Of Cardiovascular Disease. Endocrine Practice, vol. 23, no. Supplement 2, 2017; 1–87. doi:10.4158/ep171764.appgl.
3. Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways, In Journal of the American College of Cardiology, Volume 70, Issue 14, 2017; 1785-1822. doi.org/10.1016/j.jacc.2017.07.745.
4. Watts GF, Gidding S, Wierzbicki AS, et al. Integrated guidance on the care of familial hypercholesterolemia from the International FH Foundation, In International Journal of Cardiology, Volume 171, Issue 3, 2014; 309-325. doi.org/10.1016/j.ijcard.2013.11.025.
5. Grundy, SM, Stone, NJ, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, In Journal of the American College of Cardiology, November 2018. DOI: 10.1016/j.jacc.2018.11.003
6. Juxtapid® [package insert]. Cambridge, MA. Aegerion Pharmaceuticals, Inc. August 2017. Retrieved from http://www.juxtapidpro.com/prescribing-information. Accessed September 23,2019.
7. Clinical Pharmacology. [database online]. Tampa, FL. Gold Standard, Inc. Retrieved from https://www.clinicalkey.com/pharmacology/monograph/3794?sec=monindi&n=Juxtapid. Accessed September 23,2019.

Last Update: 12.1.2020, 12.4.2020, 3.1.2021, 5.11.2021, 6.28.2021, 8.1.2021, 9.13.2021, 10.1.2021, 12.17.2021, 1.9.2022, 2.1.2022, 2.17.2022, 2.28.2022, 3.11.2022, 4.5.2022, 4.7.2022, 4.26.2022, 5.11.2022, 5.19.2022, 6.7.2022, 7.9.2022, 8.1.2022, 12.16.2022, 1.1.2023, 1.13.2023, 2.1.2023
,
Current Update: 2.10.2023

8. Clinical Pharmacology. [database online]. Tampa, FL. Gold Standard, Inc. Retrieved from https://www.clinicalkey.com/pharmacology/monograph/3800?sec=monindi&n=Kynamro. Accessed September 23,2019.
9. Arnett DK, Blumenthal, SR, et al. 2019 ACC/AHA Guideline on the Management of Blood Cholesterol A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guideline). Recent guidelines included 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. Circulation. 2019;140:e596–e646. https://www.ahajournals.org/doi/10.1161/CIR.0000000000000678.
10. Rosenson RS, de Ferranti SD, Durrington P, (2018). Treatment of drug-resistant hypercholesterolemia. In GM Saperia (Ed.), *UpToDate*.. Retrieved September 23, 2019 from https://www.uptodate.com/contents/treatment-of-drug-resistant-hypercholesterolemia?search=homozygous%20familial%20hypercholesterolemia&source=search_result&selectedTitle=3~150&usage_type=default&display_rank=3#H82436065.

[xliii] **Korlym References**

1. Korlym [package insert]. Corcept Therapeutics Incorporated, Menlo Park, CA 940252; November 2019. https://www.korlym.com/hcp/wp-content/uploads/sites/2/2018/01/K-00017-NOV-2019_electronic-PI_r8_FINAL.pdf. Accessed October 28, 2019.
2. DailyMed [online database]. U.S. National Library of Medicine, 8600 Rockville Pike, Bethesda, MD 20894; updated July 2019 https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=542f3fae-8bc8-4f00-9228-e4b66c9ad6a9. Accessed October 28, 2019
3. Fleseriu M, Biller BM, Findling JW, Molitch ME, Schteingart DE, Gross C; SEISMIC Study Investigators. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome. J Clin Endocrinol Metab. 2012 Jun;97(6):2039-49. doi: 10.1210/jc.2011-3350. Epub 2012 Mar 30.
4. Facts and Comparisons [online database]. Wolters Kluwer Health, St. Louis, MO; updated November 2019. https://online.lexi.com/lco/action/search?q=Korlym&t=name&va=korl#adr-nested-1. Accessed November 1, 2019
5. Clinical Pharmacology [online database]. Tampa, FL: Gold Standard, Inc; updated October 2019. http://www.clinicalpharmacology-ip.com/Forms/Monograph/monograph.aspx?cpnum=405&sec=monindi&t=0 Accessed October 28,2019

[xliv] **Krystexxa References**

1. Krystexxa [package insert]. Lake Forest, IL: Horizon Pharma USA Inc.; March 2021. Retrieved on September 7, 2021 from https://www.hzndocs.com/KRYSTEXXA-Prescribing-Information.pdf.
2. Probenecid [package insert]. Parsippany, NJ: Actavis Pharma, Inc.; December 2016.
3. Febuxostat [package insert]. Eatontown, NJ: Hikama Pharmaceuticals USA Inc.; July 2019.
4. IBM Micromedex (electronic version). Truven Health Analytics, Ann Arbor, Michigan. Available at http://www.micromedexsolutions.com. Accessed September 7, 2021.
5. Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res. 2012;64(10):1431-1446.
6. Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76:29-42.
7. Khanna D, Khanna PP, Fitzgerald JD, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and anti-inflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res. 2012;64(10):1447-1461.
8. Hui M, Carr A, Cameron S, et al. The British Society for Rheumatology Guideline for the Management of Gout. Rheumatology. 2017;56(7):e1–e20. Available at https://doi.org/10.1093/rheumatology/kex156

Last Update: 12.1.2020, 12.4.2020, 3.1.2021, 5.11.2021, 6.28.2021, 8.1.2021, 9.13.2021, 10.1.2021, 12.17.2021, 1.9.2022, 2.1.2022, 2.17.2022, 2.28.2022, 3.11.2022, 4.5.2022, 4.7.2022, 4.26.2022, 5.11.2022, 5.19.2022, 6.7.2022, 7.9.2022, 8.1.2022, 12.16.2022, 1.1.2023, 1.13.2023, 2.1.2023
,
Current Update: 2.10.2023

9. Sivera F, Andres M, Carmona L, et al. Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systemic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. Ann Rheum Dis. 2014;73(2):328-335.
10. FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology Guideline for the Management of Gout [published correction appears in Arthritis Care Res (Hoboken). 2020 Aug;72(8):1187]. Arthritis Care Res (Hoboken). 2020;72(6):744-760.

[xlv] **Lucemrya References**

1. Lofexidine [package insert]. US WorldMeds, LLC, 4441 Springdale Road, Louisville, KY, May 2018 https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b748f308-ba71-4fd9-84ec-ec7e0f210885. Accessed November 22, 2021.
2. K Sevarino, A J Saxon, R Hermann, Waltham, MA. Medically supervised opioid withdrawal during treatment for addiction, August 18, 2020, https://www.uptodate.com/contents/medically-supervised-opioid-withdrawal-during-treatment-for-addiction. Accessed November 22, 2021.
3. Pergolizzi JV Jr, Annabi H, Gharibo C, LeQuang JA. June 8, 2019. The Role of Lofexidine in Management of Opioid Withdrawal. Pain Ther. (1):67-78. doi: 10.1007/s40122-018-0108-7. https://www.ncbi.nlm.nih.gov/pubmed?term=30565033. Accessed August 20, 2019.
4. American Society of Addiction Medicine. National practice guideline for the treatment of opioid use disorder 2020 focused update. 2019. https://www.asam.org/docs/default-source/quality-science/npg-jam-supplement.pdf?sfvrsn=a00a52c2_2. Accessed 14 Jul 2020
5. National Collaborating Centre for Mental Health. Drug misuse: opioid detoxification: the NICE guideline. 2008. https://www.nice.org.uk/guidance/cg52/evidence/drug-misuse-opioid-detoxification-full-guideline-196515037. Accessed 14 Jul 2020.
6. Soyka M, Kranzler HR, van den Brink W, Krystal J, Moller HJ, Kasper S. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of substance use and related disorders. Part 2: Opioid dependence. World J Biol Psychiatry. 2011;12(3):160–87

[xlvi] **Makena References**

1. Makena (17- hydroxyprogesterone caproate) [package insert]. Waltham, MA: AMAG Pharmaceutical, Inc; August 2017.
2. Meis PJ, Klebanoff M, Thom E, et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. *N Engl J Med.* 2003;348(24):2379-85.
3. Makena [Daily Med]. NIH, U.S. National Library of Medicine. Updated 26 Feb. 2018. Accessed 31 Dec. 2019
4. Hydroxyprogesterone caproate [prescribing information]. Baudette, MN: ANI Pharmaceuticals Inc; June 2016.
5. Obstet Gynecol. 2018 Jul;132(1):102-106. doi: 10.1097/AOG.0000000000002695
6. Norwitz, E.R.,(2018). Progesterone supplementation to reduce the risk of spontaneous preterm birth, In V.A. Barss (Ed), UpToDate. Retrieved November 12, 2018 from https://www.uptodate.com/contents/progesterone-supplementation-to-reduce-the-risk-of-spontaneous-preterm-birth?search=makena&source=search_result&selectedTitle=2~58&usage_type=default&display_rank=1
7. Makena. Clinical Pharmacology [Internet]. Tampa (FL): Gold Standard, Inc.; Retrieved from: http://www.clinicalpharmacology-ip.com/Forms/Monograph/monograph.aspx?cpnum=3534&sec=monindi&t=0. Accessed November 19, 2019

[xlvii] **Monoamine depletors References**

1. Ingrezza (valbenazine oral capsules) package insert. July 2019
2. Micromedex products. 2016 Truven Health Analytics Inc., Available at: http://www.micromedexsolutions.com/micromedex2/librarian/. Accessed on May 25, 2017.
3. Armstrong MJ, Miyasaki JM. Evidence-based guideline: Pharmacologic treatment of chorea in Huntington disease: Report of the guideline development subcommittee of the American Academy of Neurology. Neurology 2012;79:597-603

4. Austedo (deutetrabenazine) tablets package insert June 2021. https://www.austedo.com/globalassets/austedo/prescribing-information.pdf
5. Xenazine (tetrabenazine) package insert. Deerfield, IL: Lundbeck, Inc.; 2015 Jun.
6. Fernandez, Hubert H. Randomized controlled trial of deutetrabenazine for tardive dyskinesia: The ARM-TD study, Neurology 2017; 88 (21) p.2003-2010. Accessed November 20, 2018, from https://www.ncbi.nlm.nih.gov/pubmed?term=28446646.
7. Anderson, Karen E. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomized, placebo-controlled, phase 3 trial. Lancet Psychiatry 2017; S2215-0366(17)30236-5.
2. Huntington Study Group. Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial. JAMA. 2016;316(1):40–50. doi:10.1001/jama.2016.8655. Accessed November 21, 2018, from https://jamanetwork.com/journals/jama/fullarticle/2532012.

[xlviii] **Mulpleta References**

1. Mulpleta® [package insert]. Florham Park, New Jersey: Shionogi Inc.; Revised April 2020. https://www.shionogi.com/content/dam/shionogi/si/products/pdf/mulpleta.pdf. Accessed June 2, 2021.
2. Miller JB, Figueroa EJ, et. al. Thrombocytopenia in Chronic Liver Disease and the Role of Thrombopoietin Agonists. Gastroenterology & Hepatology June 2019 - Volume 15, Issue 6. https://www.gastroenterologyandhepatology.net/archives/june-2019/thrombocytopenia-in-chronic-liver-disease-and-the-role-of-thrombopoietin-agonists/. Accessed June 2, 2021.

[xlix] **Multaq References**

1. Multaq® [package insert]. Sanofi-Aventis U.S. LLC, Bridgewater, NJ; January 2017. http://products.sanofi.us/multaq/multaq.html. Accessed December 11, 2019.
2. 2014 AHA/ACC/HRS Guideline for the Management of Patients with Atrial Fibrillation: Executive Summary. *Circulation*. 2014; 130:2071-2104.
3. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal (2016) 37, 2893–2962 doi:10.1093/eurheartj/ehw210.
4. Teme, Tonye, Goldberger, Jeffrey J. Efficacy and tolerability of dronedarone for patients with atrial fibrillation. *Cardiology Journal*. 2013. 20(5): 486-490.
5. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc., URL: http://www.clinicalpharmacology-ip.com/. Updated periodically. Accessed December 11, 2019.
6. CORDARONE Amiodarone tablets [Prescribing Information]. Pfizer Wyeth Pharmaceuticals Inc. Philadelphia, PA. March 2015.
7. January CT, Wann S, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Journal of the American College of Cardiology. 2014;64(21). doi.org/10.1016/j.jacc.2014.03.022.
8. Passman, R., Giardina, E.G., (2018), Clinical uses of dronedarone, In B.C. Downey (Ed), UpToDate. Retrieved October 31, 2018 from
9. Kumar, K.K., (2017), Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations, In G.M. Saperia (Ed), UpToDate. Retrieved October 31, 2018 from https://www.uptodate.com/contents/antiarrhythmic-drugs-to-maintain-sinus-rhythm-in-patients-with-atrial-fibrillation-recommendations

[l] **Nexavar References**

1. Nexavar® [package insert]. Wayne, NJ: Bayer Healthcare Pharmaceuticals Inc.; Revised July 2020. http://labeling.bayerhealthcare.com/html/products/pi/Nexavar_PI.pdf. Accessed May 25, 2021.

Last Update: 12.1.2020, 12.4.2020, 3.1.2021, 5.11.2021, 6.28.2021, 8.1.2021, 9.13.2021, 10.1.2021, 12.17.2021, 1.9.2022, 2.1.2022, 2.17.2022, 2.28.2022, 3.11.2022, 4.5.2022, 4.7.2022, 4.26.2022, 5.11.2022, 5.19.2022, 6.7.2022, 7.9.2022, 8.1.2022, 12.16.2022, 1.1.2023, 1.13.2023, 2.1.2023
,
Current Update: 2.10.2023

2. National Comprehensive Cancer Network (NCCN). *NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer. Version 4.2021 - April 19, 2021*; National Comprehensive Cancer Network. Available from: http://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf. Accessed May 25, 2021.
3. National Comprehensive Cancer Network (NCCN). *NCCN Clinical Practice Guidelines in Oncology: Hepatobiliary Cancers. Version 2.2021 - April 16, 2021*; National Comprehensive Cancer Network. Available from: https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf. Accessed May 25, 2021.
4. National Comprehensive Cancer Network (NCCN). *NCCN Clinical Practice Guidelines in Oncology: Bone Cancer. Version 1.2021 - November 20, 2020*; National Comprehensive Cancer Network. Available from: https://www.nccn.org/professionals/physician_gls/pdf/bone.pdf.. Accessed May 25, 2021.
5. National Comprehensive Cancer Network (NCCN). *NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia. Version 3.2021 - March 2, 2021*; National Comprehensive Cancer Network. Available from: https://www.nccn.org/professionals/physician_gls/pdf/aml.pdf. Accessed May 25, 2021.
6. National Comprehensive Cancer Network (NCCN). *NCCN Clinical Practice Guidelines in Oncology: Soft Tissue Sarcoma. Version 2.2021 - April 28, 2021*; National Comprehensive Cancer Network. Available from: https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf. Accessed May 25, 2021.
7. National Comprehensive Cancer Network (NCCN). *NCCN Clinical Practice Guidelines in Oncology: Thyroid Carcinoma. Version 1.2021 - April 9, 2021*; National Comprehensive Cancer Network. Available from: https://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf. Accessed May 25, 2021.

References Non-Formulary Medication Guideline:

1. Food and Drug Administration. Off-Label" and Investigational Use Of Marketed Drugs, Biologics, and Medical Devices. Guidance for Institutional Review Boards and Clinical Investigators. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/label-and-investigational-use-marketed-drugs-biologics-and-medical-devices. Accessed May 26, 2021
2. Centers for Medicare and Medicaid Services. October 2015. https://www.cms.gov/Medicare-Medicaid-Coordination/Fraud-Prevention/Medicaid-Integrity-Education/Downloads/off-label-marketing-factsheet.pdf. Accessed May 25, 2021
3. Wittich CM, Burkle C, Lanier W. Ten Common Questions (and Their Answers) About Off-label Drug Use. Mayo Clin Proc. 2012 Oct; 87(10): 982–990. doi: 10.1016/j.mayocp.2012.04.017. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3538391/
4. Congressional Research Services (CRS); Off-Label Use of Prescription Drugs. February 23, 2021; https://fas.org/sgp/crs/misc/R45792.pdf. Accessed May 26, 2021.

[li] **Ondansetron References**

13. Zofran (ondansetron) [package insert]. Research Triangle Park, NC; GlaxoSmithKline; Revised October 2016. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020103s035_020605s019_020781s019lbl.pdf. Accessed April 28, 2021.
14. Ondansetron. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc. Available at: http://clinicalpharmacology-ip.com/Forms/Monograph/monograph.aspx?cpnum=453&sec=monindi&t=0. Accessed April 28, 2021.

Last Update: 12.1.2020, 12.4.2020, 3.1.2021, 5.11.2021, 6.28.2021, 8.1.2021, 9.13.2021, 10.1.2021, 12.17.2021, 1.9.2022, 2.1.2022, 2.17.2022, 2.28.2022, 3.11.2022, 4.5.2022, 4.7.2022, 4.26.2022, 5.11.2022, 5.19.2022, 6.7.2022, 7.9.2022, 8.1.2022, 12.16.2022, 1.1.2023, 1.13.2023, 2.1.2023
,
Current Update: 2.10.2023

15. Guidelines on Chemotherapy-induced Nausea and Vomiting in Pediatric Cancer Patients. Children's Oncology Group. https://childrensoncologygroup.org/downloads/COG_SC_CINV_Guidelines_Document.pdf. July 21, 2020. Accessed April 28, 2021.

[liii] **Sickle Cell Disease Agents References**

1. Oxbryta™ [package insert]. South San Francisco, CA: Global Therapeutics; Revised November 2019. https://www.oxbryta.com/pdf/prescribing-information.pdf. Accessed May 3, 2021.
2. National Institutes of Health (NIH): National Heart, Lung, and Blood Institute (NHLBI). Evidence-Based Management of Sickle Cell Disease: Expert Panel Report, 2014. https://www.nhlbi.nih.gov/sites/default/files/media/docs/sickle-cell-disease-report%20020816_0.pdf. Accessed May 3, 2021.
3. Vichinsky, E.P. (2020). Disease-modifying therapies for prevention of vaso-occlusive pain in sickle cell disease. In M. R. DeBaun (Ed.), *UpToDate*. Retrieved May 3, 2021 from: https://www.uptodate.com/contents/disease-modifying-therapies-for-prevention-of-vaso-occlusive-pain-in-sickle-cell-disease.
4. Endari [package insert]. Torrance, CA: Emmaus Medical, Inc; April 2020.
5. Niihara Y, Miller ST, et al. A phase 3 trial of l-glutamine in sickle cell disease. N Engl J Med. 2018;379(3):226-235

[liv] **Platelet Inhibitors References**

1. Vandvik, Per Olav, Lincoff, Michael A, Gore, Joel M, et al. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *CHEST Journal*. February 2012; 141(2_suppl)
2. O'Gara, Patrick, Kushner, Frederick et al. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: Journal of the American College of Cardiology http://www.onlinejacc.org/content/accj/61/4/e78.full.pdf?_ga=2.16281206.1583954993.1522813721-1795673358.1522813721 Accessed April 03, 2018.
3. Levine, Glenn N., Bates, Eric R., Bittl, John A., et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients with Coronary Artery Disease. A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines http://www.onlinejacc.org/content/accj/68/10/1082.full.pdf?_ga=2.139399226.861223083.1560897735-963373453.1560897735. Accessed June 18, 2019.
4. Bonaca MP1, Gutierrez JA2, Creager MA2, et al. Acute Limb Ischemia and Outcomes with Vorapaxar in Patients with Peripheral Artery Disease: Results from the Trial to Assess the Effects of Vorapaxar in Preventing Heart Attack and Stroke in Patients With Atherosclerosis-Thrombolysis in Myocardial Infarction 50 (TRA2°P-TIMI 50). Circulation. 2016 Mar 8;133(10):997-1005. doi: 10.1161/CIRCULATIONAHA.115.019355. Epub 2016 Jan 29. https://www.ncbi.nlm.nih.gov/pubmed?term=26826179. Accessed June 19, 3019.
5. BRILINTA (ticagrelor) [package insert]. Wilmington, DE: AstraZeneca LP. Revised November 2020. Retrieved from https://www.azpicentral.com/brilinta/brilinta.pdf#page=1. Accessed July 22, 2021.
6. S C Johnston, P Amarenco, H Denison, S. Evans. Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA. N Engl J Med 2020; 383:207-217. https://www.nejm.org/doi/full/10.1056/nejmoa1916870. Accessed July 22, 2021.
7. ZONTIVITY (vorapaxar) [package insert]. Kenilworth, NJ: Merck & Co., Inc. Revised November 2019. Retrieved from https://www.zontivityhcp.com/files/Zontivity_Prescribing_Information.pdf. Accessed July 22, 2021.
8. Franchi F, Rollini F, Rivas A, Wali M, et al. Platelet Inhibition with Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Circulation. 2019;139(14):1661. https://www.ncbi.nlm.nih.gov/pubmed?term=30630341. Accessed June 19, 2019.
9. Berger, JS, Davies, MG., (2019). UpToDate. Overview of lower extremity peripheral artery disease In Collins, KA, (Ed)., Retrieved from https://www.uptodate.com/contents/overview-of-lower-extremity-peripheral-artery-disease?search=Overview%20of%20lower%20extremity%20peripheral%20artery%20disease&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1. Accessed June 19, 2019.

10. Lincoff, A.M., Cutlip, D. (2019) UpToDate. Antiplatelet agents in acute ST-elevation myocardial infarction In GM Saperia (Ed)., Retrieved from https://www.uptodate.com/contents/antiplatelet-agents-in-acute-st-elevation-myocardial-infarction?search=Antiplatelet%20agents%20in%20acute%20ST-elevation%20myocardial%20infarction&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1. Accessed June 19, 2019.

[lv] **Promacta References**

1. Promacta® [package insert]. East Hanover, New Jersey: Norvartis Pharmaceuticals Corporation; Revised February 2021. https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/promacta.pdf. Accessed May 3, 2021.
2. Neunert C, Terrell DR, Arnold DM, Buchanan G, Cines DB, et al. The American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood. https://doi.org/10.1182/bloodadvances.2019000966. Accessed May 3, 2021.
3. Dahal S, Upadhyay S, Banjade R, Dhakal P, Khanal N, Bhatt VR. Thrombocytopenia in patients with chronic hepatitis c virus infection. Mediterranean Journal of Hematology and Infectious Diseases. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5333732/. Accessed February 26, 2020.
4. Olson, T.S. (2019). Aplastic anemia: Pathogesis, clinical manifestations, and diagnosis. In W.C. Mentzer (Ed.), *UpToDate*; Retrieved May 3, 2021, from: https://www.uptodate.com/contents/aplastic-anemia-pathogenesis-clinical-manifestations-and-diagnosis.
5. Olson, T.S. (2021). Treatment of aplastic anemia in adults. In W.C. Mentzer (Ed.), *UpToDate*. Retrieved May 3, 2021, from: https://www.uptodate.com/contents/treatment-of-aplastic-anemia-in-adults.

[lvi] **PCSK9 References**

1. Repatha [Prescribing Information]. Thousand Oaks, CA: Amgen Inc.; February 2019
2. Praluent [Prescribing Information]. Bridgewater, NJ,: Regeneron and Sanofi Aventis LLC; April 2019
3. Stone, NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol*. 2013; doi:10.1016/j.jacc.2013.11.002.
4. Management of familial hypercholesterolemia http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=16222 http://www.google.com/url?url=http://www.amcp.org/WorkArea/DownloadAsset.aspx%3Fid%3D16222&rct=j&frm=1&q=&esrc=s&sa=U&ei=RJSUVf2bDsuTyATgvoHwAw&ved=0CEAQFjAG&usg=AFQjCNEDp9VnIHhpJLov4D4lQgRPWNuQLQ
5. Cuchel M, Bruckert E, Ginsberg HN, et al. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J. 2014 Aug 21;35(32):2146-57. doi: 10.1093/eurheartj/ehu274. Epub 2014 Jul 22.
6. 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk; A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents
7. 2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.
8. Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 09/05/2017. 2017 ACC Recommendations for Non-Statin Therapy. https://www.acc.org/latest-in-cardiology/ten-points-to-remember/2017/09/05/10/03/2017-focused-update-of-the-2016-acc-expert-consensus-nonstatin
9. Update on the use of PCSK9 inhibitors in adults: Recommendations from an Expert Panel of the National Lipid Association. Orringer, Carl E. et al. Journal of Clinical Lipidology , Volume 11 , Issue 4 , 880 – 890. 2017 Jul - Aug;11(4):880-890. doi: 10.1016/j.jacl.2017.05.001.
10. DRUGDEX® System [Internet database]. Greenwood Village, CO: Thomson Micromedex. Accessed September 18, 2019.

Last Update: 12.1.2020, 12.4.2020, 3.1.2021, 5.11.2021, 6.28.2021, 8.1.2021, 9.13.2021, 10.1.2021, 12.17.2021, 1.9.2022, 2.1.2022, 2.17.2022, 2.28.2022, 3.11.2022, 4.5.2022, 4.7.2022, 4.26.2022, 5.11.2022, 5.19.2022, 6.7.2022, 7.9.2022, 8.1.2022, 12.16.2022, 1.1.2023, 1.13.2023, 2.1.2023
,
Current Update: 2.10.2023

11. Drug Facts and Comparisons online (www.drugfacts.com). Wolters Kluwer Health, St. Louis, MO. Accessed September 18, 2019.
12. Clinical Pharmacology [Internet database]. Elsevier/Gold Standard. Accessed September 18, 2019.

[lvii] **Increlex References**

1. Increlex (mecasermin [rDNA origin]) [prescribing information]. Cambridge, MA: Ipsen Biopharmaceuticals Inc; December 2019. https://www.ipsen.com/websites/Ipsen_Online/wp-content/uploads/sites/9/2020/04/10140519/Increlex-Full-Prescribing-Information.pdf. Accessed August 16, 2021, 2021.
2. Chernausek S, Backeljauw PF, Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity. J Clin Endocrinol Metab. 2007 Mar;92(3):902-10. Retrieved from https://academic.oup.com/jcem/article/92/3/902/2597247. Accessed August 16, 2021.
3. Rogol AD, Richmond EJ. Growth hormone insensitivity syndromes. 2021. In Geffner ME, (Ed). https://www.uptodate.com/contents/growth-hormone-insensitivity-syndromes. Accessed August 16, 2021. April 12, 2019
4. Mecasermin (recombinant human insulin-like growth factor I): Monograph Drug information Retrieved from: https://www.uptodate.com/contents/mecasermin-recombinant-human-insulin-like-growth-factor-i-drug-information?search=mecasermin&source=panel_search_result&selectedTitle=1~9&usage_type=panel&kp_tab=drug_general&display_rank=1. Accessed May 7, 2020.

[lviii] **Nuedexta References**

1. Nuedexta® (dextromethorphan hybromide and quinidine sulfate). Avanir Pharmaceuticals, Inc. Aliso Viejo, CA. June 2019. https://www.nuedexta.com/sites/default/files/pdfs/Prescribing_Information.pdf. Accessed September 7, 2021.
2. Ahmed A and Simmons Z. Pseudobulbar affect: prevalence and management. *Therapeutics and Clinical Risk Management* 2013;9:482-489.
3. Brook BR, Crumacker D, Fellus J, et al. PRISM: A novel research tool to assess the prevalence of pseudobulbar affect symptoms across neurological conditions. PLOS one.2013;8(8):e72232
4. Hammond FM, Alexnader DN, Cutler AJ, et al. PRISM II: an open-label study to assess effectiveness of dextromethorpahan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury. BMD Neurology. 2016;16(89).
5. Lapchak P. Neuronal Dysregulation in Stroke-Associated Pseudobulbar Affect (PBA): Diagnostic scales and current treatment options. *J Neurol Neurophysiol*. 2016;6(5):323.
6. Miden SL, Feintein A, Kalk RS, et al. Evidence-based guideline: Assessment and management of psychiatric disorders in individuals with MS. *Neurology*. 2014;82(2):174-181.
7. Robinson RG, Parikh RM, and Lipsey JR, et al. Pathological laughing and crying following stroke: validation of a measurement scale and a double-blind treatment study. *Am J Psychiatry*. 1993;150(2): 286-293.
8. Woodard T.J, Charles K, et al. Review of the Diagnosis and Management of Pseudobulbar Affect. US Pharm. 2017;42(11)31-35.
9. Demier TL, Chen JJ. Pseudobulbar Affect: Considerations for Managed Care Professionals. *The American Journal of Managed Care, 2017;23:-S0.*
10. AJMC Managed Markets Network, Pharmacotherapeutic Management of Pseudobulbar Affect, December 2017; available from https://www.ajmc.com/journals/supplement/2017/pseudobulbar-affect-considerations-for-managed-care-professionals/pharmacotherapeutic-management-of-pseudobulbar-affect?p=2. Accessed September 7, 2021.

[lix] **Oxervate References**

1. Oxervate [package insert]. Boston, MA: Dompe U.S. Inc.; October 2019. https://oxervate.com/wp-content/uploads/2020/05/OXERVATE_Prescribing_Information_102019.pdf. Accessed September 7, 2021.

[lx] **Idiopathic Pulmonary Fibrosis Agents References**

1. Esbriet® [package insert]. Brisbane, CA: InterMune, Inc.; Revised July 2019. https://www.gene.com/download/pdf/esbriet_prescribing.pdf. Accessed July 29, 2021.

Last Update: 12.1.2020, 12.4.2020, 3.1.2021, 5.11.2021, 6.28.2021, 8.1.2021, 9.13.2021, 10.1.2021, 12.17.2021, 1.9.2022, 2.1.2022, 2.17.2022, 2.28.2022, 3.11.2022, 4.5.2022, 4.7.2022, 4.26.2022, 5.11.2022, 5.19.2022, 6.7.2022, 7.9.2022, 8.1.2022, 12.16.2022, 1.1.2023, 1.13.2023, 2.1.2023
,
Current Update: 2.10.2023

2. Ofev® [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; Revised October 2020. https://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Ofev/ofev.pdf. Accessed July 29, 2021.
3. Raghu G, Collard HR, Egan JJ et al. for the ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management. Am J Respir Crit Care Med 2011; 183: 788-824.
4. Raghu, Ganesh et al. "An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management." American journal of respiratory and critical care medicine vol. 183,6 (2011): 788-824. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5450933/. Accessed July 7, 2017.
5. King TE Jr, Bradford WZ. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083. Epub 2014 May 18.
6. Noble PW, Albera C. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomized trials. Lancet. 2011;377(9779):1760. Epub 2011 May 13
7. Richeldi L, Costabel U. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011;365(12):1079.
8. TE King Jr, HR Collard. Idiopathic pulmonary fibrosis. The Lancet. 2011; 378: 1649-61.
9. Van den Hoogen F, Khanna D, Fransen J, Fransen J, Johnson SR, Baron M, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European league against rheumatism collaborative initiative. Arthritis Rheum. 2013;65:2737–47.

[lxi] **Pulmonary Arterial Hypertension references**

1. https://www.uptodate.com/contents/treatment-of-pulmonary-arterial-hypertension-group-1-in-adults-pulmonary-hypertension-specific-therapy?search=pulmonary%20arterial%20hypertension&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1#H1336334212
2. DrugPoints® System (www.statref.com) Thomson Micromedex, Greenwood Village, CO. DRUGDEX® System (Internet database). Greenwood Village, CO; Thomson Micromedex.
3. Drug Facts and Comparisons on-line. (www.drugfacts.com), Wolters Kluwer Health, St. Louis, MO.
4. Clinical Pharmacology (Internet database). Gold Standard Inc. Tampa, FL.
5. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002:346:896-903.
6. Barst RJ, McGoon M, Torbicki A, et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiology 2004:43(Suppl S): 40S-7S.
7. Galie N, Rubin LJ, Hoeper MM, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomized controlled trial. Lancet 2008:371:2093-100.
8. Galie N, Badesch D, Oudiz R, et al. Ambrisentan Therapy for Pulmonary Arterial Hypertension. J Am Coll Cardiol 2005:46:529-35.
9. Wilkins MR, Paul G, Strange J, et al. Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study. Am J Respir Crit Care Med 2005:171:1292-1297.
10. Hrometz S, Shields KM. Role of Ambrisentan in the management of pulmonary hypertension. Ann Pharmacother 2008:42:1653-9.
11. Badesch DB, Abman SH, Ahearn GS, et al. Medical therapy for pulmonary arterial hypertension. ACCP evidence-based clinical practice guidelines. Chest 2004:126:35S-62S.
12. McLaughlin VV, Arther SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: A report of the American College of Cardiology Foundation task force on expert consensus documents and the American Heart Association. Circulation 2009:199:2250-94.
13. Adempas® (prescribing information). Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc.; September 2021. http://labeling.bayerhealthcare.com/html/products/pi/Adempas_PI.pdf. Accessed November 30, 2021.
14. Opsumit® (prescribing information). South San Francisco, CA: Actelion Pharmaceuticals US, Inc.; Apr 2019. https://opsumit.com/opsumit-prescribing-information.pdf. Accessed November 30, 2021.
15. Orenitram® (prescribing information). Research Triangle Park, NC: United Therapeutics Corp.; May 2021. https://www.orenitram.com/pdf/Orenitram-Prescribing-Information.pdf. Accessed November 30, 2021.
16. Ventavis (prescribing information). South San Francisco, CA: Actelion Pharmaceuticals US, Inc.; January 2021. https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/VENTAVIS-pi.pdf. Accessed November 30, 2021.
17. Remodulin® (prescribing information). Research Triangle Park, NC: United Therapeutics Corp., Julzy 2021. https://www.remodulin.com/files/remodulin-pi.pdf. Accessed November 30, 2021.
18. Treprostinil (prescribing information). Princeton, NJ: Sandoz Inc.; May 2021. https://www.orenitramhcp.com/pdf/Orenitram_Full_Prescribing_Information.pdf. Accessed November 30, 2021.
19. Taichman DB, Ornelas J, Chung L, et al. Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report. Chest 2014:146(2):449-475.
20. Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013; 62:D34. UptoDate(Internet database) Waltham, MA.(Accessed 08/06/2020)

21. Uptravi® (prescribing information). South San Francisco, CA: Actelion Pharmaceuticals US, Inc.; October 2021. https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/UPTRAVI-pi.pdf. Accessed November 30, 2021.
22. Tyvaso (prescribing information). Research Triangle Park, NC: United Therapeutics Corp., March 2021. https://www.tyvaso.com/pdf/TYVASO-PI.pdf. Accessed November 30, 2021.
23. Tracleer (prescribing information). South San Francisco, CA: Actelion Pharmaceuticals US, Inc.; January 2021. https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TRACLEER-pi.pdf. Accessed November 30, 2021.
24. Adcirca (prescribing information). Indianapolis, IN: Eli Lilly and Company; September 2020. http://pi.lilly.com/us/adcirca-pi.pdf. Accessed November 30, 2021.
25. Letairis (prescribing information). Foster City, CA: Gilead Sciences, Inc.; Aug 2019. https://www.gilead.com/-/media/files/pdfs/medicines/cardiovascular/letairis/letairis_pi.pdf. Accessed November 30, 2021.
26. Revatio (prescribing information). New York, NY: Division of Pfizer Inc.; Feb 2020. http://labeling.pfizer.com/ShowLabeling.aspx?id=645. Accessed November 30, 2021
27. Flolan (prescribing information). Research Triangle Park, NC: GlaxoSmithKline; August 2021. https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Flolan/pdf/FLOLAN-PI-PIL.PDF. Accessed November 30, 2021.
28. Veletri (prescribing information). South San Francisco, CA: Actelion Pharmaceuticals US, Inc; Dec 2018. https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/VELETRI-pi.pdf. Accessed November 30, 2021
29. Nicholas S. Hill, MJ. Cawley, and Cherilyn L. HP; New Therapeutic Paradigms and Guidelines in the Management of Pulmonary Arterial Hypertension; Journal of Managed Care & Specialty Pharmacy 2016 22:3-a Suppl, s3-s2. Accessed November 30, 2021.
30. Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). *Eur Heart J*. 2016:37(1):67-119. Available at: https://academic.oup.com/eurheartj/article/37/1/67/2887599/2015-ESC-ERS-Guidelines-for-the-diagnosis-and. Accessed November 30, 2021
31. Klinger JR, Elliott CG, Levine DJ, et al. Therapy for Pulmonary Arterial Hypertension in Adults. *Chest*. 2019;155(3):565-586. doi:10.1016/j.chest.2018.11.030. https://journal.chestnet.org/article/S0012-3692(19)30002-9/fulltext
32. Hopkins, W, Rubin, LJ, Treatment of pulmonary hypertension in adults, (2021). UpToDate. In G. Finlay, (Ed.), retrieved from https://www.uptodate.com/contents/treatment-of-pulmonary-arterial-hypertension-group-1-in-adults-pulmonary-hypertension-specific-therapy?search=pulmonary%20arterial%20hypertension&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1#H1336334212. Accessed November 30, 2021.

[lxii] **Revlimid References**

1. Revlimid® [package insert]. Summit, NJ: Celgene Corporation; Revised October 2019. https://media.celgene.com/content/uploads/revlimid-pi.pdf. Accessed May 14, 2021.
2. National Comprehensive Cancer Network (NCCN). *NCCN Clinical Practice Guidelines in Oncology. Multiple Myeloma. Version 7.2021.* 2021 April 26; National Comprehensive Cancer Network. Available from: http://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf. Accessed May 14, 2021.
3. National Comprehensive Cancer Network (NCCN). *NCCN Clinical Practice Guidelines in Oncology. B-Cell Lymphomas. Version 4.2021.* 2021 May 5; National Comprehensive Cancer Network. Available from: https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf. Accessed May 14, 2021.
4. National Comprehensive Cancer Network (NCCN). *NCCN Clinical Practice Guidelines in Oncology. Myelodysplastic Syndromes. Version 3.2021.* 2021 Jan 15; National Comprehensive Cancer Network. Available from: http://www.nccn.org/professionals/physician_gls/pdf/mds.pdf. Accessed May 14, 2021.
5. National Comprehensive Cancer Network (NCCN). *NCCN Clinical Practice Guidelines in Oncology. Systemic Light Chain Amyloidosis. Version 2.2021.* 2021 Feb 8; National Comprehensive Cancer Network. Available from: http://www.nccn.org/professionals/physician_gls/pdf/amyloidosis.pdf. Accessed May 14, 2021.

Last Update: 12.1.2020, 12.4.2020, 3.1.2021, 5.11.2021, 6.28.2021, 8.1.2021, 9.13.2021, 10.1.2021, 12.17.2021, 1.9.2022, 2.1.2022, 2.17.2022, 2.28.2022, 3.11.2022, 4.5.2022, 4.7.2022, 4.26.2022, 5.11.2022, 5.19.2022, 6.7.2022, 7.9.2022, 8.1.2022, 12.16.2022, 1.1.2023, 1.13.2023, 2.1.2023
,
Current Update: 2.10.2023

6. National Comprehensive Cancer Network (NCCN). *NCCN Clinical Practice Guidelines in Oncology. Myeloproliferative Neoplasms. Version 1.2021.* 2021 April 13; National Comprehensive Cancer Network. Available from: https://www.nccn.org/professionals/physician_gls/pdf/mpn.pdf. Accessed May 14, 2021.
7. National Comprehensive Cancer Network (NCCN). *NCCN Clinical Practice Guidelines in Oncology. T-Cell Lymphomas. Version 1.2021.* 2020 Oct 5; National Comprehensive Cancer Network. Available from: https://www.nccn.org/professionals/physician_gls/pdf/t-cell.pdf. Accessed May 14, 2021.
8. National Comprehensive Cancer Network (NCCN). *NCCN Clinical Practice Guidelines in Oncology. Primary Cutaneous Lymphomas. Version 2.2021.* 2021 March 4; National Comprehensive Cancer Network. Available from: https://www.nccn.org/professionals/physician_gls/pdf/primary_cutaneous.pdf. Accessed May 14, 2021.
9. National Comprehensive Cancer Network (NCCN). *NCCN Clinical Practice Guidelines in Oncology. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Version 4.2021.* 2021 April 29; National Comprehensive Cancer Network. Available from: https://www.nccn.org/professionals/physician_gls/pdf/cll.pdf . Accessed May 14, 2021.
10. National Comprehensive Cancer Network (NCCN). *NCCN Clinical Practice Guidelines in Oncology. Hodgkin Lymphoma. Version 1.2020.* 2021 April 20; National Comprehensive Cancer Network. Available from: https://www.nccn.org/professionals/physician_gls/pdf/hodgkins.pdf. Accessed May 14, 2021.

[lxiii] **Rybelsus References:**

1. Rybelsus [package insert]. Plainsboro, NJ: Novo Nordisk Inc.; https://www.novo-pi.com/rybelsus.pdf April 2021.
2. Lexicomp Online, AHFS DI (Adult and Pediatric) Online, Hudson, Ohio: UpToDate, Inc.; 2021; Accessed July 1, 2021.
3. Micromedex (electronic version). IBM Watson Health, Greenwood Village, Colorado, USA. Available at: http://www.micromedexsolutions.com Accessed July 1, 2021.
4. American Diabetes Association (ADA) Standards of Medical Care in Diabetes—2021. Dia Care. 2021; 44(Supplement 1); S1-S232.
5. Garber AJ, et al. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm 2020 Executive Summary, Endocr Pract. January 2020; 26 (No 1); 107-139.

[lxiv] **Second Generation TKI References**

1. Tasigna® [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; Revised December 2020. https://www.novartis.us/sites/www.novartis.us/files/tasigna.pdf. Accessed May 19, 2021.
2. Sprycel® [package insert]. Princeton, NJ: Bristol Myer Squibb; Revised March 2021. https://packageinserts.bms.com/pi/pi_sprycel.pdf. Accessed May 19, 2021.
3. Bosulif® [package insert]. New York, NY: Pfizer Labs; Revised June 2020. http://labeling.pfizer.com/ShowLabeling.aspx?id=884. Accessed May 19, 2021.
4. Iclusig® [package insert]. Cambridge, MA: Ariad Pharmaceuticals; Revised December 2020. https://www.iclusig.com/pdf/ICLUSIG-Prescribing-Information.pdf. Accessed May 19, 2021.
5. Gleevec® [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; Revised July 2018. https://www.novartis.us/sites/www.novartis.us/files/gleevec_tabs.pdf. Accessed May 19, 2021.

Last Update: 12.1.2020, 12.4.2020, 3.1.2021, 5.11.2021, 6.28.2021, 8.1.2021, 9.13.2021, 10.1.2021, 12.17.2021, 1.9.2022, 2.1.2022, 2.17.2022, 2.28.2022, 3.11.2022, 4.5.2022, 4.7.2022, 4.26.2022, 5.11.2022, 5.19.2022, 6.7.2022, 7.9.2022, 8.1.2022, 12.16.2022, 1.1.2023, 1.13.2023, 2.1.2023
,
Current Update: 2.10.2023

6. National Comprehensive Cancer Network (NCCN). *NCCN Clinical Practice Guidelines in Oncology: Chronic Myeloid Leukemia. Version 3.2021.* 2021 Jan 13; National Comprehensive Care Network. Available from http://www.nccn.org/professionals/physician_gls/pdf/cml.pdf. Accessed May 20, 2021.
7. National Comprehensive Cancer Network (NCCN). *Clinical Practice Guidelines in Oncology: Acute Lymphoblastic Leukemia. Version 1.2021.* 2021 April 6; National Comprehensive Care Network. Available from http://www.nccn.org/professionals/physician_gls/pdf/all.pdf. Accessed May 20, 2021.
8. Cortes JE, et al, Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial. *J Clin Oncol*, 2012;30(28):3486-3492.
9. Cortes JE, et al, Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. *Blood.* 2011;118(17): 4567-4576.
10. Khoury HJ, et al, Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. *Blood*, 2012;119(15)3403-3412.
11. Shieh MP, Mitsuhashi M, LillyM. Moving on up: Second-Line Agents as Initial Treatment for Newly-Diagnosed Patients with Chronic Phase CML. *Clin Med Insights Oncol,* 2011;5:185-199.
12. Antineoplastics - Pharmacy Clinical Policy Bulletins Aetna Non-Medicare Prescription Drug Plan. Aetna Clinical Pharmacy Bulletins
13. Schiffer, C.A., & Atallah, E. (2021). Initial treatment of chronic myeloid leukemia in chronic phase. In R.A. Larson (Ed.), *UpToDate*. Retrieved May 20, 2021, from https://www.uptodate.com/contents/initial-treatment-of-chronic-myeloid-leukemia-in-chronic-phase.
14. Larson, R.A. (2021). Induction therapy for Philadelphia chromosome positive acute lymphoblastic leukemia in adults. In B. Lowenberg (Ed.), *UpToDate.* Retrieved May 20, 2021, from https://www.uptodate.com/contents/induction-therapy-for-philadelphia-chromosome-positive-acute-lymphoblastic-leukemia-in-adults.
15. Schiffer, C.A., & Atallah, E. (2021). Overview of the treatment of chronic myeloid leukemia. In R.A. Larson (Ed.), *UpToDate*. Retrieved May 20, 2021. https://www.uptodate.com/contents/overview-of-the-treatment-of-chronic-myeloid-leukemia.

[lxv] **Soliris References**

1. Soliris [prescribing information]. New Haven, CT: Alexion Pharmaceuticals, Inc.; November 2020. https://alexion.com/Documents/Soliris_USPI.pdf. Accessed November 30, 2021.
2. Loirat C, Fakhouri F, Ariceta G, et al. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. *Pediatr Nephrol*. Published online: April 11, 2015.
3. Parker CJ. Management of paroxysmal nocturnal hemoglobulinuria in the era of complement inhibitory therapy. *Hematology*. 2011; 21-29.
4. Sanders D, Wolfe G, Benatar M et al. International consensus guidance for management of myasthenia gravis. *Neurology*. 2016; 87 (4):419-425.
5. Jaretzki A, Barohn RJ, Ernstoff RM et al. Myasthenia Gravis: Recommendations for Clinical Research Standards. *Ann Thorac Surg*. 2000;70: 327-34.
6. Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. *NEJM*. 2006;335:1233-43.
7. Howard JF, Utsugisawa K, Benatar M. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalized myasthenia gravis (REGAIN); a phase 3, randomized, double-blind, placebo-controlled, multicenter study. *Lancet Neurol*. 2017 Oct 20. http://dx.doi.org/10.1016/S1474-4422(17)30369-1Ingenix HCPCS Level II, Expert 2011.
8. Brodsky RA, Young NS, Antonioli E, et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. *Blood*. 2008;111(4):1840-1847.
9. Borowitz MJ, Craig F, DiGiuseppe JA, et al. Guidelines for the Diagnosis and Monitoring of Paroxysmal Nocturnal Hemoglobinuria and Related Disorders by Flow Cytometry. *Cytometry B Clin Cytom*. 2010; 78: 211-230.

10. Preis M, Lowrey CH. Laboratory tests for paroxysmal nocturnal hemoglobinuria (PNH). Am J Hematol. 2014;89(3):339-341.
11. Lee JW, Sicre de Fontbrune F, Wong LL, et al. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: The 301 study. Blood. 2018 Dec 3; pii: blood-2018-09-876136.
12. Brodsky RA, (2021). Treatment and prognosis of paroxysmal nocturnal hemoglobinuria In (Ed.), AG Rosmarin; UpToDate; Retrieved from https://www.uptodate.com/contents/treatment-and-prognosis-of-paroxysmal-nocturnal-hemoglobinuria?search=soliris&source=search_result&selectedTitle=3~71&usage_type=default&display_rank=2. Accessed November 30, 2021.
13. Pittock SJ, Berthele A, Kim HJ, et al. Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. *N Engl J Med*. 2019 May 3. doi: 10.1056/NEJMoA1900866.
14. Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. *Neurology*. 2015; 85:177-189.
15. Glisson C, González-Scarano F, (2021). Neuromyelitis optica spectrum disorders (NMOSD): Treatment and prognosis. In (Ed.), JF Dashe; UpToDate. Retrieved from https://www.uptodate.com/contents/neuromyelitis-optica-spectrum-disorders-nmosd-treatment-and-prognosis?search=soliris&source=search_result&selectedTitle=2~71&usage_type=default&display_rank=1#H1889061698. Accessed November 30, 2021.

[lxvii] **Spinraza References**

1. Spinraza® [package insert]. Biogen Inc. Cambridge, MA; Revised June 2020. https://www.spinraza.com/content/dam/commercial/specialty/spinraza/caregiver/en_us/pdf/spinraza-prescribing-information.pdf. Accessed May 24, 2021
2. Bodamer, O.A., (2021). Spinal Muscular Atrophy. In J.F. Dashe (Ed). UpToDate. Retrieved May 24, 2021, from https://www.uptodate.com/contents/spinal-muscular-atrophy.
3. Ramsey, D, Scoto, M, et al. Revised Hammersmith Scale for Spinal Muscular Atrophy: A SMA Specific Clinical Outcome Assessment Tool. PLOS One. 2017; 12(2): e0172346. doi: 10.1371/journal.pone.0172346. Accessed February 4, 2019 from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5319655/
4. PNCR Network for SMA. Expanded Hammersmith Functional Motor Scale for SMA (HFMSE). 2009, http://columbiasma.org/docs/cme-2010/Hammersmith%20Functional%20Motor%20Scale%20Expanded%20for%20SMA%20Type%20II%20and%20III%20-%20Manual%20of%20Procedures.pdf. Accessed February 4, 2019.
5. Finkel RS, Mercuri E, et al. Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy for the ENDEAR Study Group. N Engl J Med, 2017; 377:1723-1732. DOI: 10.1056/NEJMoa1702752. Accessed February 4, 2019 from https://www.nejm.org/doi/full/10.1056/NEJMoa1702752.
6. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2018 Feb 21 - . Identifier NCT02292537, A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA) (CHERISH), Available from: https://clinicaltrials.gov/ct2/show/results/NCT02292537. Accessed February 4, 2019.
7. Young D, Montes J, et al. Six-minute walk test is reliable and valid in spinal muscular atrophy. Muscle Nerve. 2016; 54(5):836-842. doi: 10.1002/mus.25120. https://www.ncbi.nlm.nih.gov/pubmed/27015431. Accessed February 5, 2019.
8. National Organization of Rare Disorders. Spinal Muscular Atrophy. 2012. https://rarediseases.org/rare-diseases/spinal-muscular-atrophy/. Accessed February 5, 2019.
9. Together in SMA with Biogen. 2018. Accessed February 5, 2019. Available from https://www.togetherinsma-hcp.com/en_us/home/sma-care/motor-function-measures.html.

[lxviii] **Spiriva Respimat**

1. Spiriva Handihaler® [package insert]. Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT; Revised February 2018. https://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Spiriva/Spiriva.pdf. Accessed August 22, 2019.
2. Spiriva Respimat® [package insert]. Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT; Revised May 2019. https://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Spiriva%20Respimat/spirivarespimat.pdf. Accessed July 16, 2020.
3. Yupelri™ [package insert]. Mylan Specialty LP, Morgantown, WV; Revised November 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210598s000lbl.pdf. Accessed August 22, 2019.
4. Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma (GINA) 2019. https://ginasthma.org/wp-content/uploads/2019/06/GINA-2019-main-report-June-2019-wms.pdf. Accessed August 23, 2019.
5. Szefler SJ, Murphy K, Harper T 3rd, et al. A phase III randomized controlled trial of tiotropium add-on therapy in children with severe symptomatic asthma. Journal of Allergy and Clinical Immunology. 2017;140(5):1277-1287.[PubMed 28189771]10.1016/j.jaci.2017.01.014

[lxix] **Synagis References**

1. Aetna.com. 2019. *Clinical Policy Bulletin: Synagis (Palivizumab)*. [online] November 25, 2020. Available at: http://www.aetna.com/cpb/medical/data/300_399/0318.html, last reviewed . Accessed July 28, 2021.
2. Perrin, MD, FAAP, J., Meissner, MD, FAAP, H. and Ralston, MD, FAAP, S. 2019. *Updated AAP Guidance for Palivizumab Prophylaxis For Infants and Young Children at Increased Risk of RESPIRATORY SYNCYTIAL VIRUS (RESPIRATORY SYNCYTIAL VIRUS (RSV)) Hospitalization*. [e-book] pp. 1-23. Available through: American Academy of Pediatrics http://www.aap.org/en-us/my-aap/Pages/Respiratory Syncytial Virus (RESPIRATORY SYNCYTIAL VIRUS (RSV)).aspx. Accessed July 28, 2021.
3. Ralston SL, Lieberthal AS, Meissner H. Clinical Practice Guideline: The Diagnosis, Management, and Prevention of Bronchiolitis.Pediatrics. 2014;134(5):e1474, Accessed online on 6/21/2019 at https://pediatrics.aappublications.org/content/134/5/e1474.long. [Accessed: 22 May 2020].
4. Synagis [package insert]. MedImmune, LLC, Gaithersburg, MD; May 2017. https://www.azpicentral.com/synagis/synagis.pdf#page=1. Accessed July 28, 2021
5. The American Academy of Pediatrics. RSV recommendations unchanged after review of new data. http://www.aappublications.org/news/2017/10/19/RSV101917.Accessed July 28, 2021.
6. Farber HJ, Buckwold FJ, Lachman B, et al. Observed Effectiveness of Palivizumab for 29–36-Week Gestation Infants. *Pediatrics*. 2016; e20160627; DOI: 10.1542/peds.2016-0627.
7. Barr Frederick, Graham Barney; Respiratory syncytial virus infection: Treatment. (2021) *UpToDate.* In M Torchia (Ed.), retrieved from https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-treatment?search=rsv%20treatment&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1. Accessed July 28, 2021.

[lxx] **Cialis References**

1. Cialis (tadalafil) [package insert]. Indianapolis, IN: Eli Lilly and Company; Revised February 2018. https://pi.lilly.com/us/cialis-pi.pdf. Accessed May 26, 2021.
2. McVary KT, Roehrborn CG, et al. Management of Benign Prostatic Hyperplasia. American Urological Association. https://www.auanet.org/benign-prostatic-hyperplasia-(2010-reviewed-and-validity-confirmed-2014). Accessed May 26, 2021.
3. Dahm P, Brasure M, et al. Comparative Effectiveness of Newer Medications for Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: A Systematic Review and Meta-analysis. European Urology. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5337128/. Accessed February, 11, 2020

Last Update: 12.1.2020, 12.4.2020, 3.1.2021, 5.11.2021, 6.28.2021, 8.1.2021, 9.13.2021, 10.1.2021, 12.17.2021, 1.9.2022, 2.1.2022, 2.17.2022, 2.28.2022, 3.11.2022, 4.5.2022, 4.7.2022, 4.26.2022, 5.11.2022, 5.19.2022, 6.7.2022, 7.9.2022, 8.1.2022, 12.16.2022, 1.1.2023, 1.13.2023, 2.1.2023
,
Current Update: 2.10.2023

4. McVary, KT. Medical Treatment of Benign Prostatic Hyperplasia. Waltham, MA. UpToDate. Last modified January 25, 2021. https://www.uptodate.com/contents/medical-treatment-of-benign-prostatic-hyperplasia. Accessed May 26, 2021.

[lxxi] **Tarceva References**

1. Tarceva® [package insert]. South San Francisco, CA: Genentech, Inc.; Revised October 2016. https://www.gene.com/download/pdf/tarceva_prescribing.pdf. Accessed May 26, 2021.
2. National Comprehensive Cancer Network (NCCN). *NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer. Version 4.2021.* 2021 April 1; National Comprehensive Cancer Network. Available from: http://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf. Accessed May 26, 2021.
3. National Comprehensive Cancer Network (NCCN). *NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma Version 2.2021*. 2021 Feb 25; National Comprehensive Care Network. Available from: https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf. Accessed May 26, 2021.
4. National Comprehensive Cancer Network (NCCN). *NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer Version 4.2021*. 2021 Mar 3; National Comprehensive Care Network. Available from: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed May 26, 2021.
5. National Comprehensive Cancer Network (NCCN). *NCCN Clinical Practice Guidelines in Oncology: Central Nervous System Cancers Version 5.2020*. 2021 Apr 15; National Comprehensive Care Network. Available from: https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf. Accessed May 26, 2021.
6. National Comprehensive Cancer Network (NCCN). *NCCN Clinical Practice Guidelines in Oncology: Vulvar Cancer (Squamous Cell Carcinoma) Version 3.2021*. 2021 Apr 26; National Comprehensive Care Network. Available from: https://www.nccn.org/professionals/physician_gls/pdf/vulvar.pdf. Accessed May 26, 2021.
7. National Comprehensive Cancer Network (NCCN). *NCCN Clinical Practice Guidelines in Oncology: Bone Cancer Version 1.2021*. 2020 Nov 20; National Comprehensive Care Network. Available from: https://www.nccn.org/professionals/physician_gls/pdf/bone.pdf. Accessed May 26, 2021.

[lxxii] **Tavalisse References**

1. Tavalisse™ [packet insert]. Rigel Pharmaceuticals, Inc., South San Francisco, CA; Revised November 2020. https://tavalisse.com/downloads/pdf/Tavalisse-Full-Prescribing-Information.pdf. Accessed May 5, 2021.
2. Neunert C, Terrell DR, Arnold DM, Buchanan G, Cines DB, et al. The American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood. https://doi.org/10.1182/bloodadvances.2019000966. Accessed May 5, 2021.
3. Newland A, Lee EJ, McDonald V, Bussel JB. Fostamatinib for persistent/chronic adult immune thrombocytopenia. Immunotherapy 2018; 10:9. https://pubmed.ncbi.nlm.nih.gov/28967793/. Accessed May 25, 2020.
4. Bussel J, Arnold DM, Grossbard E, et al. Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials. *Am J Hematol*. 2018;93(7):921–930. https://pubmed.ncbi.nlm.nih.gov/29696684/. Accessed May 25, 2020.
5.

[lxxiii] **References Tepezza[lxxiii] (teprotumumab-trbw)**

1. Douglas RS, Kahaly GJ, Patel A, et al. Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med. 2020;382(4):341-352. doi: 10.1056/NEJMoa1910434. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed?term=31971679

Last Update: 12.1.2020, 12.4.2020, 3.1.2021, 5.11.2021, 6.28.2021, 8.1.2021, 9.13.2021, 10.1.2021, 12.17.2021, 1.9.2022, 2.1.2022, 2.17.2022, 2.28.2022, 3.11.2022, 4.5.2022, 4.7.2022, 4.26.2022, 5.11.2022, 5.19.2022, 6.7.2022, 7.9.2022, 8.1.2022, 12.16.2022, 1.1.2023, 1.13.2023, 2.1.2023
,
Current Update: 2.10.2023

2. Tepezza [prescribing information]. Lake Forest, IL: Horizon Therapeutics USA Inc; January 2020. https://www.hzndocs.com/TEPEZZA-Prescribing-Information.pdf. Accessed July 30, 2021
3. Davies TF, Burch HB. (2020). Treatment of Graves' orbitopathy (ophthalmopathy). In JE Mulder (Ed.) UpToDate. Accessed July 30, 2021 from https://www.uptodate.com/contents/treatment-of-graves-orbitopathy-ophthalmopathy?search=tepezza&source=search_result&selectedTitle=2~5&usage_type=default&display_rank=1#H8

[lxxiv] **TIRF References**

1. Abstral® [package insert]. Sentynl Therapeutics, Solana Beach, CA; December 2019. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e60f00e9-2cf4-4c20-b570-1c2ea426c8c7. Accessed June 1, 2021.
2. Actiq® [package insert]. Cephalon Inc., Frazer, PA; March 2021. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=90b94524-f913-48b3-3771-7b2fcffd888a. Accessed June 1, 2021.
3. Fentora® [package insert]. Cephalon, Inc., Fazer, PA; March 2021. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8f549d95-985b-f783-1ebb-ef57bd2ecb05. Accessed June 1, 2021.
4. Lazanda® [package insert]. West Therapeutic Development, LLC, Northbrook, IL; March 2021. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=73f38bde-2132-2b5a-e053-2a91aa0a6efb. Accessed June 1, 2021.
5. Onsolis® [package insert]. BioDelivery Sciences, International, Inc., Raleigh, NC; March 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022266s025lbl.pdf. Accessed June 1, 2021.
6. Subsys® [package insert]. Phoenix, AZ, Insys Therapeutics, Inc.; October 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202788s016lbl.pdf. Accessed June 1, 2021.
7. Gold Standard, Inc. Clinical Pharmacology [database online]. Available at: http://www.clinicalpharmacology.com. Accessed June 1, 2021.
8. TIRF REMS Access Program Website. https://www.tirfremsaccess.com/TirfUI/rems/home.action. Accessed June 1, 2021.
9. Portenoy, R.K., Mehta, Z., Ahmed, E. (2021) Cancer pain management with opioids: Optimizing analgesia. In J. Abrahm (Ed.), *UpToDate*. Retrieved June 1, 2021 from: https://www.uptodate.com/contents/cancer-pain-management-with-opioids-optimizing-analgesia.

[lxxv] **Tykerb References**

1. Tykerb® [package insert.] East Hanover, NJ: Novartis Pharmaceuticals Corporation; Revised February 2021. https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/tykerb.pdf. Accessed May 27, 2021.
2. National Comprehensive Cancer Network (NCCN). *NCCN Clinical Practice Guidelines in Oncology. Breast Cancer Version 4.2021*. 2021 Apr 28; National Comprehensive Cancer Network. Available from: http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed May 27, 2021.
3. National Comprehensive Cancer Network (NCCN). *NCCN Clinical Practice Guidelines in Oncology. Bone Cancer Version 1.2021*. 2020 Nov 20; National Comprehensive Cancer Network. Available from: https://www.nccn.org/professionals/physician_gls/pdf/bone.pdf. Accessed May 27, 2021.
4. National Comprehensive Cancer Network (NCCN). *NCCN Clinical Practice Guidelines in Oncology. Colon Cancer Version 2.2021*. 2021 Jan 21; National Comprehensive Cancer Network. Available from: https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf. Accessed May 27, 2021.
5. National Comprehensive Cancer Network (NCCN). *NCCN Clinical Practice Guidelines in Oncology. Rectal Cancer Version 1.2021*. 2020 Dec 22; National Comprehensive Cancer Network. Available from: https://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf. Accessed May 27, 2021.
6. National Comprehensive Cancer Network (NCCN). *NCCN Clinical Practice Guidelines in Oncology. Central Nervous System Cancers Version 5.2020*. 2021 Apr 15; National Comprehensive Cancer Network. Available from: https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf. Accessed May 27, 2021.

[lxxvi] **Viscosupplements References:**

1. Durolane® [package insert]. Durham, NC: Bioventus LLC; Revised October 2017. https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170007D.pdf. Accessed August 20, 2020.
2. Euflexxa® [package insert]. Parsippany, NJ: Ferring Pharmaceuticals Inc.; Revised July 2016. http://www.ferringusa.com/wp-content/uploads/2018/04/EuflexxaPI-07-2016.pdf. Accessed August 20, 2020.
3. Gel-One® [package insert]. Warsaw, IN: Zimmer; Revised May 2011. https://www.zimmerbiomet.com/content/dam/zimmer-web/documents/en-US/pdf/medical-professionals/biologics-sports-medicine/Gel-One-Pkg-Insert-Final.pdf. Accessed August 20, 2020.
4. GelSyn-3™ [package insert]. Durham, NC: Bioventus LLC; Revised January 2016. https://www.gelsyn3.com/wp-content/uploads/2016/09/ifu.pdf. Accessed August 20, 2020
5. GenVisc® 850 [package insert]. Doylestown, PA: OrthogenRx, Inc.; Revised September 2015. https://www.accessdata.fda.gov/cdrh_docs/pdf14/P140005d.pdf. Accessed August 20, 2020.
6. Hyalgan® [package insert]. Parsippany, NJ: Fidia Pharma USA Inc.; Revised May 2014. https://hyalgan.com/wp-content/themes/Nebula-master/pdf/hyalgan_pi.pdf. Accessed August 20, 2020.
7. Hymovis® [package insert]. Parsippany, NJ: Fidia Pharma USA Inc.; Revised October 2015. http://hymovis.com/wp-content/uploads/2017/04/HYMOVIS_PI.pdf. Accessed August 20, 2020.
8. Monovisc™ [package insert]. Bedford, MA: Anika Therapeutics, Inc.; Revised December 2013. https://www.accessdata.fda.gov/cdrh_docs/pdf9/P090031c.pdf. Accessed August 20, 2020.
9. Orthovisc® [package insert]. Woburn, MA: Anika Therapeutics, Inc.; Revised September 2014. https://www.accessdata.fda.gov/cdrh_docs/pdf3/p030019c.pdf. Accessed August 20, 2020.
10. Supartz FX™ [package insert]. Durham, NC; Bioventus LLC; Revised April 2015. http://www.supartzfx.com/wp-content/uploads/2015/07/SUPARTZ_FX_Package_Insert.pdf. Accessed August 20, 2020.
11. Synvisc® [package insert]. Ridgefield, NJ: Genzyme Biosurgery; Revised September 2014. http://products.sanofi.us/synvisc/synvisc.html. Accessed August 20, 2020.
12. Synvisc-One® [package insert]. Ridgefield, NJ: Genzyme Biosurgery; Revised September 2014. http://products.sanofi.us/synviscone/synviscone.html. August 20, 2020.
13. Visco-3™ [package insert]. Warsaw, IN: Zimmer; Revised April 2017. https://www.accessdata.fda.gov/cdrh_docs/pdf/p980044s027d.pdf. Accessed August 20, 2020.
14. TriVisc™ [package insert]. Doylestown, PA: OrthogenRx Inc; Revised September 2018. https://www.accessdata.fda.gov/cdrh_docs/pdf16/P160057D.pdf. Accessed August 20, 2020.
15. Triluron™ [package insert]. Florham Park, NJ: Fidia Pharma USA Inc.; Revised July 2019. https://www.accessdata.fda.gov/cdrh_docs/pdf18/P180040C.pdf. Accessed August 20, 2020.
16. Drug Facts and Comparisons on-line. (www.drugfacts.com), Wolters Kluwer Health, St. Louis, MO. Updated periodically.
17. Clinical Pharmacology [Internet database]. Gold Standard Inc. Tampa, FL. Updated periodically.
18. American Academy of Orthopedic Surgeons. (Resource of the World Wide Web). Treatment of Osteoarthritis of the Knee Practice guidelines 2nd Edition May, 2013. (National guideline Clearinghouse, 2012) (Osteoarthritis: Care and management in adults, 2014). Accessed August 20, 2020.
19. Hochberg MC, Altman RD, April KT, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and [illegible]

Last update: 12.2020, 1.2.2020, 3.1.2021, 5.1.2021, 6.28.2021, 8.1.2021, 8.1.2021, 9.1.2021, 10.1.2021, 11.1.2021, 12.1.2021, 1.1.2022, 2.1.2022, 3.1.2022, 4.1.2022, 4.5.2022, 4.7.2022, 4.26.2022, 5.11.2022, 5.19.2022, 6.7.2022, 7.9.2022, 8.1.2022, 12.16.2022, 1.1.2023, 1.13.2023, 2.1.2023
,
Current Update: 2.10.2023

20. McAlindon TE, Bannuru RR, Sullivan MC et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. March 14 Volume 22, Issue 3, Pages 363–388.
21. Osteoarthritis: Care and management in Adults. NICE Guidelines (cg177) published date: February 2014. https://www.nice.org.uk/guidance/cg177. Accessed August 20, 2020.
22. Washington State Health Care Authority Health Technology Assessment. Hyaluronic Acid/Viscosupplementation (Re-Review) Final Evidence Report. October 14, 2013. http://www.hca.wa.gov/hta/Documents/ha-visco_final_report_101113.pdf. Accessed August 20, 2020.
23. Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016. MMWR Recomm Rep 2016;65(No. RR-1):1–49. DOI: http://dx.doi.org/10.15585/mmwr.rr6501e1
24. Altman R, Asch E, Bloch D, et al. (1986), Development of Criteria for the Classification and Reporting of Osteoarthritis: Classification of Osteoarthritis of the Knee. Arthritis & Rheumatism, 29: 1039-1049. doi:10.1002/art.1780290816
25. Yong Wu, En Lin Goh, Dong Wang, and Shaocheng Ma. Novel treatments for osteoarthritis: an update. 2018; 10: 135–140. Published online 2018 Oct. doi: 10.2147/OARRR.S176666. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6174890/. Accessed August 20, 2020.
26. Frakes EP, Risser RC, Ball TD, Hochberg MC, Wohlreich MM. Duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, double-blind, placebo-controlled trial. Curr Med Res Opin. 2011;27(12):2361–2372.

[lxxvii] **Votrient References**

1. Votrient® [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; Revised August 2020. https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/votrient.pdf. Accessed May 28, 2021.
2. National Comprehensive Cancer Network (NCCN). *NCCN Clinical Practice Guideline in Oncology: Kidney Cancer. Version 4.2021.* 2021 Apr 19; National Comprehensive Care Network. Available from: https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf. Accessed May 28, 2021.
3. National Comprehensive Cancer Network (NCCN). *NCCN Clinical Practice Guideline in Oncology: Soft Tissue Sarcoma. Version 2.2021.* 2021 Apr 28; National Comprehensive Care Network. Available from: https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf. Accessed May 28, 2021.
4. National Comprehensive Cancer Network (NCCN). *NCCN Clinical Practice Guideline in Oncology: Gastrointestinal Stromal Tumors. Version 1.2021.* 2020 Oct 30; National Comprehensive Care Network. Available from: https://www.nccn.org/professionals/physician_gls/pdf/gist.pdf. Accessed May 28, 2021.
5. National Comprehensive Cancer Network (NCCN). *NCCN Clinical Practice Guideline in Oncology: Dermatofibrosarcoma Protuberans. Version 1.2021.* 2021 Feb 8; National Comprehensive Care Network. Available from: https://www.nccn.org/professionals/physician_gls/pdf/dfsp.pdf. Accessed May 28, 2021.
6. National Comprehensive Cancer Network (NCCN). *NCCN Clinical Practice Guideline in Oncology: Ovarian Cancer. Version 1.2021.* 2021 Feb 26; National Comprehensive Care Network. Available from: https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf. Accessed May 28, 2021.
7. National Comprehensive Cancer Network (NCCN). *NCCN Clinical Practice Guideline in Oncology: Uterine Neoplasms. Version 2.2021.* 2021 May 7; National Comprehensive Care Network. Available from: https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf. Accessed May 28, 2021.
8. National Comprehensive Cancer Network (NCCN). *NCCN Clinical Practice Guidelines in Oncology: Thyroid Carcinoma. Version 1.2021.* 2021 Apr 9; National Comprehensive Cancer Network. Available from: https://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf. Accessed May 28, 2021.

[lxxviii] **Wakefulness Agents References**

Last Update: 12.1.2020, 12.4.2020, 3.1.2021, 5.11.2021, 6.28.2021, 8.1.2021, 9.13.2021, 10.1.2021, 12.17.2021, 1.9.2022, 2.1.2022, 2.17.2022, 2.28.2022, 3.11.2022, 4.5.2022, 4.7.2022, 4.26.2022, 5.11.2022, 5.19.2022, 6.7.2022, 7.9.2022, 8.1.2022, 12.16.2022, 1.1.2023, 1.13.2023, 2.1.2023
,
Current Update: 2.10.2023

1. Nuvigil® [package insert]. North Wales, PA; TEVA Pharmaceuticals/Cephalon, Inc. November 2018. https://www.nuvigil.com/globalassets/nuvigil-consumer/nuv-40995-nuvigil-pi-nuv-010-11-2018-digital2.pdf. Accessed 7/26/2019.
2. Provigil® [package insert]. North Wales, PA; TEVA Pharmaceuticals/Cephalon, Inc. November 2018. http://www.provigil.com/pdfs/prescribing_info.pdf. Accessed July 26, 2019.
3. Sunosi™ [package insert]. Palo Alto, CA; Jazz Pharmaceuticals. June 2019. https://pp.jazzpharma.com/pi/sunosi.en.USPI.pdf. Accessed July 30, 2019.
4. Wakix® [package insert]. Plymouth Meeting, PA; Harmony Biosciences, LLC. August 2019. https://wakix.com/assets/pdf/wakix_prescribinginformation_us.pdf. Accessed October 1, 2019.
5. Gold Standard, Inc. Clinical Pharmacology [database online]. http://www.clinicalpharmacology.com. Accessed July 30, 2019.
6. Chervin RD. Approach to the Patient with Excessive Daytime Sleepiness. Waltham, MA. UpToDate. Last Modified September 14, 2017. https://www.uptodate.com/contents/approach-to-the-patient-with-excessive-daytime-sleepiness. Accessed July 29, 2019.
7. Morgenthaler TJ, Kapur VK, Brown T, et al. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. Sleep 2007;30(12):1705-11.
8. Epstein LJ, Kristo D, Strollo PJ Jr, et al. Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults. J Clin Sleep Med. 2009;5(3):263–276.
9. Cheng P, Drake CL. Sleep-wake Disturbances in Shift Workers. Waltham, MA. UpToDate. Last Modified June 17, 2019. https://www.uptodate.com/contents/sleep-wake-disturbances-in-shift-workers. Accessed July 30, 2019.

[lxxix] **Xolair References**

1. XOLAIR (Omalizumab) [package insert]. South San Francisco, CA; Genentech, Inc.; Revised July 2021. https://www.gene.com/download/pdf/xolair_prescribing.pdf. Accessed August 9, 2021.
2. Hamilos DL, Holbrook EH. (2021). Chronic rhinosinusitis: Management; In AM Feldweg (Ed.), UpToDate. Retrieved August 11, 2021 from https://www.uptodate.com/contents/chronic-rhinosinusitis-management?sectionName=CRS%20WITH%20NASAL%20POLYPOSIS&search=treatment%20for%20nasal%20polyps&topicRef=14609&anchor=H21&source=see_link#H21
3. Lanier B, Bridges T, Kulus M, et al. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. *J Allergy Clin Immunol*. 2009;124(6):1210-6. doi: 10.1016/j.jaci.2009.09.021.
4. Luong, A., Role of Anti-leukotriene Agents in the Management of Chronic Rhinosinusitis with Nasal Polyps. University of Texas Health and Sciences. Otorhinolaryngology – Head & Neck Surgery. https://med.uth.edu/orl/2009/08/12/role-anti-leukotriene-agents-management-chronic-rhinosinusitis-nasal-polyps/. Accessed August 25, 2021
5. National Institute for Health and Care Excellence (NICE). Omalizumab for treating severe persistent allergic asthma (review of technology appraisal guidance 133 and 201). London (UK): National Institute for Health and Care Excellence (NICE); 2013 Apr. 64 p. (Technology appraisal guidance; no. 278).
6. Global Initiative for Asthma (GINA) 2020. Global strategy for asthma management and prevention. https://ginasthma.org/wp-content/uploads/2020/04/GINA-2020-full-report_-final-_wms.pdf. Accessed August 12, 2021.
7. National Heart, Blood, and Lung Institute Expert Panel Report 4 (EPR 4): Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 08-4051, 2007. https://www.nhlbi.nih.gov/about/advisory-and-peer-review-committees/national-asthma-education-and-prevention-program-coordinating/EPR4-working-group
8. National Institute for Health and Care Excellence (NICE). Omalizumab for previously treated chronic spontaneous urticaria. London (UK): National Institute for Health and Care Excellence (NICE); 2015 June. (Technology appraisal guidance; no. 339).
9. Bernstein JA, Lang DM, Khan DA, et al. The diagnosis and management of acute and chronic urticaria: 2014 update. *J Allergy Clin Immunol.* 2014;133:1270-1277.
10. Khan D. Chronic urticaria: Treatment of refractory symptoms. (2021) UpToDate. https://www.uptodate.com/contents/chronic-spontaneous-urticaria-treatment-of-refractory

symptoms?search=Chronic%20urticaria:%20Treatment%20of%20refractory%20symptoms&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1. Accessed August 12, 2021.

11. Casale T, Stokes J. Anti-IgE therapy. (2021) UptoDate. https://www.uptodate.com/contents/anti-ige-therapy?search=Anti-IgE%20therapy&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1. Accessed August 12, 2021
12. DRUGDEX® System [Internet database]. Greenwood Village, CO: Thomson Micromedex. Accessed . May 11, 2020
13. Drug Facts and Comparisons online (www.drugfacts.com). Wolters Kluwer Health, St. Louis, MO. Accessed May 18, 2020
14. National Asthma Education and Prevention Program: Expert Panel Report 3: Guidelines for the diagnosis and management of asthma. October 2007. Available at: http://www.nhlbi.nih.gov/guidelines/asthma/asthsumm.pdf.
15. Clinical Pharmacology [https://www.clinicalkey.com/pharmacology/]. Accessed August 12, 2021.

[lxxx] **Xyrem References:**

1. Xywav prescribing information. Palo Alto, CA. Jazz Pharmaceuticals, Inc. Revised August 2021. https://pp.jazzpharma.com/pi/xywav.en.USPI.pdf
2. Xyrem prescribing information. Palo Alto, CA. Jazz Pharmaceuticals, Inc. Revised September 2020. http://pp.jazzpharma.com/pi/xyrem.en.USPI.pdf. Accessed August 30, 2021.
3. Scammell, TE. (2020). Treatment of narcolepsy in adults. In AF Eichler (Ed.), UpToDate. Retrieved May 11, 2020 from https://www.uptodate.com/contents/treatment-of-narcolepsy-in-adults?search=xyrem&source=search_result&selectedTitle=4~36&usage_type=default&display_rank=3#H3
4. Morgenthaler TI, Kapur VK, et al. Practice Parameters for the Treatment of Narcolepsy and other Hypersomnia's of Central Origin: An American Academy of Sleep Medicine Report. December 1, 2007, available from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2276123/. Accessed August 30, 2021.
5. Wise MS, Arand DL, et al. Treatment of narcolepsy and other hypersomnia's of central origin: An American Academy of Sleep Medicine Review. December 1, 2007, available from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2276130/. Accessed August 30, 2021.
6. Food and Drug Administration (FDA) drug safety communication: warning against the use of Xyrem (sodium oxybate) with alcohol or drugs causing respiratory depression. December 2012. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-warning-against-use-xyrem-sodium-oxybate-alcohol-or-drugs-causing. Accessed August 30, 2021.
7. Judd, BG, Sateia, MJ, (2020). Classification of sleep disorders. In A.F. Eichler (Ed.), retrieved May , 2020, from https://www.uptodate.com/contents/classification-of-sleep-disorders#H618724283
8. Kotagal, S., (2021). Management and prognosis of narcolepsy in children.. In A.F. Eichler (Ed.), retrieved August 30, 2021, from https://www.uptodate.com/contents/management-and-prognosis-of-narcolepsy-in-children?search=Treatment%20of%20narcolepsy%20&source=search_result&selectedTitle=2~119&usage_type=default&display_rank=2

[lxxxi] **Zeposia for UC References**

1. Zeposia (ozanimod) [prescribing information]. Summit, NJ: Celgene Corporation; Revised May 2021. https://packageinserts.bms.com/pi/pi_zeposia.pdf. Accessed September 3, 2021.